




OREGON BOARD OF PHARMACY

2027–29 Agency Request Budget

BUDGET NARRATIVE — 2027–29

TABLE OF CONTENTS

	Page
INTRODUCTORY INFORMATION	
Table of Contents	2-3
Certification (107BFO1).....	4
A: LEGISLATIVE ACTION	
Summary of Budgetary Legislative Actions (BSM002a)	6
Legislatively Approved 2023 – 2025 Key Performance Measures	7
B: AGENCY SUMMARY	
Agency Summary Narrative.	10
• Agency Programs.....	11
• Budget Summary Graphics.....	12
• Mission Statement and Statutory Authority.	14
• 2024-2029 OBOP Strategic Plan.	18
• Agency IT Strategic Plan	18
• Program Objectives.	19
• Environmental Factors.....	20
• Agency Process Improvement Efforts.	21
• Criteria for 2027–2029 Budget Development.....	22
• Agency Diversity, Equity, Inclusion and Belonging Action Plan.	22
• 2027–29 Racial Equity Impact Statement (REIS): Agency Questions	23
• 2027–29 Racial Equity Impact Statement (REIS): Policy Option Package (POP) 101 Questions	26
• 2027–29 Racial Equity Impact Statement (REIS): Policy Option Package (POP) 102 Questions	32
• Summary of 2027–29 Budget (BDV104).....	38
• Program Prioritization for 2027–29 (107BF23).....	45
• 10% Reduction Option.	46
• Reduction Options (ORBITS Narrative, 107BF17)	47
2027–2029 Organizational Chart.	51
2027–2029 Proposed Organizational Chart.	53

BUDGET NARRATIVE — 2027–29

C: REVENUES

Revenue Forecast Narrative/Graphics	56
Fee Change Detail Memo	59
Fee Change Detail Report (107BF22)	60
Fee Approval Forms	61
Detail of Fee License Assessment Revenue Increase (107BF08)	64
Detail of Lottery Funds, Other Funds, and Federal Funds Revenue (107BF07)	65
ORBITS Detail of Lottery Funds, Other Funds, and Federal Funds Revenue (BPR012)	67

D: PROGRAM UNITS

Organization Chart 2025–2027	70
Proposed Organization Chart for 2027–29	72
Program Unit Executive Summary.	74
Program Funding Request.	76
Program Description	77
Program Justification and Link to 10 Year Outcomes.	77
Program Performance & Graphics	78
Essential Packages	82
Policy Packages	83
ORBITS Essential and Policy Package Fiscal Impact Summary (BPR013)	87
Detail of Lottery Funds, Other Funds, and Federal Funds Revenue (107BF07)	95
ORBITS Net Package Fiscal Impact Report Essential & Policy Packages (POS116)	97
ORBITS Detail of Lottery Funds, Other Funds, and Federal Funds Revenue (BPR012)	100

E: SPECIAL REPORTS

2025 Annual Performance Progress Report	104
Affirmative Action Report.	105
Ethnic Breakdown (graphic)	121
Bi-lingual Information (graphic)	122
Summary Cross Reference Listing and Packages (BSU003A)	123
Policy Package List by Priority (BSU-004A)	125
Agency Worksheet – Revenues & Expenditures (BDV001A)	126
Detail Revenues and Expenditures – Requested Budget (BDV002A)	140
Detail Revenues and Expenditures – Essential Packages (BDV004B)	150
Detail Revenues and Expenditures – Policy Packages (BDV004B)	158
Position Budget Report by DCR - (PIC 100)	162

BUDGET NARRATIVE — 2027–29

CERTIFICATION


I hereby certify that the accompanying summary and detailed statements are true and correct to the best of my knowledge and belief and that the accuracy of all numerical information has been verified.

Oregon Board of Pharmacy

AGENCY NAME

800 NE Oregon St, Suite 150, Portland, OR, 97232

AGENCY ADDRESS


SIGNATURE

Board President

TITLE

Notice: Requests of agencies headed by a board or commission must be approved by official action of those bodies and signed by the board or commission chairperson. The requests of other agencies must be approved and signed by the agency director or administrator.

☒ Agency Request

☐ Governor's Budget

☐ Legislatively Adopted

2027-29

107BF01



LEGISLATIVE ACTION

BUDGET NARRATIVE — 2027–29

Summary of Budgetary Legislative Actions

85500 - Oregon Board of Pharmacy

Agency Contact: Gary Runyon, Executive Director

Date Submitted: 6/26/2026

CFO Analyst: JeaLinda Patton

Session/Eboard	Month (Eboard only)	Year	Bill Number	Short Description of Action Taken
2025 Regular Session		2025	HB 5028	Agency primary budget bill
2026 Regular Session		2026	HB 5204	End of Session True up
2026 Regular Session		2026	HB 5204	End of Session Sal Pot

BUDGET NARRATIVE — 2027–29

Legislatively Approved 2025 - 2027 Key Performance Measures

Published: 5/14/2025 11:12:58 AM

Agency: Board of Pharmacy

Mission Statement:

The Oregon Board of Pharmacy serves to promote and protect public health, safety, and welfare by ensuring high standards in the practice of pharmacy and through effective regulation of the manufacture and distribution of drugs.

Legislatively Approved KPMs	Metrics	Agency Request	Last Reported Result	Target 2026	Target 2027
1. Percent of inspected pharmacies that are in compliance annually.		Approved	64%	85%	85%
2. Percentage of individual and facility licenses that are issued within 30 days.		Approved	74%	75%	75%
3. Percent of pharmacies inspected every two years.		Approved	63%	50%	50%
4. Average number of days to complete an investigation from complaint to board presentation.		Approved	138.25	100	100
5. Customer Service - Percent of customers rating their satisfaction with the agency's customer service as "Good" or "Excellent": Overall Customer Service, Timeliness, Accuracy, Helpfulness, Expertise, and Availability of Information.	a) Timeliness	Approved	75%	90%	90%
	b) Expertise		91%	90%	90%
	c) Accuracy		85%	90%	90%
	d) Helpfulness		84%	90%	90%
	e) Overall		83%	90%	90%
	f) Availability of Information		77%	90%	90%
6. Board Best Practices - Percent of total best practices met by the Board.		Approved	70%	100%	100%

LFO Recommendation:

LFO recommends approval of the KPMs and targets as presented.

SubCommittee Action:

The Education Subcommittee approved the KPMs and targets.

PAGE LEFT INTENTIONALLY BLANK



AGENCY SUMMARY

BUDGET NARRATIVE — 2027–29

Agency Summary Narrative

The Oregon Board of Pharmacy (Board) is an Other Funds agency, meaning its operations are entirely supported by licensing fees and civil penalties rather than the state's General or Lottery Funds. Established in 1891, the Board's mission is to promote and protect public health, safety, and welfare by ensuring high standards in the practice of pharmacy and through effective regulation of the manufacture and distribution of drugs.

To fulfill this mandate, the Board is composed of an appointed governing body and dedicated operational staff. Together, they ensure that only qualified and competent individuals engage in the practice of pharmacy.

Board Members:

The Board's governing body consists of nine members appointed by the Governor and confirmed by the State Senate. These members are responsible for deliberating on disciplinary cases, guiding administrative rulemaking, reviewing recommendations from the Public Health and Pharmacy Formulary Advisory Committee (PHPFAC), and assessing the Executive Director's work. By statute, the Board's composition must include:

- Five licensed pharmacists
- Two licensed pharmacy technicians
- Two representatives of the public

Board Staff:

Day-to-day operations and regulatory enforcement are carried out by 24 full-time equivalent (FTE) staff that implement the Board's directives across three core divisions:

- Licensing
- Compliance
- Executive


BUDGET NARRATIVE — 2027–29

Agency Programs:


The Board is budgeted and accounted for as a single program unit, and its services are organized into three functional divisions:

- **The Licensing Department (7 FTE)**—manages more than 31,000 active licenses and registrations across 33 different categories for individuals and drug outlets. This team processes all applications for initial licensure and renewals. Their comprehensive workflow also includes providing technical assistance, conducting continuing education audits, performing primary source verification, and processing criminal background checks.
- **The Compliance Department (12FTE / 13 Employees)**—conducts pharmacy inspections and investigates alleged violations of laws and rules. This team drafts disciplinary actions, monitors licensees and registrants on probation, responds to public inquiries, and provides educational outreach. Furthermore, they collaborate closely with federal agencies, the Department of Justice, and the Office of Administrative Hearings to ensure patient safety.
- **The Executive Department (5 FTE)**—guides day-to-day operations, legislation, and communications, and is responsible for drafting, implementing, and tracking key Board plans (e.g., Strategic, Affirmative Action, DEIB, and Succession Plans). Additionally, this team ensures compliance with state standards for financial management, procurement, and contracts, while managing public record requests, records retention, and overall office operations.

**Oregon Board of Pharmacy
Funding Limitations 25-27 LAB**




**Oregon Board of Pharmacy
Funding Limitations 27-29 ARB**



BUDGET NARRATIVE — 2027–29

Budget Summary Graphics




2025-2027 Program Allocation

- Operations (Administration, Communications & Policy) 31%
- Board Meeting and Member Activities 0.90%
- Licensing 15.00%
- Compliance 53.00%
- Public Health & Pharmacy Formulary Advisory Committee 0.10%


2027-2029 Program Allocation

- Operations (Administration, Communications & Policy) 28.6%
- Board Meeting and Member Activities 0.77%
- Licensing 15.98%
- Compliance 55.13%
- Public Health & Pharmacy Formulary Advisory Committee 0.07%



BUDGET NARRATIVE — 2027–29


2025-2027 Expenditures by Type \$14,719,811



- Personnel Services 61.79%
- Attorney General 6.47%
- Other Services & Supplies, Banking 3.5%
- Data Processing & Telecommunications 2.91%
- Prof. Services, HPSP, Hearings Panel 3.62%
- Facilities & Rent 2.38%
- Agency Program Related S & S (Fingerprinting) 1.89% *PASS THRU
- IT Professional Services 11.68%
- Office Expenses/Supplies (Includes Storage Fees & Postage) 1.07%
- Travel 1.01%
- State Government Service Charges 2.56%
- Publicity & Publications 0.38%
- IT Expendable Property 0.34%
- Employee Training 0.23%
- Expendable Property 0.15%
- Medical Services & Supplies 0.01%

- Personnel Services 69.90%
- Attorney General 7.38%
- Other Services & Supplies, Banking 4.54%
- Data Processing & Telecommunications 2.96%
- Prof. Services/Hearings Panel, HPSP 3.87%
- Facilities & Rent 2.87%
- Agency Program Related S & S (Fingerprinting) 2.07% *PASS THRU
- IT Professional Services 0.34%
- Office Expenses/Supplies (Includes Storage Fees & Postage) 1.02%
- Travel 1.09%
- State Government Service Charges 3.08%
- Publicity & Publications 0.30%
- IT Expendable Property 0.26%
- Employee Training 0.25%
- Expendable Property 0.07%
- Medical Services & Supplies 0.01%

2027-2029 Expenditures by Type \$13,789,888



BUDGET NARRATIVE — 2027–29

Mission Statement and Statutory Authority

Mission

The Oregon Board of Pharmacy serves to promote and protect public health, safety, and welfare by ensuring high standards in the practice of pharmacy and through effective regulation of the manufacture and distribution of drugs.

Statutory Authority

The authority and responsibilities of the Board of Pharmacy are contained in Chapter 689 of the Oregon Revised Statutes (The Oregon Pharmacy Act) and Chapter 475 (Uniform Controlled Substances Act). The Oregon Administrative Rules for the Oregon Board of Pharmacy reside in Chapter 855.

- | | |
|-----------------------------|--|
| • ORS 689.005 - 995 | Pharmacists; Pharmacy Technicians, Drug Outlets; Drug Sales |
| • ORS 475.005 - 980 | Controlled Substances; Illegal Drug Cleanup; Paraphernalia; Precursors |
| • OAR 855 Divisions 006-143 | Board of Pharmacy Oregon Administrative Rules |

Statement of Purpose

The practice of pharmacy in the State of Oregon is declared a professional practice affecting public health, safety and welfare and is subject to regulation and control in the public interest. It is further declared to be a matter of public interest and concern that the practice of pharmacy merits and receive the confidence of the public and that only qualified persons be permitted to engage in the practice of pharmacy in the State of Oregon.

In healthcare, most board practice acts are specific to the profession and scope of practice, however the pharmacy practice act includes both the professional practice of pharmacy as well as regulation of drug outlets, distributors, and manufacturers. The purpose of the Board of Pharmacy under Chapter 689 is to promote, preserve, and protect the public health, safety, and welfare by and through:

1. The effective control and regulation of the practice of pharmacy.
2. Regulation through registration of all entities involved in the commerce, manufacture, production, sale, and distribution of:
 - a. Prescription drugs
 - b. Over-the-counter (nonprescription) drugs
 - c. Controlled substances (drugs with abuse or dependency potential)
 - d. Devices
 - e. Other materials used in the diagnosis and treatment of injury, illness, and disease.

BUDGET NARRATIVE — 2027–29

Practice of Pharmacy” means: [\[ORS 689.005\(29\)\]](#)

- (a) The interpretation and evaluation of prescription orders;
- (b) The compounding, dispensing and labeling of drugs and devices, except labeling by a manufacturer, packer or distributor of nonprescription drugs and commercially packaged legend drugs and devices;
- (c) The prescribing and administering of vaccines and immunizations and the providing of patient care services pursuant to ORS 689.645;
- (d) The administering of drugs and devices to the extent permitted under ORS 689.655;
- (e) The participation in drug selection and drug utilization reviews;
- (f) The proper and safe storage of drugs and devices and the maintenance of proper records regarding the safe storage of drugs and devices;
- (g) The responsibility for advising, where necessary or where regulated, of therapeutic values, content, hazards and use of drugs and devices;
- (h) The monitoring of therapeutic response or adverse effect to drug therapy;
- (i) The optimizing of drug therapy through the practice of clinical pharmacy;
- (j) Patient care services, including medication therapy management and comprehensive medication review;
- (k) The offering or performing of those acts, services, operations, or transactions necessary in the conduct, operation, management, and control of pharmacy;
- (l) The prescribing and administering of injectable hormonal contraceptives and the prescribing and dispensing of self-administered hormonal contraceptives pursuant to ORS 689.689;
- (m) The prescribing and dispensing of emergency refills of insulin and associated insulin-related devices and supplies pursuant to ORS 689.696;
- (n) The prescribing, dispensing and administering of preexposure prophylactic antiretroviral therapies and post-exposure prophylactic antiretroviral therapies, pursuant to ORS 689.704 and rules adopted by the board under ORS 689.645 and 689.704; and
- (o) The delegation of tasks to other health care providers who are appropriately trained and authorized to perform the delegated tasks.
- (p) The prescribing, dispensing and administering of medication for the treatment of opioid use disorder pursuant to ORS 689.698 or rules adopted under ORS 689.698.

BUDGET NARRATIVE — 2027–29

“Drug Outlet” means: [\[ORS 689.005\(12\)\]](#)

Any pharmacy, nursing home, shelter home, convalescent home, extended care facility, drug abuse treatment center, penal institution, hospital, family planning clinic, student health center, retail store, wholesaler, manufacturer, mail-order vendor or other establishment with facilities located within or out of this state that is engaged in dispensing, delivery or distribution of drugs within this state.

Licensing, Standards and Discipline for Individuals [\[ORS 689.151, ORS 689.225 – 689.295, ORS 689.486 – 689.499\]](#)

Any individual engaged in the practice of pharmacy on behalf of an Oregon patient must be licensed by the board.

INDIVIDUALS LICENSED IN OREGON	
This includes the following individual categories as of 7/1/2026	
Pharmacist	9,209
Intern	553
Certified Oregon Pharmacy Technician	5,339
Pharmacy Technician	2,042
Preceptor*	3,543
Federal Preceptor*	35
Non-Pharmacist Preceptor*	5
TOTAL	20,726

*(*Note: All preceptors are licensed Pharmacists in Oregon with the exception of non-pharmacist preceptors)*

Registration of drug outlets; rules [\[ORS 689.305\]](#)

- (1) All drug outlets shall annually register with the State Board of Pharmacy.
- (2) (a) Each drug outlet shall apply for a certificate of registration in one or more of the following classifications:
 - (A) Retail drug outlet.
 - (B) Institutional drug outlet.
 - (C) Manufacturing drug outlet.
 - (D) Wholesale drug outlet.
 - (E) Nonprescription drug outlet.

BUDGET NARRATIVE — 2027–29

(F) Third-party logistics provider drug outlet.

(b) An individual who is employed by a corporation which is registered under any classification listed in paragraph (a) of this subsection is not required to register under the provisions of this section.

- (3) The board shall establish by rule pursuant to ORS 689.155 and 689.205 the criteria that each drug outlet must meet to qualify for registration in each classification designated in subsection (2)(a) of this section. The board may issue various types of certificates of registration with varying restrictions to the designated outlets where the board deems it necessary by reason of the type of drug outlet requesting a certificate.
- (4) The board shall establish by rule pursuant to ORS 689.155 and 689.205 the criteria that each drug outlet must meet to qualify for registration in each classification designated in subsection (2)(a) of this section. The board may issue various types of certificates of registration with varying restrictions to the designated outlets where the board deems it necessary by reason of the type of drug outlet requesting a certificate.


DRUG OUTLETS REGISTERED IN OREGON			
This includes the following categories of drug outlets as of 7/1/2026			
Animal Euthanasia	21	Non-Prescript Drug Outlet-A	2,982
Charitable Pharmacy	3	Non-Prescript Drug Outlet-D	2
Community Health Clinic	106	Non-Prescript Drug Outlet-E	9
Controlled Substance	2,054	Pharmacy Prescription Kiosk	1
Correctional Facility	54	Precursor	10
Dispensing Practitioner Drug Outlet	120	Prophylactic/Contraceptive	46
Drug Distribution Agent	525	Remote Dispensing Machine	1
Home Dialysis Drug Outlet	7	Remote Distribution Facility	4
Hospital Drug Room	19	Remote Dispensing Site Pharmacy	1
Institutional Drug Outlet	124	Retail Drug Outlet	1,529
Manufacturer	1,617	Wholesaler - Class III	256
Med Device/Equip/Gases-C	512	Wholesaler - Nonprescription	201
Mobile Pharmacy	0	Wholesaler with Prescription	574
OUTLET TOTAL			10,778

The total number of Board of Pharmacy licensees and registrants as of 07/01/2026.

BUDGET NARRATIVE — 2027–29

Agency Strategic Plan

The [Oregon Board of Pharmacy 2024-2029 Strategic Plan](#) is available on the agency website. Adopted at the April 2024 board meeting, the board reaffirmed its purpose as stated in its Mission, Vision, Equity Statement, and Values.



Agency IT Strategic Plan

The [Oregon Board of Pharmacy 2024-2029 Strategic Plan](#) is available on the board website.

BUDGET NARRATIVE — 2027–29

Program Objectives

On-site Inspections of Drug Outlets:

Board Compliance Officers perform on-site inspections of pharmacies and other drug outlets. The board provides a self-inspection form for each type of drug outlet annually to provide clarity of expectations and transparency in the inspection process. This communication provides licensees and registrants the opportunity to review applicable laws and rules to aid in compliance and ensure patient safety. Inspections are a critical tool for the board to ensure public safety.

Investigate all Complaints of Alleged Violations of Law and Rule:

The Board's Compliance team investigates all complaints of alleged violation of laws and rules as required by ORS 689.405. Board investigations include, but are not limited to, drug theft or diversion, licensees impairment, practicing pharmacy without a license, fraud, and unregistered drug outlets. The board regulates licensees and registrants which creates an additional layer of complexity to investigations in an already dynamic and complex practice setting. All investigations are presented to the board to determine if a violation has occurred and if disciplinary action is warranted. The board and agency staff work closely with the Oregon Department of Justice (DOJ) legal counsel during investigations, proposed disciplinary action and the hearing process.

Collaborate with Federal, State and Local Partners:

The board collaborates with federal and state government agencies to protect the health, safety and welfare of Oregonians. The board works closely with the Medical, Nursing, Veterinary, Dental and Naturopathic Boards, the Drug Enforcement Agency (DEA), the Food and Drug Administration (FDA), and the Office of the Inspector General (OIG). The board registers Dispensing Practitioner Drug Outlets in collaboration with the Oregon Medical Board and Oregon Board of Nursing for their licensees who dispense drugs directly to their patients. The board also communicates regularly with national and state pharmacy associations, the National Association of the Boards of Pharmacy, and the state schools/colleges of pharmacy to ensure that interested party input is maintained. The board utilizes the Health Professionals Services Program (HPSP) established in 2010 for licensees who have been diagnosed with substance use or mental health disorders. This program allows the board to refer licensees for monitoring of drug testing as part of disciplinary orders.

Maintain Staffing Levels and Necessary Resources:

To achieve the goals and actions as directed by the board's 2024-2029 Strategic Plan as well as legislative mandates and other directives, it is critical that the Agency maintain or increase staffing levels as applicable. As the Agency's workload and responsibilities continue to increase, so must the Agency's staffing and resource levels.

BUDGET NARRATIVE — 2027–29

Environmental Factors

1. **Rulemaking Modernization ("Division Vision"):** The Board is currently executing a five-to-eight-year comprehensive overhaul of our Oregon Administrative Rules (OAR Chapter 855). This initiative demands sustained administrative capacity to systematically restructure and standardize our regulatory framework, evidenced by the adoption of over 100 rules in 2023 alone.
2. **Federal Supply Chain Mandates:** Implementing the federal Drug Supply Chain Security Act (DSCSA) requires extensive, ongoing collaboration with state and federal partners. This is critical to establishing interoperable, package-level tracking to prevent counterfeit, stolen, or diverted drugs from entering Oregon's supply chain.
3. **Corporate Consolidation & Investigation Complexity:** Pharmacy ownership is increasingly dominated by large, multinational corporations with heavily staffed legal teams. This has significantly increased the duration, legal complexity, and staff time required to resolve complaints, conduct investigations, and prepare for administrative hearings.
4. **Demographic Shifts & Demand:** Oregon's aging and growing population is driving a steady increase in prescription drug utilization, compounding the operational strain on existing pharmacies and increasing our baseline regulatory workload.
5. **Expanding Scope of Practice:** The pharmacy profession is rapidly evolving toward direct patient care. Pharmacists and interns are increasingly focused on clinical responsibilities—including prescribing immunizations, COVID-19 therapeutics, contraceptives, PEP/PrEP, and collaborative drug therapy management—while licensed Pharmacy Technicians assume greater responsibility for mechanical medication preparation and production. This fundamental shift requires continuous regulatory adaptation and rigorous oversight to ensure public safety.
6. **Unprecedented Pharmacy Closures & Access Crisis:** The state and nation experienced an unprecedented surge in pharmacy closures between 2024 and 2025 as large multinational corporate locations shut down. This rapid contraction has created widespread "pharmacy deserts," severely restricting patient access to essential medications and overwhelming remaining retail locations. For the Board, this instability has driven a sharp increase in complex inquiries and complaints regarding medication access and emergency closures, further straining our already limited regulatory resources.

BUDGET NARRATIVE — 2027–29

Agency Process Improvement Efforts

The agency continuously analyzes and streamlines operations to enhance service delivery, improve customer experience, and meet performance metrics across licensing and compliance. Following the concise, action-oriented format utilized by the Oregon Medical Board, the most significant recent improvements include:

- **Strategic Planning & Governance:** Modernizing the Board’s Continuity of Operations Plan, 2024–2029 Strategic Plan, 2024–2026 DEIB Action Plan, 2027–2029 Affirmative Action Plan, and Workforce and Succession Plan.
- **Systems Modernization & Access:** Continuously improving the eGov online system to provide secure, 24/7 access for initial licensure, renewals, and public verifications. Deploying new online 2026 Self-Inspection forms and launched a virtual, on-demand PIC training course to maximize accessibility and compliance efficiency.
- **Operational Efficiency:** Integrating LEAN methodologies to standardize workflows and implementing a strategic staff realignment focused on customer service, brand management, and fulfilling the Governor’s priorities.
- **Workplace Culture & Development:** Establishing internal staff committees (DEI Champions, Employee Engagement, Leadership Development, etc.), overhauling the Board and Staff Member Orientation process, and increasing professional development opportunities to foster a collaborative and accountable workforce.

BUDGET NARRATIVE — 2027–29

Criteria for 2027–29 Budget Development

In addition to the baseline operations described above and the directives established in the Board's 2024–2029 Strategic Plan and 2024–2026 DEIB Action Plan, the following core goals serve as the framework for this budget proposal. These overarching objectives guide agency activities and resource allocations. The Executive Director and staff continuously align agency strategy with our foundational mission: to promote, preserve, and protect the public health, safety, and welfare of all Oregonians.

- **Goal 1:** Protect Oregonians by regulating the practice of pharmacy and the manufacture and distribution of drugs.
- **Goal 2:** Implement the Governor's expectations.
- **Goal 3:** Execute all directives within the Board's 2024–2029 Strategic Plan, 2024–2026 DEIB Action Plan, 2027–2029 Affirmative Action Plan, and Workforce and Succession Plan.
- **Goal 4:** Incorporate DEIB principles into the development and revision of all administrative rules, internal policies, and procedures.

Agency Diversity, Equity, Inclusion and Belonging Action Plan 2024-2026

The [2024 – 2026 OBOP Diversity, Equity, Inclusion and Belonging Action Plan](#) is located on the agency website.

BUDGET NARRATIVE — 2027–29

2027–29 Racial Equity Impact Statement (REIS): Agency Questions

1. Who is completing this agency REIS?

Gary Runyon, the Executive Director of the Oregon Board of Pharmacy.

2. Does your agency have a DEIB practitioner?

No.

a. If yes, describe how you collaborated with them on this REIS.

Not applicable.

b. If they were not involved in the development of this REIS, please explain why. Describe what you did instead to incorporate equity expertise and community input (e.g. listening sessions, advisory review, analysis of existing community feedback, partnering with trusted community partners, etc.).

Not applicable.

3. How do the agency's mission, goals and programs impact racial equity?

The Board actively integrates racial equity into its core functions, particularly during internal hiring processes and when drafting Oregon Administrative Rules (OARs). In our hiring practices, the Board leverages strategies from our Affirmative Action Plan and DEIB Action Plan to mitigate implicit bias, expand recruitment outreach to underrepresented communities, and utilize diverse interview panels to cultivate a workforce that better reflects the public we serve.

Concurrently, by critically reviewing proposed rules, the Board attempts to eliminate unintended consequences that might disproportionately affect marginalized communities. This intentional approach reduces structural barriers to professional licensure and ensures that underserved patient populations have safe, equitable access to medications.

BUDGET NARRATIVE — 2027–29

4. What barriers exist in your agency's mission, goals, and programs that could hinder the advancement of racial equity?

A major barrier is that individual patient voices and the perspectives of marginalized communities have historically been missing from the public comment portions of both administrative rulemaking and policy discussions. This is largely due to systemic challenges in how information is disseminated; members of the public often do not know about these participation opportunities or where to find them. Furthermore, rigid state mandated administrative structures strictly limit public comment to published agenda items, which leaves no general, proactive feedback mechanism for the public to share their lived experiences outside of filing a formal complaint.

Consequently, public input is heavily dominated by well-resourced pharmacy corporations and professional organizations. Additionally, strict administrative regulations designed for safety, such as drug compounding or drug dispensing rules, can create operational hurdles that delay equitable, timely access to care.

5. What opportunities exist in your agency's mission, goals, and programs that could help advance racial equity?

The Board is capitalizing on external opportunities by actively adopting new rules and amending existing rules and internal policies to be accessible, in plain language, by removing outdated and gendered phrasing. Internally, the Board has the opportunity to leverage previously established committees—such as the DEIB Champions, Employee Engagement Committee, and Leadership Development Committee—to ensure that every department is represented and that diverse perspectives actively shape Board decisions.

6. How is community voice included in your assessments of progress, equity, and racial disparities?

The Board gathers external perspectives through oral or written public comments during administrative rulemaking. However, large corporate pharmacy chains often overshadow patients and small-scale pharmacists.

To address this disparity and facilitate enhanced communication between the Board and its partners, the Executive Director has worked to strengthen relationships with interested parties, including state pharmacy associations and other state agencies. These proactive efforts aim to expand feedback loops and amplify voices traditionally underrepresented in the administrative process.

BUDGET NARRATIVE — 2027–29

7. What measures are you using to track equity changes over time?

To track equity changes without increasing administrative burdens, the Board relies on the quantitative and qualitative measures established in the 2024–2026 DEIB Action Plan and the 2027–2029 Affirmative Action Plan. We track external impacts and internal cultural shifts through the following measures:

- Analysis of licensee demographic and workforce data.
- Oregon Health Authority (OHA) workforce supply and population-to-provider access ratios.
- Year-over-year tracking of community organization partnerships.
- Gallup Q12 Employee Engagement Survey results.
- Staff exit surveys and annual stay interviews.
- Participation rates in biannual DEIB training sessions.
- Quarterly Performance Accountability and Feedback (PAF) check-ins on equity.
- Demographic tracking for Board, committee, and staff members.

8. Describe any racial disparities or trends you are noticing across your agency, programs, and data.

Based on the workforce and demographic data compiled in our 2024–2026 DEIB Action Plan, we are tracking several key disparities:

- **Board Workforce Representation:** Our internal demographic data indicates that the Board staff members are predominantly White (82%). When compared to statewide labor force statistics, we recognize a relative lack of representation from Black or African American, Hispanic or Latino, and American Indian or Alaska Native communities.
- **Licensee Demographics:** An analysis of OHA’s 2024 data shows clear racial disparities within our regulated professions compared to the state’s general population. For example, Black or African American and Hispanic or Latino individuals are underrepresented in the licensee pool (Pharmacists are 2.9% Hispanic or Latino and 1.9% Black or African American; Certified Pharmacy Technicians are 10.4% Hispanic or Latino and 1.7% Black or African American).
- **Geographic Access to Care:** Our OHA workforce supply maps highlight stark population-to-provider disparities across Oregon counties. Certain rural and historically underserved regions show significantly higher ratios (fewer providers per capita), demonstrating unequal geographic access to pharmacy care.

BUDGET NARRATIVE — 2027–29

2027–29 Racial Equity Impact Statement (REIS): Policy Option Package (POP) 101 Questions

Program Overview

1. Please describe the POP being proposed.

Policy Option Package 101 (New Positions) is a cost-neutral staffing reallocation that bolsters frontline administrative support by eliminating a vacant, executive-level position. Overall, this results in a net increase of 1.0 FTE on the frontline while maintaining total cost neutrality. It specifically executes the following staffing changes:

- Abolishes one (1.0 FTE) Strategic Initiatives Manager
- Establishes one (1.0 FTE) Office Specialist 2
- Establishes one (1.0 FTE) Administrative Specialist 1

2. Why is the POP being proposed?

The Board regulates over 31,000 active licenses and registrations. Administrative bottlenecks currently fuel processing backlogs for initial license applications and renewals, while stalling delays in public records requests and inquiries. Reallocating funds from executive strategy to frontline licensing and administrative support directly targets these backlogs. This accelerates workforce entry for qualified healthcare professionals and enhances public responsiveness without increasing Board expenditures or raising fees.

Consultation

3. Who is completing this REIS?

Gary Runyon, the Executive Director of the Oregon Board of Pharmacy.

4. Who is responsible for tracking equity outcomes? What method(s) are they using to track outcomes?

Executive Director Gary Runyon and Strategic Initiatives Manager Laura Sonoiki are responsible for tracking equity outcomes. Since this POP is a cost-neutral staffing reallocation designed to bolster basic frontline administrative support, approval will not generate new or separate equity programs. Instead, positive equity outcomes will be reflected broadly through improved Key Performance Measures (KPMs).

BUDGET NARRATIVE — 2027–29

Because the relationship between objective operational data and subjective community equity impacts is indirect, any broader impact on equity can only be extrapolated rather than directly observed.

The primary equity risk occurs if the POP is rejected and the Board lacks adequate frontline support. In that scenario, compounding administrative bottlenecks could disproportionately harm marginalized applicants who rely on timely licensure for employment. The Board will monitor these equity impacts by tracking KPMs, specifically licensing application processing times, the percentage of pharmacies inspected every biennium, and the average number of days to complete an investigation from complaint to Board presentation.

5. Does your agency have a DEIB practitioner?

No.

- a. If yes, describe how you collaborated with them on this REIS.

Not applicable.

- b. If they were not involved in the development of this REIS, please explain why. Describe what you did instead to incorporate equity expertise and community input (e.g. listening sessions, advisory review, analysis of existing community feedback, partnering with trusted community partners, etc.).

Not applicable.

6. Did you collaborate with your agency's data analysts, community engagement managers, outreach managers, and/or others that regularly interact with underserved and marginalized communities on this REIS?

Not applicable.

- a. If yes, describe how you collaborated with them on this REIS.

Not applicable.

- b. If they were not involved in the development of this REIS, please explain why. Describe what you did instead to incorporate equity expertise and community input (e.g. listening sessions, advisory review, analysis of existing community feedback, partnering with trusted community partners, etc.).

Not applicable.

BUDGET NARRATIVE — 2027–29

Community Engagement and Data

7. Identify the specific racial groups and communities that may be impacted by this POP, both directly and indirectly. In your answer, include responses to the following questions:

After a thorough internal review of this proposal, we have determined that there will not be any asymmetrical or inequitable negative impact on any specific racial group or community. Because the essential duties of the vacant Strategic Initiatives Manager position have been temporarily absorbed by the Executive Director over the last year, critical administrative functions will continue to be maintained without disruption to core operations.

Instead, establishing two frontline administrative positions out of this single vacancy will positively impact all communities, including those that are marginalized or otherwise underrepresented. Increased capacity on the frontlines will ensure faster response times to inquiries from the public, licensees, and interested parties. Furthermore, shorter processing times for licensing will help reduce barriers to accessing care—particularly for historically underserved populations residing in critical access areas, rural areas, and frontier regions—by ensuring drug outlets can staff their locations properly, unencumbered by licensure delays caused by administrative lag.

a. How did you identify these impacted groups?

The Board identified these impacted groups through an internal evaluation of current administrative bottlenecks and their downstream effects on statewide pharmacy staffing. This analysis confirmed that no specific groups are disproportionately or negatively impacted.

b. What data are you using to validate your assessment? If possible, use outreach and engagement feedback to gather information and insight.

The internal operational data was used to assess application processing times, alongside existing engagement feedback from pharmacy partners regarding staffing challenges in rural and frontier communities.

c. If possible, disaggregate the data by race, ethnicity, geography, income level, and other relevant characteristics. If disaggregated data is not available, please describe why.

The operational improvements of this internal staffing shift will universally benefit all demographics interacting with the Board or seeking care at a regulated facility; therefore, detailed demographic disaggregation is not available or necessary for this specific internal reorganization.

BUDGET NARRATIVE — 2027–29

d. How are communities impacted by this POP? What are the disproportionate impacts? Please be specific.

There are no detectable disproportionate negative impacts. The impact is universally positive, as faster administrative processing reduces the structural lag that prevents qualified healthcare professionals from entering the workforce and serving communities across the state, particularly in underserved rural regions.

8. How did you ensure multiple perspectives were part of the decision-making process for this POP? In your answer, include responses to the following questions:

To ensure multiple perspectives informed the decision-making process for this POP, we conducted a comprehensive review of historical internal staffing structures and relevant data. The Executive Director consulted directly with operational managers, the Department of Administrative Services (DAS) analyst, and the Legislative Fiscal Office (LFO) analyst to gather structural and fiscal input.

Additionally, the Executive Director engaged Board members; this POP was introduced and discussed during open sessions at several Board meetings, providing opportunities for public testimony and stakeholder input.

a. Identify how you have or are planning to engage multiple perspectives and impacted groups to provide feedback on this POP (e.g. program design, budget, policy decisions, etc.). Please give specific examples.

The Board's primary method for engaging multiple perspectives was leveraging public Board meetings. By presenting this proposed administrative reorganization during the open session of these meetings, we provided a forum for Board members—who represent various facets of the pharmacy profession and the public—to review and provide feedback. This open forum approach ensured policy transparency and allowed the Board to gather valuable feedback from healthcare partners, industry representatives, and public stakeholders in attendance.

b. If community engagement is not part of your approach, please explain why and what you did instead to incorporate community perspectives. In your response, describe the following: the decision-making process used to determine engagement was not feasible or appropriate, the specific barriers (beyond general time or capacity), and how you mitigated the risk of missing community input (e.g. using existing feedback, partnering with trusted organizations, review from advisory bodies, etc.).

While we utilized public Board meetings for transparency, a broader, traditional community engagement campaign was not appropriate or feasible for this specific POP. The request is fundamentally an internal, cost-neutral administrative staffing conversion aimed at workflow optimization, rather than the design of a new public-facing program.

BUDGET NARRATIVE — 2027–29

The specific barriers to broader community engagement stem from the strictly internal administrative nature of the change and our Board's lack of a dedicated outreach team or data analysts to conduct qualitative community polling.

We mitigated the risk of missing critical community input by ensuring the proposal was vetted publicly by our Board, acting as an open advisory body. This process has maintained complete accessibility for all public stakeholders.

Impacts and Accountability

9. If this POP is not funded, please describe the following:

a. Which racial or ethnic communities would be most impacted.

If this POP is not funded, the impact of ongoing administrative backlogs would be universal across all demographics and communities. However, the relative impact would be significantly greater for underrepresented, marginalized, and rural communities in critical access areas that lack overlapping healthcare resources.

For example, a licensing delay of several weeks for a single pharmacy technician in the Portland metro area might have no discernible impact on public access to care. Conversely, the same delay for a single professional in a critical access area—where there may be only one drug outlet that serves the entire community—profoundly disrupts local medication access.

Similarly, administrative bottlenecks will perpetuate delayed public responses and complaint processing. A patient in a well-resourced urban area has multiple alternative options if they encounter a pharmacy issue, whereas an underserved resident is entirely reliant on the Board's timely communication and regulatory intervention.

b. How disparities would likely persist or worsen.

Without this cost-neutral reallocation, existing disparities in healthcare access and safety will worsen as the structural administrative lag remains unmitigated. Drug outlets in underserved regions will face prolonged staffing vacancies due to licensing delays, while public inquiries and complaints encounter longer processing times. Because critical access areas lack robust alternative healthcare infrastructure, these combined bottlenecks directly translate into reduced pharmacy operating hours, delayed resolutions to patient safety violations, and a lack of timely guidance for already vulnerable populations.

BUDGET NARRATIVE — 2027–29

10. Who will be monitoring racial equity outcomes over time for this POP?

The Executive Director and the Strategic Initiatives Manager will collectively monitor the outcomes related to this POP.

a. How will progress be reported?

Because the Board lacks dedicated data analysts or outreach managers to conduct qualitative research, progress will be reported by tracking objective operational endpoints. The Board will monitor core KPMs—specifically licensing application processing times, the percentage of pharmacies inspected every biennium, and the average number of days to complete an investigation from complaint to Board presentation—from which broader impacts on underserved communities can be extrapolated.

b. How will leadership be informed of equity impacts?

Leadership will stay consistently informed of these extrapolated impacts and operational shifts during monthly manager meetings held between the Executive Director, the Compliance Director, and the Licensing Director. Given that the relationship between objective operational data and subjective community equity impacts is indirect, leadership will evaluate these broader outcomes as analytical inferences rather than discrete performance indicators.

c. How will the community be involved in monitoring outcomes?

The community will participate in monitoring outcomes by utilizing the Board's established public input channels. This includes submitting public comments during Board meetings and rulemaking hearings, speaking directly with the Compliance Officer on phone duty, or filing formal submissions through the online complaint portal on the Board's website.

BUDGET NARRATIVE — 2027–29

2027–29 Racial Equity Impact Statement (REIS): Policy Option Package (POP) 102 Questions

Program Overview

1. Please describe the POP being proposed.

Policy Option Package 102 (Staffing Reclass) is a cost-neutral staffing reclassification that aligns personnel compensation with expanded operational responsibilities. This package utilizes existing salary savings to maintain organizational stability without changing total positions or FTE. It specifically funds the following internal upgrades:

- Operations and Policy Analyst 2 to a Level 3
- Compliance and Regulatory Manager 1 to a Level 2

2. Why is the POP being proposed?

These reclassifications ensure that leadership and specialized staff are appropriately compensated for their increasingly complex roles, expanded workload, and personnel management responsibilities. This alignment is essential to retain staff and safeguard their irreplaceable historical knowledge of operations. Ultimately, it mitigates the risk of severe administrative bottlenecks that would occur if these key employees were to depart due to excessive workloads without commensurate compensation.

Consultation

3. Who is completing this REIS?

Gary Runyon, the Executive Director of the Oregon Board of Pharmacy.

4. Who is responsible for tracking equity outcomes? What method(s) are they using to track outcomes?

The Executive Director and the Strategic Initiatives Manager are responsible for tracking equity outcomes. However, because this POP is strictly a cost-neutral reclassification of existing personnel with no changes to the total number of positions or FTE, there are no foreseeable new equity outcomes to track if the package is approved. This realignment provides commensurate compensation for existing, expanded responsibilities.

BUDGET NARRATIVE — 2027–29

The primary equity risk occurs if the POP is rejected and key employees depart due to inadequate compensation. In that scenario, the resulting operational decline will be monitored through objective operational endpoints: licensing application processing times, the percentage of pharmacies inspected every biennium, and the average number of days to complete an investigation from complaint to Board presentation.

5. Does your agency have a DEIB practitioner?

No.

a. If yes, describe how you collaborated with them on this REIS.

Not applicable.

b. If they were not involved in the development of this REIS, please explain why. Describe what you did instead to incorporate equity expertise and community input (e.g. listening sessions, advisory review, analysis of existing community feedback, partnering with trusted community partners, etc.).

Not applicable.

6. Did you collaborate with your agency's data analysts, community engagement managers, outreach managers, and/or others that regularly interact with underserved and marginalized communities on this REIS? (Yes, no, or not applicable)

Not applicable.

a. If yes, describe how you collaborated with them on this REIS.

Not applicable.

b. If they were not involved in the development of this REIS, please explain why. Describe what you did instead to incorporate equity expertise and community input (e.g. listening sessions, advisory review, analysis of existing community feedback, partnering with trusted community partners, etc.).

Not applicable.

BUDGET NARRATIVE — 2027–29

Community Engagement and Data

7. Identify the specific racial groups and communities that may be impacted by this POP, both directly and indirectly. In your answer, include responses to the following questions:

After a thorough internal review of this proposal, we have determined that there will not be any asymmetrical or inequitable negative impact on any specific racial group or community. The goal of this package is internal retention; reclassifying and appropriately compensating these roles maintains organizational stability, which provides universal benefits across all communities interacting with the Board.

a. How did you identify these impacted groups?

No specific groups are disproportionately negatively impacted. The universally positive impacts of retaining expert staff were identified through an internal evaluation of the expanded duties of these roles and the severe operational risks to the public if these positions become vacant.

b. What data are you using to validate your assessment? If possible, use outreach and engagement feedback to gather information and insight.

This assessment is validated by combining internal operational data regarding the expanded scope of compliance oversight, IT management, and administrative rule coordination, alongside historical recruitment and training challenges for highly specialized regulatory leadership roles.

c. If possible, disaggregate the data by race, ethnicity, geography, income level, and other relevant characteristics. If disaggregated data is not available, please describe why.

This is unavailable because the operational stability provided by this internal reclassification universally benefits all demographics interacting with the Board; therefore, detailed demographic disaggregation is unavailable for this specific internal reorganization.

d. How are communities impacted by this POP? What are the disproportionate impacts? Please be specific.

There are no detectable disproportionate negative impacts. The impact is universally positive, as retaining experienced leadership ensures stable day-to-day operations. This stability directly maintains timely compliance interventions, steady progress in drafting, revising, and filing administrative rules, and seamless public engagement during public Board meetings.

BUDGET NARRATIVE — 2027–29

8. How did you ensure multiple perspectives were part of the decision-making process for this POP? In your answer, include responses to the following questions:

To ensure multiple perspectives informed the decision-making process for this POP, we conducted a comprehensive review of internal historical staffing structures and compensation data. Because this request addresses internal human resources and salary alignment, our approach focused entirely on administrative, structural, and fiscal oversight—rather than external community feedback.

a. Identify how you have or are planning to engage multiple perspectives and impacted groups to provide feedback on this POP (e.g. program design, budget, policy decisions, etc.). Please give specific examples.

Because this Policy Option Package focuses entirely on an internal, cost-neutral personnel reclassification to align compensation with currently performed duties, broader community engagement was not conducted. Approving this POP does not alter program design, external policies, or public-facing services. Instead, the Board targeted its engagement at the fiscal and structural realities of the request. For example, the Executive Director directly consulted with Department of Administrative Services (DAS) and Legislative Fiscal Office (LFO) partners to validate the fiscal framework and provided internal updates to Board members to allow for individual feedback.

b. If community engagement is not part of your approach, please explain why and what you did instead to incorporate community perspectives. In your response, describe the following: the decision-making process used to determine engagement was not feasible or appropriate, the specific barriers (beyond general time or capacity), and how you mitigated the risk of missing community input (e.g. using existing feedback, partnering with trusted organizations, review from advisory bodies, etc.).

The decision-making process determined that traditional community engagement was not appropriate because the request relies entirely on the direct internal observation of workload and work product.

The specific barrier to external engagement—beyond the Board’s lack of a dedicated outreach team or data analysts—is that the subject matter does not overlap with community-facing policy.

We mitigated the risk of missing critical input by ensuring the personnel reclassifications were thoroughly vetted by our DAS and LFO partners. This fiscal vetting validates the business need to retain these key roles, which directly protects the community from the negative downstream impacts (such as compliance and rulemaking delays) that would occur if the POP were not approved and turnover resulted.

BUDGET NARRATIVE — 2027–29

Impacts and Accountability

9. If this POP is not funded, please describe the following:

a. Which racial or ethnic communities would be most impacted.

While the absolute impact of these administrative and compliance bottlenecks would be universal, the relative impact would be significantly greater for underrepresented, marginalized, and rural communities in critical access areas. A patient in a well-resourced urban area has multiple alternative options if they encounter an issue at a pharmacy or need timely guidance. A patient in an underserved area does not, making them disproportionately reliant on the Board's timely regulatory intervention and communication.

b. How disparities would likely persist or worsen.

Without this cost-neutral reclassification, existing disparities in healthcare access and safety will worsen as the administrative lag remains unmitigated. If key compliance and operational roles become vacant, complaints originating from underserved areas will encounter longer processing times, directly translating into delayed resolutions to potential patient safety violations. Furthermore, disruptions to the rulemaking process, IT management, and Board meeting execution hinder the Board's ability to maintain public transparency and meet critical public health needs.

10. Who will be monitoring racial equity outcomes over time for this POP?

The Executive Director and the Strategic Initiatives Manager will be responsible for monitoring racial equity outcomes over time for this POP.

a. How will progress be reported?

Because this Policy Option Package is strictly an internal reclassification, there are no foreseeable new equity outcomes to track if it is approved. Consequently, tracking will only occur if the POP is rejected. In that scenario, the resulting negative operational impacts from key personnel departures will be reported using core Key Performance Measures (KPMs). The Board will monitor licensing application processing times, the percentage of pharmacies inspected every biennium, and the average number of days to complete an investigation from complaint to Board presentation—from which broader impacts on underserved communities can be extrapolated.

b. How will leadership be informed of equity impacts?

There will be no new equity outcomes or metrics to track unless this Policy Option Package is denied and key individuals leave the Board. Should that occur, the Board will monitor the objective operational endpoints detailed above. Any identifiable shifts or impacts

BUDGET NARRATIVE — 2027–29

to these metrics will be presented and discussed during the monthly manager meetings held between the Executive Director, the Compliance Director, and the Licensing Director. Given that the relationship between objective operational data and subjective community equity impacts is indirect, leadership will evaluate these broader outcomes as analytical inferences rather than discrete performance indicators.

c. How will the community be involved in monitoring outcomes?

The community will participate in monitoring outcomes by utilizing the Board's established public input channels. This includes submitting public comments during Board meetings and rulemaking hearings, speaking directly with the Compliance Officer assigned to phone duty, or filing formal submissions through the online complaint portal on the Board's website.

BUDGET NARRATIVE — 2027–29

Summary of 2027–29 Budget

Summary of 2027-29 Biennium Budget

Pharmacy, Board of
Pharmacy, Board Of
2027-29 Biennium

Agency Request Budget
Cross Reference Number: 85500-000-00-00-00000

Description	Positions	Full-Time Equivalent (FTE)	ALL FUNDS	General Fund	Lottery Funds	Other Funds	Federal Funds	Nonlimited Other Funds	Nonlimited Federal Funds
2025-27 Leg Adopted Budget	24	24.00	14,387,474	-	-	14,387,474	-	-	-
2025-27 Emergency Boards	-	-	332,337	-	-	332,337	-	-	-
2025-27 Leg Approved Budget	24	24.00	14,719,811	-	-	14,719,811	-	-	-
2027-29 Base Budget Adjustments									
Net Cost of Position Actions									
Administrative Biennialized E-Board, Phase-Out	-	-	246,043	-	-	246,043	-	-	-
Estimated Cost of Merit Increase			-	-	-	-	-	-	-
Base Debt Service Adjustment			-	-	-	-	-	-	-
Base Nonlimited Adjustment			-	-	-	-	-	-	-
Capital Construction			-	-	-	-	-	-	-
Subtotal 2027-29 Base Budget	24	24.00	14,965,854	-	-	14,965,854	-	-	-
Essential Packages									
010 - Non-PICS Pers Svc/Vacancy Factor									
Non-PICS Personal Service Increase/(Decrease)	-	-	18,360	-	-	18,360	-	-	-
Subtotal	-	-	18,360	-	-	18,360	-	-	-
020 - Phase In / Out Pgm & One-time Cost									
021 - Phase-in	-	-	-	-	-	-	-	-	-
022 - Phase-out Pgm & One-time Costs	-	-	(1,500,000)	-	-	(1,500,000)	-	-	-
Subtotal	-	-	(1,500,000)	-	-	(1,500,000)	-	-	-
030 - Inflation & Price List Adjustments									
Cost of Goods & Services Increase/(Decrease)	-	-	249,595	-	-	249,595	-	-	-
State Gov't & Services Charges Increase/(Decrease)			56,079	-	-	56,079	-	-	-
Subtotal	-	-	305,674	-	-	305,674	-	-	-

07/08/26
9:45 PM

Page 1 of 6

BDV104 - Biennial Budget Summary
BDV104

BUDGET NARRATIVE — 2027–29

Summary of 2027-29 Biennium Budget

Pharmacy, Board of
Pharmacy, Board Of
2027-29 Biennium

Agency Request Budget
Cross Reference Number: 85500-000-00-00-00000

<i>Description</i>	<i>Positions</i>	<i>Full-Time Equivalent (FTE)</i>	<i>ALL FUNDS</i>	<i>General Fund</i>	<i>Lottery Funds</i>	<i>Other Funds</i>	<i>Federal Funds</i>	<i>Nonlimited Other Funds</i>	<i>Nonlimited Federal Funds</i>
040 - Mandated Caseload									
040 - Mandated Caseload	-	-	-	-	-	-	-	-	-
050 - Fundshifts and Revenue Reductions									
050 - Fundshifts	-	-	-	-	-	-	-	-	-
060 - Technical Adjustments									
060 - Technical Adjustments	-	-	-	-	-	-	-	-	-
Subtotal: 2027-29 Current Service Level	24	24.00	13,789,888	-	-	13,789,888	-	-	-

07/08/26
9:45 PM

Page 2 of 6

BDV104 - Biennial Budget Summary
BDV104

BUDGET NARRATIVE — 2027–29

Summary of 2027-29 Biennium Budget

Pharmacy, Board of
Pharmacy, Board Of
2027-29 Biennium

Agency Request Budget
Cross Reference Number: 85500-000-00-00-00000

Description	Positions	Full-Time Equivalent (FTE)	ALL FUNDS	General Fund	Lottery Funds	Other Funds	Federal Funds	Nonlimited Other Funds	Nonlimited Federal Funds
Subtotal: 2027-29 Current Service Level	24	24.00	13,789,888	-	-	13,789,888	-	-	-
070 - Revenue Reductions/Shortfall									
070 - Revenue Shortfalls	-	-	-	-	-	-	-	-	-
Modified 2027-29 Current Service Level	24	24.00	13,789,888	-	-	13,789,888	-	-	-
080 - E-Boards									
081 - June 2026 Emergency Board	-	-	-	-	-	-	-	-	-
Subtotal Emergency Board Packages	-	-	-	-	-	-	-	-	-
Policy Packages									
101 - New Positions	1	1.00	-	-	-	-	-	-	-
102 - Staffing Reclass	-	-	-	-	-	-	-	-	-
Subtotal Policy Packages	1	1.00	-	-	-	-	-	-	-
Total 2027-29 Agency Request Budget	25	25.00	13,789,888	-	-	13,789,888	-	-	-
Percentage Change From 2025-27 Leg Approved Budget	4.17%	4.17%	-6.32%	-	-	-6.32%	-	-	-
Percentage Change From 2027-29 Current Service Level	4.17%	4.17%	-	-	-	-	-	-	-

07/08/26
9:45 PM

Page 3 of 6

BDV104 - Biennial Budget Summary
BDV104

BUDGET NARRATIVE — 2027–29

Summary of 2027-29 Biennium Budget

Pharmacy, Board of
Board of Pharmacy
2027-29 Biennium

Agency Request Budget
Cross Reference Number: 85500-001-00-00-00000

Description	Positions	Full-Time Equivalent (FTE)	ALL FUNDS	General Fund	Lottery Funds	Other Funds	Federal Funds	Nonlimited Other Funds	Nonlimited Federal Funds
2025-27 Leg Adopted Budget	24	24.00	14,387,474	-	-	14,387,474	-	-	-
2025-27 Emergency Boards	-	-	332,337	-	-	332,337	-	-	-
2025-27 Leg Approved Budget	24	24.00	14,719,811	-	-	14,719,811	-	-	-
2027-29 Base Budget Adjustments									
Net Cost of Position Actions									
Administrative Biennialized E-Board, Phase-Out	-	-	246,043	-	-	246,043	-	-	-
Estimated Cost of Merit Increase			-	-	-	-	-	-	-
Base Debt Service Adjustment			-	-	-	-	-	-	-
Base Nonlimited Adjustment			-	-	-	-	-	-	-
Capital Construction			-	-	-	-	-	-	-
Subtotal 2027-29 Base Budget	24	24.00	14,965,854	-	-	14,965,854	-	-	-
Essential Packages									
010 - Non-PICS Pers Svc/Vacancy Factor									
Non-PICS Personal Service Increase/(Decrease)	-	-	18,360	-	-	18,360	-	-	-
Subtotal	-	-	18,360	-	-	18,360	-	-	-
020 - Phase In / Out Pgm & One-time Cost									
021 - Phase-in	-	-	-	-	-	-	-	-	-
022 - Phase-out Pgm & One-time Costs	-	-	(1,500,000)	-	-	(1,500,000)	-	-	-
Subtotal	-	-	(1,500,000)	-	-	(1,500,000)	-	-	-
030 - Inflation & Price List Adjustments									
Cost of Goods & Services Increase/(Decrease)	-	-	249,595	-	-	249,595	-	-	-
State Gov't & Services Charges Increase/(Decrease)			56,079	-	-	56,079	-	-	-
Subtotal	-	-	305,674	-	-	305,674	-	-	-

07/08/26
9:45 PM

Page 4 of 6

BDV104 - Biennial Budget Summary
BDV104

BUDGET NARRATIVE — 2027–29

Summary of 2027-29 Biennium Budget

Pharmacy, Board of
Board of Pharmacy
2027-29 Biennium

Agency Request Budget
Cross Reference Number: 85500-001-00-00-00000

<i>Description</i>	<i>Positions</i>	<i>Full-Time Equivalent (FTE)</i>	<i>ALL FUNDS</i>	<i>General Fund</i>	<i>Lottery Funds</i>	<i>Other Funds</i>	<i>Federal Funds</i>	<i>Nonlimited Other Funds</i>	<i>Nonlimited Federal Funds</i>
040 - Mandated Caseload									
040 - Mandated Caseload	-	-	-	-	-	-	-	-	-
050 - Fundshifts and Revenue Reductions									
050 - Fundshifts	-	-	-	-	-	-	-	-	-
060 - Technical Adjustments									
060 - Technical Adjustments	-	-	-	-	-	-	-	-	-
Subtotal: 2027-29 Current Service Level	24	24.00	13,789,888	-	-	13,789,888	-	-	-

07/08/26
9:45 PM

Page 5 of 6

BDV104 - Biennial Budget Summary
BDV104

BUDGET NARRATIVE — 2027–29

Summary of 2027-29 Biennium Budget

Pharmacy, Board of
Board of Pharmacy
2027-29 Biennium

Agency Request Budget
Cross Reference Number: 85500-001-00-00-00000

Description	Positions	Full-Time Equivalent (FTE)	ALL FUNDS	General Fund	Lottery Funds	Other Funds	Federal Funds	Nonlimited Other Funds	Nonlimited Federal Funds
Subtotal: 2027-29 Current Service Level	24	24.00	13,789,888	-	-	13,789,888	-	-	-
070 - Revenue Reductions/Shortfall									
070 - Revenue Shortfalls	-	-	-	-	-	-	-	-	-
Modified 2027-29 Current Service Level	24	24.00	13,789,888	-	-	13,789,888	-	-	-
080 - E-Boards									
081 - June 2026 Emergency Board	-	-	-	-	-	-	-	-	-
Subtotal Emergency Board Packages	-	-	-	-	-	-	-	-	-
Policy Packages									
101 - New Positions	1	1.00	-	-	-	-	-	-	-
102 - Staffing Reclass	-	-	-	-	-	-	-	-	-
Subtotal Policy Packages	1	1.00	-	-	-	-	-	-	-
Total 2027-29 Agency Request Budget	25	25.00	13,789,888	-	-	13,789,888	-	-	-
Percentage Change From 2025-27 Leg Approved Budget	4.17%	4.17%	-6.32%	-	-	-6.32%	-	-	-
Percentage Change From 2027-29 Current Service Level	4.17%	4.17%	-	-	-	-	-	-	-

07/08/26
9:45 PM

Page 6 of 6

BDV104 - Biennial Budget Summary
BDV104

BUDGET NARRATIVE — 2027–29

Pharmacy, Board of

Agency Number: 85500

Agencywide Program Unit Summary
2027-29 Biennium

Version: V - 01 - Agency Request Budget

Summary Cross Reference Number	Cross Reference Description	2023-25 Actuals	2025-27 Leg Adopted Budget	2025-27 Leg Approved Budget	2027-29 Agency Request Budget	2027-29 Governor's Budget	2027-29 Leg. Adopted Budget
001-00-00-00000	Board of Pharmacy						
	Other Funds	10,194,003	14,387,474	14,719,811	13,789,888	-	-
TOTAL AGENCY							
	Other Funds	10,194,003	14,387,474	14,719,811	13,789,888	-	-

____ Agency Request
2027-29 Biennium

____ Governor's Budget
Page _____

____ Legislatively Adopted
Agencywide Program Unit Summary - BPR010

BUDGET NARRATIVE — 2027–29

Program Prioritization for 2027–29

Program Prioritization for 2027-29

Agency Name: Oregon Board of Pharmacy																					
2027-29 Biennium																			Agency Number: 85500		
Program 1																					
Program/Division Priorities for 2027-29 Biennium																					
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22
Priority (ranked with highest priority first)	Agency Initials	Program or Activity Initials	Program Unit/Activity Description	Identify Key Performance Measure(s)	Primary Purpose Program- Activity Code	GF	LF	OF	NL-OF	FF	NL-FF	TOTAL FUNDS	Pos.	FTE	New or Enhanced Program (Y/N)	Included as Reduction Option (Y/N)	Legal Req. Code (C, D, FM, FO, S)	Legal Citation	Explain What is Mandatory (for C, FM, and FO Only)	Comments on Proposed Changes to CSL included in Agency Request	
Agcy	Prgm/ Div																				
85500	1	OBOP	Operations (Administration, Communications & Policy)	85500 1-6	3			4,107,047				\$ 4,107,047	5	4	N	Y	S	ORS 475 & 689		1. Reclassification for position 0000576 from Executive Support Specialist 2 (\$244,228) to Admin Specialist 1 \$190,345. 2. Reclassification for position 0000592 from Operations Policy Analyst 2 to Operations Policy Analyst 3 \$20,266.	
85500	1	OBOP	Licensing & Exams	85500 2,5	3			2,147,585				\$ 2,147,585	7	8	N	Y	S	ORS 475 & 689		Adds one additional FTE - Office Specialist 1 \$168,295.	
85500	1	OBOP	Compliance	85500 1,3,4,5	3			7,404,079				\$ 7,404,079	12	13	N	Y	S	ORS 475 & 689		1. Reclassification for position 0000574 from Compliance & Regulatory Manager 1 to Compliance & Regulatory Manager 2 \$15,900. 2. Adds one additional FTE - Administrative Specialist 1 \$190,345 from reclassification of position 0000576 Executive Support Specialist 2 (\$244,228).	
85500	1	OBOP	Board Activities	85500 6	3			120,676				\$ 120,676	0	0	N	N	S	ORS 475 & 689		The Board has 9 members, if in-state or out of state travel is reduced, there will be an impact.	
85500	1	OBOP	Formulary Committee	Agency Mission	3			10,501				\$ 10,501	0	0	N	N	S	ORS 689.645 and .649		This Committee includes 7 members, legislatively authorized and effective 1/1/18. The Committee is meeting approximately 4 times per year.	
								13,789,888				\$ 13,789,888	24	25							

7. Primary Purpose Program/Activity Exists

- 1 Civil Justice
- 2 Community Development
- 3 Consumer Protection
- 4 Administrative Function
- 5 Criminal Justice
- 6 Economic Development
- 7 Education & Skill Development
- 8 Emergency Services
- 9 Environmental Protection
- 10 Public Health
- 11 Recreation, Heritage, or Cultural
- 12 Social Support

19. Legal Requirement Code

- C Constitutional
- D Debt Service
- FM Federal - Mandatory
- FO Federal - Optional (once you choose to participate, certain requirements exist)
- S Statutory

Within each Program/Division area, prioritize each Budget Program Unit (Activities) by detail budget level in ORBITS

Document criteria used to prioritize activities:

The agency is budgeted as one Program Unit. For the purpose of this exercise, we have broken out the key areas of agency function. However, all areas are required to accomplish the statutory mission of the agency.

BUDGET NARRATIVE — 2027–29

10% REDUCTION OPTIONS

The Board is a small, Other Funds agency; therefore, any staffing reductions would challenge its ability to maintain current service levels. A 10% reduction to the agency's 2027–2029 current service levels equals \$1,378,988. A reduction of this magnitude would have critical ramifications, negatively impacting the Board's ability to fulfill its statutory requirements.

To meet the mandatory requirement, the Board submits these reduction options below. (See Form 107BF17 on the next page for additional details.)

2027–2029 Proposed Reductions 10% Exercise	Amount
Personnel and Services & Supplies	
Executive Support Specialist 2	\$244,228
Business Operations Supervisor 2	\$298,685
Health Care Investigator/Advisor (Pharmacy Consultant) reduced 100%	\$458,264
Public Service Representative 3	\$184,163
Services & Supplies	
Board Meeting Reduction	\$76,220
Professional Services Reduction	\$17,428
TOTAL	\$1,378,988

Fund Type: Other Funds

BUDGET NARRATIVE — 2027–29

Reduction Options

10% Reduction Options (ORS 291.216)

ACTIVITY OR PROGRAM (WHICH PROGRAM OR ACTIVITY WILL NOT BE UNDERTAKEN)	DESCRIBE REDUCTION (DESCRIBE THE EFFECTS OF THIS REDUCTION)	AMOUNT AND FUND TYPE (GF, LF, OF, FF. IDENTIFY REVENUE SOURCE FOR OF, FF)	RANK AND JUSTIFICATION (RANK THE ACTIVITIES OR PROGRAMS NOT UNDERTAKEN IN ORDER OF LOWEST COST FOR BENEFIT OBTAINED)
1. Eliminate Funding for Professional Services	This reduction represents an almost negligible portion of this overall allocation, and it will therefore have minimal impact on the Board's ability to continue delivering services at the current service level.	\$17,428 (OF)	Rank #1 (negligible impact to both agency operations and public health, safety and welfare)
2. Eliminate Funding for Services & Supplies	Moving from 3-day to 2-day board meetings and having 3 in-person meetings per year and 3 virtual meetings per year will significantly reduce costs in the areas of in-state travel, lodging, daily per diem, meal per diem, parking reimbursement and catering costs. Negative impacts due to less board meetings may include a longer timeline to implement strategic plan initiatives such as reviewing and amending administrative rules and other policy discussions.	\$76,220 (OF)	Rank #2 (negligible impact to both agency operations and public health, safety and welfare)
3. Executive Support Specialist 2 (Position #0000576) – Personal Services – Services and Supplies	Eliminate one full-time Executive Support Specialist 2 position. Removing this full-time role would critically bottleneck operations for our Other Funds agency. This reduction removes vital capacity by: Degrading administrative capacity, which removes	\$244,228 (OF) \$25,000 S&S (OF)	Rank #3 (lowest impact to both agency operations and public health, safety and welfare)

BUDGET NARRATIVE — 2027–29

	essential support for legislative tracking, Board reporting, and budget preparation. • Delaying strategic execution and hindering long-term operational goals and internal policy development. • Impairing external relations, which compromises executive leadership support, media responses, and stakeholder collaboration.		
4. Business Operations Supervisor 2 (Position 0000591) – Personal Services – Services and Supplies	Eliminate one full-time Business Operations Supervisor 2 position. Phasing out this full-time financial leader and designated procurement officer would severely compromise agency operations. This reduction would result in: • Halting procurement, consequently suspending contract negotiations and jeopardizing essential vendor payments. • Impeding financial oversight, thus crippling budget adherence to state and federal accounting laws. • Stalling strategic initiatives and directly impairing audit responses, KPM reporting, and Strategic Plan execution.	\$298,685 (OF) \$25,000 S&S (OF)	Rank #4 (moderate impact to agency operations)

BUDGET NARRATIVE — 2027–29

5. Healthcare Inspector/Investigator (Position 0000657) – Personal Services – Services and Supplies	Eliminate one full-time Health Care Investigator/Advisor position. Cutting this full-time position would severely degrade our regulatory framework and overburden remaining Compliance staff. This reduction removes specialized pharmacy consultant capacity, directly: • Jeopardizing statutory mandates, ultimately delaying routine inspections and creating investigative backlogs that threaten the 120-day board-reporting requirement. • Slowing rule implementation, inevitably halting PHPFAC-driven Oregon Administrative Rule (OAR) drafting and critical updates to the Formulary and Protocol Compendium. • Diminishing stakeholder outreach and bottlenecking vital communication with licensees and academic institutions, paralyzing the Board's strategic initiatives.	\$458,264 (OF) \$25,000 S&S (OF)	Rank #5 (significant impact to public health, safety and welfare)
6. Public Service Representative 3 (Position 0000590) – Personal Services – Services and Supplies	Eliminate one full-time Public Service Representative 3 position. Eliminating this full-time frontline role would severely impede application processing for over 31,000 individuals and facilities. This reduction removes critical administrative capacity by:	\$184,163 (OF) \$25,000 S&S (OF)	Rank #6 (highest impact to both agency operations and public health, safety and welfare)


BUDGET NARRATIVE — 2027–29

	• Hampering licensing processing and delaying essential qualification analysis, including criminal background checks, educational credentials, and out-of-state verifications. • Eroding customer service and operations, as a result drastically slowing response times to public inquiries and disrupting the daily reconciliation of licensing fee payments. • Compromising patient safety and workforce entry, thereby delaying the entry of qualified pharmacy professionals into Oregon's workforce, and halting mandatory Continuing Pharmacy Education (CPE) audits.		
--	--	--	--


BUDGET NARRATIVE — 2027–29

Oregon Board of Pharmacy – Organizational Chart 2025–27

24 FTE (9 Board Member & 7 Public Health & Pharmacy Formulary Advisory Committee)



BUDGET NARRATIVE — 2027–29




PUBLIC HEALTH AND PHARMACY FORMULARY ADVISORY COMMITTEE
Established January 1, 2018


Members are appointed by the Governor to make recommendations to the Oregon Board of Pharmacy regarding pharmacist prescriptive authority

BUDGET NARRATIVE — 2027–29

Oregon Board of Pharmacy – Proposed Organizational Chart 2027–29 25 FTE (9 Board Member & 7 Public Health & Pharmacy Formulary Advisory Committee)



BUDGET NARRATIVE — 2027–29



PUBLIC HEALTH AND PHARMACY FORMULARY ADVISORY COMMITTEE
Established January 1, 2018

Members are appointed by the Governor to make recommendations to the Oregon Board of Pharmacy regarding pharmacist prescriptive authority




REVENUES

BUDGET NARRATIVE — 2027–29


Other Fund Revenues

2025-27 LAB Proposed Revenues \$13,576,081

- Business Licensing Fees | 88.47%
- Non-Businesss License & Fees | 2.23%
- Delinquent Fees & Civil Penalites | 1.23%
- Interest Income | 3.40%
- Miscellaneous Fees | 0.43%
- Includes \$629,280 Transfer to OHA | 4.24%



2027-29 LAB Proposed Revenues \$14,123,263



- Business Licensing Fees - 87.52%
- Non-Businesss Lic & Fees - 2.57%
- Delinquent Fees & Civil Penalites - 1.37%
- Interest Income - 3.25%
- Miscellaneous Sales - 0.41%
- Includes \$764,364 Transfer to OHA 4.88%

BUDGET NARRATIVE — 2027–29

Revenue Forecast Narrative

Funding Streams and Forecast Assumptions:

The Board is an Other Funds agency. Revenue is generated primarily from the licensure of individuals and the registration of drug outlets, as well as from civil penalties, interest income, and administrative fees for public records and document production.

Revenue projections for the 2027–2029 biennium are based on:

- **Historical Trends:** An analysis of license volume over the past five biennia, adjusted for anticipated population growth and industry shifts.
- **Fee Structure:** The 40% fee increase authorized by the Oregon Legislature, effective July 2025, remains the primary driver of revenue stability for this cycle.
- **Licensing Cycles:** A model that accounts for the biennial renewal of individual licenses (technicians in even years and pharmacists in odd years) and the annual cycle for facility registrations.
- **Pass-through Revenue:** Approximately 2.9% of collected revenue consists of pass-through funds for external programs, including national fingerprint-based background checks (Oregon State Police), the Prescription Drug Monitoring Program (PDMP), and Workforce Data Collection (Oregon Health Authority).

Fines and Forfeitures: Civil penalty revenue declined as the Board transitioned to a compliance-based disciplinary model. This approach prioritizes educational interventions and corrective actions over punitive financial assessments. As a result, the agency conservatively projects civil penalty revenue relative to historical collection peaks.

Fiscal Impacts and Legislative Changes: The 2027–2029 revenue forecast reflects the full biennial implementation of the 2025 fee adjustments. Our analysts continue to integrate minor revenue shifts based on statutory updates, such as the repeal of certain facility registrations (e.g., pharmacy prescription lockers) and the streamlining of wholesale drug outlet registration requirements, which consolidates renewals for multi-category registrants.

Legislative Concepts: The Board is not proposing any legislative concepts for 2027–2029.

BUDGET NARRATIVE — 2027–29

Policy Option Packages: The Board is proposing two policy packages for 2027–2029:

Policy Option Package 101: New Positions

Purpose: This package proposes a strategic reallocation of staffing resources to increase the agency's frontline operational capacity. Specifically, it abolishes one vacant Strategic Initiatives Manager position and utilizes the associated funds to establish one Office Specialist 2 and one Administrative Specialist 1 position.

Staffing Impact: This action abolishes one position and establishes two new positions.

Quantifying Results: By realigning these roles, the agency aims to reduce the current backlog in processing licensing applications and significantly improve responsiveness to public records requests, thereby enhancing customer service and overall operational efficiency.

Revenue Source: This proposal is cost-neutral and will be funded through existing resources and vacancy savings, requiring no additional fee increases or legislative revenue allocations. This package increases Personnel Services by **\$114,412**

Policy Option Package 102: Staffing Reclass

Purpose: This package focuses on aligning personnel compensation with the reality of expanded operational responsibilities and oversight within the agency. It proposes upgrading one Operations and Policy Analyst 2 to a Level 3 and one Compliance and Regulatory Manager 1 to a Level 2.

Staffing Impact: There are no changes to the total number of positions or FTE; this package involves position reclassifications only.

Quantifying Results: These reclassifications ensure that agency leadership and specialized analysts are compensated appropriately for the increased complexity of their roles, particularly regarding oversight of compliance outcomes and legislative interpretation. This alignment is essential for staff retention and maintaining the agency's expertise.

Revenue Source: This package is cost-neutral, reallocating existing salary savings and budget resources to maintain internal equity and organizational stability. This package increases Personnel Services by **\$36,166**

BUDGET NARRATIVE — 2027–29



Oregon

Tina Kotek, Governor

Oregon Board of Pharmacy

800 NE Oregon St., Suite 150

Portland, OR, 97232

Phone: 971-673-0001

Fax: 971-673-0002

pharmacy.licensing@bop.oregon.gov

www.oregon.gov/pharmacy

July 28, 2026

Sent via Email

JeaLinda Patton (jealinda.patton@das.oregon.gov)

Assistant Policy and Budget Analyst

DAS Chief Financial Office

RE: Request for Other Funds Fee Establishment, Fee Increase and Fee Decrease

Hello,

Pursuant to ORS 291.055, the Oregon Board of Pharmacy (Board) formally requests to establish a new Other Funds fee of \$315 for the annual registration of mobile pharmacies. [2026 HB 4131](#) mandates that the Board issue a license to operate a mobile pharmacy to an applicant that is a retail drug outlet registered under ORS 689.305, if certain criteria are met. If the proposed annual registration fee of \$315 is permanently adopted by the Board during its December 2026 meeting, it would likely be filed with the Secretary of State on December 14, 2026, and become effective on January 1, 2027. Although the Board is unable to determine how many qualified retail drug outlets will apply to operate a mobile pharmacy, the agency estimates a small impact on revenue, which is reflected in the attached Form 107bf22.

The Oregon Health Authority informed the Board that the Workforce Data Collection Fee will increase by \$4, effective July 1, 2026. To comply with this mandate, the Board formally requests a corresponding \$4 increase to this Other Funds fee, which will raise the current rate from \$4 to \$8. The Board will consider adopting a temporary rule during its August 2026 meeting, to be effective upon filing. The estimated revenue impact for both the 2025-27 and 2027-29 budget cycles is detailed in the attached Form 107bf22.

The Board formally requests an Other Funds fee decrease regarding the Pharmacy Prescription Locker (PPL) registration. Because [2025 SB 236](#) mandates that PPLs are now considered part of their associated retail drug outlets, a separate license or registration is no longer required. The Board is actively repealing the \$168 annual fee from rule, with permanent adoption scheduled for December 2026 and an effective date of January 1, 2027. The agency has not collected this fee since the legislation passed in July 2025, at which time the application was removed from our website.

Sincerely,

Gary Runyon, Pharm.D., R.Ph.

Executive Director

Oregon Board of Pharmacy

Attachments: 107bf21, 107bf22

CC: Chelsey Herrmann-Nordness, Legislative Analyst, Legislative Fiscal Office

(Chelsey.Herrmann-Nordness@oregonlegislature.gov)

The Oregon Board of Pharmacy serves to promote and protect public health, safety, and welfare by ensuring high standards in the practice of pharmacy and through effective regulation of the manufacture and distribution of drugs.

FEE CHANGE DETAIL REPORT

This form and accompanying cover letter must be completed and submitted for three separate purposes:

- 1) Submitted to DAS with the Fee Approval Form (107bf21) when requesting DAS approval to change a fee administratively (Legislative Concept/Policy Package columns not relevant).
- 2) Submitted to DAS with a Legislative Concept, if that concept would increase a fee or asse (2025-2027 columns not relevant)
- 3) Submitted electronically to CFO analyst, at same time as Agency Request Budget, if budget includes a fee establishment, increase, or decrease (2025-27 columns not relevant).

See instructions on following page for more information.

Oregon Board of Pharmacy 2027–29 Agency Request Budget Page 60 of 61

BUDGET NARRATIVE — 2027–29

Fee Approval Form REQUEST FOR FEE INCREASE/ESTABLISHMENT/DECREASE	
PART 1 (State agencies: Complete when requesting authority to increase or establish fees administratively, or when notifying DAS of a fee decrease.) Agency Name: <u>Oregon Board of Pharmacy</u> Agency Number: <u>85500</u> Gary Runyon, Executive Director 971-673-0001 Rachel Melvin, Operations Manager 971-673-0001 (Name and phone number.) <u>800 NE Oregon St., Suite 150</u> (Address) <u>Portland, OR 97232</u> (City, State, Zip) Division/Program: _____ Contact: _____ Brief Description of Fee Change: Establishes new annual registration fee of \$315 for mobile pharmacies. 2026 HB 4131 mandates that the Board issue a license to operate a mobile pharmacy to qualified Retail Drug Outlets, therefore the Board must adopt a new registration type and establish a new fee.	Date received:
Check one: ☐ Fee Increase ☒ Fee Establishment ☐ Fee Decrease Statutory Authority for fee: <u>2026 HB 4131</u> Please check all statements that apply and provide the anticipated date(s) below: ☒ Date proposed rule(s), or rule(s) change, to be filed with the Secretary of State: <u>12/15/26</u> ☒ Anticipated rule adoption date: <u>During the December 9-11, 2026 board meeting</u> ☒ Date fee schedule becomes effective: <u>1/1/2027</u> ☐ Date of proposed E-Board Action: _____	
REQUIRED - Attach Form 107BF22 and cover letter, with information on each fee affected. (See instructions on back.)	
Approved: ☐ Denied: ☐ Date: ____/____/____ ☐ Reviewed by: _____ By: _____ Director, Department of Administrative Services	
PART 2 (State agencies: Complete following rule adoption or fee effective date.) Administrative Rule Reference: _____ Date rule adopted or fee effective: ____/____/____* Actual fee amount(s) adopted: _____ Authorized agency signature: _____ Date: ____/____/____	

BUDGET NARRATIVE — 2027–29

Fee Approval Form REQUEST FOR FEE INCREASE/ESTABLISHMENT/DECREASE	
PART 1 (State agencies: Complete when requesting authority to increase or establish fees administratively, or when notifying DAS of a fee decrease.) Agency Name: <u>Oregon Board of Pharmacy</u> Agency Number: <u>85500</u> Gary Runyon, Executive Director 971-673-0001 Rachel Melvin, Operations Manager 971-673-0001 (Name and phone number.) <u>800 NE Oregon St., Suite 150</u> (Address) <u>Portland, OR 97232</u> (City, State, Zip) Division/Program: _____ Contact: _____ Brief Description of Fee Change: Increases the existing Workforce Data Collection fee by \$4. The Oregon Health Authority filed rules effective 7/1/2026 to increase the current mandated \$4 fee to \$8. This applies to all licensees who renew their license.	Date received:
Check one: ☒ Fee Increase ☐ Fee Establishment ☐ Fee Decrease Statutory Authority for fee: <u>ORS 676.410</u>	
Please check all statements that apply and provide the anticipated date(s) below: ☒ Date proposed rule(s), or rule(s) change, to be filed with the Secretary of State: <u>8/14/2026</u>	
☒ Anticipated rule adoption date: <u>The Board will consider adopting a Temporary Rule during the 8/13/2026 board mtg</u>	
☒ Date fee schedule becomes effective: <u>Upon filing 8/14/2026</u>	
REQUIRED - Attach Form 107BF22 and cover letter, with information on each fee affected. (See instructions on back.)	
Approved: ☐ Denied: ☐ Date: ____/____/____ By: _____ Director, Department of Administrative Services ☐ Reviewed by: _____	
PART 2 (State agencies: Complete following rule adoption or fee effective date.) Administrative Rule Reference: _____ Date rule adopted or fee effective: ____/____/____* Actual fee amount(s) adopted: _____ Authorized agency signature: _____ Date: ____/____/____	

BUDGET NARRATIVE — 2027–29

Fee Approval Form REQUEST FOR FEE INCREASE/ESTABLISHMENT/DECREASE	
PART 1 (State agencies: Complete when requesting authority to increase or establish fees administratively, or when notifying DAS of a fee decrease.) Agency Name: <u>Oregon Board of Pharmacy</u> Agency Number: <u>85500</u> Gary Runyon, Executive Director 971-673-0001 Rachel Melvin, Operations Manager Division/Program: _____ Contact: <u>971-673-0001</u> (Name and phone number.) <u>800 NE Oregon St., Suite 150</u> (Address) <u>Portland, OR 97232</u> (City, State, Zip) Brief Description of Fee Change: Decreases current Pharmacy Prescription Locker (PPL) registration fee. The Board is currently in the process of permanently repealing the current fee of \$168 as required by the legislative mandates of 2025 SB 236.	Date received:
Check one: ☐ Fee Increase ☐ Fee Establishment ☒ Fee Decrease Statutory Authority for fee: <u>ORS 689.338</u>	
Please check all statements that apply and provide the anticipated date(s) below: ☒ Date proposed rule(s), or rule(s) change, to be filed with the Secretary of State: <u>12/2026</u>	
☒ Anticipated rule adoption date: <u>During the Board's December 2026 board meeting</u>	
☒ Date fee schedule becomes effective: <u>1/1/2027</u>	
REQUIRED - Attach Form 107BF22 and cover letter, with information on each fee affected. (See instructions on back.)	
Approved: ☐ Denied: ☐ Date: ____/____/____ By: _____ Director, Department of Administrative Services ☐ Reviewed by: _____	
PART 2 (State agencies: Complete following rule adoption or fee effective date.) Administrative Rule Reference: _____ Date rule adopted or fee effective: ____/____/____* Actual fee amount(s) adopted: _____ Authorized agency signature: _____ Date: ____/____/____	

BUDGET NARRATIVE — 2027–29

Detail of Fee, License, or Assessment Revenue Proposed for Increase

Detail of Fee, License, or Assessment Revenue Increase Proposed For Increase/Establishment						
Purpose or Type of Fee, License or Assessment	Who Pays	2025–27 Estimated Revenue	2027–29 Agency Request	2027–29 Governor's Budget	2027–29 Legislatively Adopted	Explanation
Mobile Pharmacy	Drug Outlets	\$ 1,260	\$ 10,080			Fee Establish Requested - \$315 ORS 689.305
Workforce Data Collection Fee	Pharmacist, Pharmacy Technicians	\$ 36,128	\$ 140,176			Fee Increase Requested - \$4 to \$8 ORS 676.410 / OAR 855-110-0005 / OAR 409-026-0130

2027–29

107BF08

BUDGET NARRATIVE — 2027–29

Detail of Lottery Funds, Other Funds, and Federal Funds Revenue

Source	Fund	ORBITS Revenue Acct	2023–25 Actual	2025–27 Leg Adopted	2025–27 Estimates	2027–29		
						Agency Requested	Governor's Budget	Legislatively Adopted
Animal Euthanasia	4360	205	\$3,225	\$4,830	\$4,410	\$4,830		
Certified Pharmacy Technician	4360	205	\$621,666	\$955,500	\$880,600	\$893,900		
Charitable Pharmacy	4360	205	\$900	\$1,260	\$630	\$840		
Community Health Clinic	4360	205	\$23,200	\$33,600	\$32,200	\$33,040		
Controlled Substance	4360	205	\$445,400	\$663,040	\$631,400	\$679,140		
Correctional Facility / Hospital Drug Room	4360	205	\$14,700	\$19,600	\$20,720	\$20,720		
Criminal Conviction Predetermination	4360	205	-	-	\$1,000	\$1,000		
Dispensing Practitioner Drug Outlet	4360	205	\$25,000	\$29,400	\$37,800	\$39,200		
Drug Distribution Agents	4360	205	\$432,150	\$ 594,720	\$577,920	\$637,258		
Interns	4360	205	\$69,350	\$100,800	\$72,800	\$77,000		
Manufacturers	4360	205	\$1,785,125	\$2,462,250	\$2,648,646	\$2,674,114		
Med Device/Equip/Gases-Class C	4360	205	\$83,450	\$121,380	\$116,424	\$118,850		
Mobile Pharmacy	4360	205	-	-	\$1,260	\$10,080		
Non-Prescript – Drug Outlet – Class A	4360	205	\$508,805	\$763,980	\$776,160	\$788,288		
Non-Prescript – Drug Outlet – Class D	4360	205	\$700	\$560	\$560	\$840		
Pharmacist	4360	205	\$2,487,752	\$3,426,500	\$3436,125	\$3,608,115		
Pharmacy Kiosk	4360	205	-	-\$840	\$672	-		
Pharmacy Locker	4360	205	-	-\$1,680	-	-		
Pharmacy Technician	4360	205	\$395,662	\$423,500	\$518,000	\$528,500		
Schedule 2 Precursor	4360	205	\$1,275	\$2,100	\$2,100	\$2,100		
Prophylactic/Contraceptive	4360	205	\$4,100	\$4,200	\$5,600	\$5,600		

BUDGET NARRATIVE — 2027–29

Remote Dispensing /Distribution/Pharmacy Kiosk	4360	205	\$1,210	\$1,344	\$2,352	\$2,352		
Remote Dispensing Site Pharmacy	4360	205	\$550	\$3,150	\$630	\$630		
Retail/Institutional Drug Outlet	4360	205	\$821,624	\$1,172,010	\$1,174,950	\$1,190,936		
Wholesalers	4360	505	\$1,088,250	\$1,528,800	\$1,666,061	\$1,600,316		
Delinquent Fees	4360	205	\$32,670	\$32,000	\$32,000	\$32,000		
Reciprocity	4360	205	\$71,950	\$85,000	\$75,000	\$85,000		
Score Transfer/NAPLEX	4360	505	\$16,700	\$32,500	\$17,500	\$18,000		
Civil Penalty	4360	605	\$232,473	\$182,000	\$182,000	\$182,000		
Interest Income	4360	975	\$452,817	\$504,000	\$504,000	\$508,500		
NSF	4360	975	\$1,890	\$1,750	\$1,750	\$1,750		
Misc Fees	4360	975	\$61,232	\$59,600	\$60,850	\$60,600		
Laws & Rules	4360	205	\$3,100	\$2,500	\$2,500	\$2,250		
Prescription Drug Monitoring Fee – transfer to OHA	4360	210	\$635,368	\$609,000	\$632,247	\$685,542		
Workforce Data Collection – Transfer to OHA	4360	210	\$64,793	\$78,560	\$103, 835	\$140,176		
Fingerprinting Fees – Transfer to OSP	4360	210	\$217,669	\$249,750	\$243,000	\$255,150		

2027–29

107BF07

BUDGET NARRATIVE — 2027–29

DETAIL OF LOTTERY FUNDS, OTHER FUNDS, AND FEDERAL FUNDS REVENUE

Pharmacy, Board of
2027-29 Biennium

Agency Number: 85500

Cross Reference Number: 85500-000-00-00-00000

Source	2023-25 Actuals	2025-27 Leg Adopted Budget	2025-27 Leg Approved Budget	2027-29 Agency Request Budget	2027-29 Governor's Budget	2027-29 Leg. Adopted Budget
Other Funds						
Business Lic and Fees	9,538,386	13,124,581	13,124,581	13,698,001	-	-
Non-business Lic. and Fees	282,461	330,930	330,930	402,526	-	-
Fines and Forfeitures	265,143	182,000	182,000	214,000	-	-
Interest Income	452,817	504,000	504,000	508,500	-	-
Other Revenues	66,222	63,850	63,850	64,600	-	-
Tsfr To Oregon Health Authority	(635,152)	(629,280)	(629,280)	(764,364)	-	-
Total Other Funds	\$9,969,877	\$13,576,081	\$13,576,081	\$14,123,263	-	-

____ Agency Request
2027-29 Biennium

____ Governor's Budget
Page _____

____ Legislatively Adopted
Detail of LF, OF, and FF Revenues - BPR012

BUDGET NARRATIVE — 2027–29

DETAIL OF LOTTERY FUNDS, OTHER FUNDS, AND FEDERAL FUNDS REVENUE

Pharmacy, Board of
2027-29 Biennium

Agency Number: 85500

Cross Reference Number: 85500-001-00-00-00000

Source	2023-25 Actuals	2025-27 Leg Adopted Budget	2025-27 Leg Approved Budget	2027-29 Agency Request Budget	2027-29 Governor's Budget	2027-29 Leg. Adopted Budget
Other Funds						
Business Lic and Fees	9,538,386	13,124,581	13,124,581	13,698,001	-	-
Non-business Lic. and Fees	282,461	330,930	330,930	402,526	-	-
Fines and Forfeitures	265,143	182,000	182,000	214,000	-	-
Interest Income	452,817	504,000	504,000	508,500	-	-
Other Revenues	66,222	63,850	63,850	64,600	-	-
Tsfr To Oregon Health Authority	(635,152)	(629,280)	(629,280)	(764,364)	-	-
Total Other Funds	\$9,969,877	\$13,576,081	\$13,576,081	\$14,123,263	-	-

____ Agency Request
2027-29 Biennium

____ Governor's Budget
Page _____

____ Legislatively Adopted
Detail of LF, OF, and FF Revenues - BPR012




PROGRAM UNITS


BUDGET NARRATIVE — 2027–29

Oregon Board of Pharmacy – Organizational Chart 2025–27

24 FTE (9 Board Member & 7 Public Health & Pharmacy Formulary Advisory Committee)




BUDGET NARRATIVE — 2027–29



PUBLIC HEALTH AND PHARMACY FORMULARY ADVISORY COMMITTEE
Established January 1, 2018

Members are appointed by the Governor to make recommendations to the Oregon Board of Pharmacy regarding pharmacist prescriptive authority

BUDGET NARRATIVE — 2027–29



PUBLIC HEALTH AND PHARMACY FORMULARY ADVISORY COMMITTEE
Established January 1, 2018

Members are appointed by the Governor to make recommendations to the Oregon Board of Pharmacy regarding pharmacist prescriptive authority

BUDGET NARRATIVE — 2027–29

PROGRAM UNIT

PROGRAM UNIT EXECUTIVE SUMMARY

10 Year Plan Outcome Areas Impacted by the Program


Primary Outcome Area:	Patient Safety
Secondary Outcome Area:	N/A
Program Contact:	Gary Runyon 971-673-0001

The following chart reflects the actual and estimated expenditures and licensee numbers for the Oregon Board of Pharmacy from 2013–2031.

The pharmacy profession is undergoing a rapid transformation driven by technological advancements—such as generative artificial intelligence, electronic health records, and telepharmacy—that are expanding access to care. There is an increased emphasis on preventive care and chronic disease management, and pharmacists are playing a growing role as healthcare providers, expanding their services well beyond their traditional role of dispensing medication. Furthermore, the aging population with complex medication regimens and the rising prevalence of chronic diseases have created a surge in demand for personalized medication management and patient education.

Because of these factors, the Board continues to see an increase in the number of licensees and registrants and anticipates significant future growth. The Board acknowledges these industry trends and incorporates these environmental factors into the development of the goals and actions outlined in the 2024–2029 Strategic Plan.

BUDGET NARRATIVE — 2027–29



BUDGET NARRATIVE — 2027–29

Program Overview

Operating under the statutory authority of ORS Chapter 689, the Board is budgeted and accounted for as a single program unit. The Oregon Legislature recognizes pharmacy as a healthcare profession requiring rigorous regulatory oversight. To fulfill this mandate, the Board safeguards the pharmaceutical supply chain. By ensuring only strictly regulated facilities and qualified individuals operate within the state, the Board maintains public confidence in Oregon's pharmacy practice.

Program Funding Request

The Board's budget request is an Other Funds budget limitation designed to support expanding workload and program needs for the 2027–2029 biennium. The request includes funding for the Current Service Level and two Policy Option Packages aimed at strategically aligning agency personnel with operational demands:

- **Policy Option Package 101: New Positions**
 - **Purpose:** This cost-neutral package proposes a strategic reallocation of staffing resources to increase frontline operational capacity. It abolishes one vacant Strategic Initiatives Manager position and utilizes the associated funds to establish one Office Specialist 2 and one Administrative Specialist 1 position.
 - **Desired Outcome:** By realigning these roles, the agency will reduce current backlogs in processing licensing applications and significantly improve responsiveness to public records requests, thereby enhancing customer service and overall operational efficiency.
- **Policy Option Package 102: Staffing Reclass**
 - **Purpose:** This cost-neutral package aligns personnel compensation with expanded operational responsibilities and oversight. It proposes upgrading one Operations and Policy Analyst 2 to Level 3, and one Compliance and Regulatory Manager 1 to Level 2.
 - **Desired Outcome:** These reclassifications ensure that agency leadership and specialized analysts are compensated appropriately for the increased complexity of their roles, particularly regarding compliance oversight and legislative interpretation, aiding in vital staff retention.

BUDGET NARRATIVE — 2027–29

Program Description

The Board executes its statutory mandate by enforcing strict standards for individual licensure, facility registration, and professional examinations, alongside conducting comprehensive investigations, routine inspections, and professional outreach.

As an Other Funds agency, costs are primarily driven by the personnel and operational resources necessary to maintain this statewide regulatory compliance. Major cost drivers include:

- **Personnel:** As the Board's largest expenditure, adequately staffing the licensure and compliance oversight of over 31,000 active licenses across 37 categories is critical to meeting statutory obligations, governor expectations, and strategic plan directives.
- **Attorney General:** Board counsel represents the second highest operational expenditure and is essential for the compliance, enforcement, and communications functions of the Board.
- **In-State Travel:** Ongoing statewide travel is required for pharmacy inspections and compliance investigations. Board members also travel from across Oregon to attend bimonthly meetings, which are typically held at the Portland State Office Building.
- **Administrative Initiatives:** Significant staff time and resources are dedicated to budget preparation, business continuity planning, workforce data collection, cybersecurity, administrative rulemaking, and public meeting logistics.
- **Legislative Mandates:** Recent biennia introduced heavy mandates impacting the scope of pharmacy practice, including expanded vaccination authorities, new prescribing abilities for opioid use disorder and emergency reversal medications, the regulation of unstaffed prescription lockers, and sweeping behavioral health accountability measures.

Program Justification and Link to 10-Year Outcome

The Primary Outcome Area is Patient Safety: Through the rigorous administration of the Oregon Pharmacy Act and the Oregon Controlled Substances Act, the ultimate priority of the Board is the safety of Oregonians. Every function outlined in the program description—from vetting out-of-state drug manufacturers to inspecting local retail pharmacies and reviewing disciplinary cases—works to ensure the Board successfully achieves its statutory mission to promote and protect public health, safety, and welfare.

BUDGET NARRATIVE — 2027–29

Program Performance

Compliance

The Compliance program is facing a sustained surge in case volume driven by rising public complaints, an increase in the number of drug outlets that require routine inspection, and a shift in access to care due to regional and nationwide pharmacy closures. We project this upward trajectory will persist as the pharmaceutical supply chain grows more complex and healthcare delivery models shift. Because investigating every complaint is a statutory mandate, this escalating workload demands significant time, specialized expertise, and analytical rigor from our Compliance staff to protect public health and uphold the integrity of the profession.

Licensing


The Board continues to receive over 200 new applications per month. The following is a list of the current active licenses and registrations by category. The chart is a graphic representation of the 37 different categories of licensure and registration issued by the Board and the percentage each represents. Each license and registration type is unique and requires all Board staff to understand the statutes and rules associated with each type.

Please see the KPMs in the Special Report tab to review performance metrics for both Compliance and Licensing programs. For this exercise, a rough estimate would be the 2027–29 ARB limitation request divided by the current number of licensees and registrants equals \$437.81 per service unit.

However, it is difficult to estimate the cost per service unit due to the many variables related to our programs. Not all licenses are alike and not all services the Board provides directly impact individual licenses or registrants.

BUDGET NARRATIVE — 2027–29

Licensure and Registration Categories



BUDGET NARRATIVE — 2027–29

Enabling Legislation/Program Authorization

The Board was established and received its authority and responsibility through a mandate of the Oregon Legislature, ORS Chapter 689, the Oregon Pharmacy Act. The Board received further authority and responsibility through ORS Chapter 475, the Oregon Controlled Substances Act.

Funding Streams

The Board is entirely Other Funded and receives revenue by fees charged to licensees, civil penalties, and a handful of administrative user fees authorized by ORS 689.135. No lottery or general funds are allotted to the Board.

Significant Proposed Program Changes from 2025–27

There are no significant proposed program changes for the 2027–29 biennium.

BUDGET NARRATIVE — 2027–29

Program Unit Narrative

The Board is budgeted and accounted for as a single program unit. To effectively manage its statewide regulatory responsibilities, the Board operates with 24 FTE staff organized into three functional departments:

1. **Licensing:** Manages applications, renewals, and background checks for over 31,000 licenses and registrations.
2. **Compliance:** Conducts statewide inspections, investigates complaints, and manages disciplinary and probation monitoring.
3. **Executive:** Directs day-to-day operations, strategic planning, rulemaking, and legislative engagement, while ensuring financial compliance, procurement, and records management.

BUDGET NARRATIVE — 2027–29

Packages

Pharmacy – 85500 ESSENTIAL PACKAGES

010 – Vacancy Factor and Non-ORPICS Personal Services

Package Description

This essential package includes vacancy savings position costs identified as salary adjustments in the 2027–29 biennium.

This package totals: \$18,360

022 – Phase-out

Package Description

This essential package includes budget adjustment resulting from a one-time program expenditure during the 2025–27 biennium.

This package totals: \$1,500,000

031- Standard Inflation

Package Description

This essential package consists of a standard general inflation for costs increases in Services and Supplies.

This package totals: \$305,674

060- Technical Adjustments

Package Description

This essential package includes a technical adjustment for DAS Price List item: Facilities Rental and Taxes.

This package totals: \$36,000

BUDGET NARRATIVE — 2027–29

Pharmacy - 85500

POLICY PACKAGES

- **Policy Option Package 101: New Positions**

- **Purpose:** This cost-neutral package proposes a strategic reallocation of staffing resources to increase frontline operational capacity. It abolishes one vacant Strategic Initiatives Manager position and utilizes the associated funds to establish one Office Specialist 2 and one Administrative Specialist 1 position.
- **Desired Outcome:** By realigning these roles, the agency will reduce current backlogs in processing licensing applications and significantly improve responsiveness to public records requests, thereby enhancing customer service and overall operational efficiency.

This package increases Personnel Services by **\$114,412**.


- **Policy Option Package 102: Staffing Reclass**

- **Purpose:** This cost-neutral package aligns personnel compensation with expanded operational responsibilities and oversight. It proposes upgrading one Operations and Policy Analyst 2 to a Level 3, and one Compliance and Regulatory Manager 1 to a Level 2.
- **Desired Outcome:** These reclassifications ensure that agency leadership and specialized analysts are compensated appropriately for the increased complexity of their roles, particularly regarding compliance oversight and legislative interpretation, aiding in vital staff retention.

This package increases Personnel Services by **\$36,166**.


BUDGET NARRATIVE — 2027–29

Compliance Case History



BUDGET NARRATIVE — 2027–29

Pharmacy Related Oregon Administrative Rule Changes Per Year



BUDGET NARRATIVE — 2027–29

How Achieved:

The approval of these policy option packages will allow the agency to strategically realign its workforce to meet expanded operational responsibilities and frontline capacity needs. By reallocating existing resources, the agency can operate at the service levels required to comply with legislative mandates, the Governor's expectations, and the Board's directives without requiring additional funding.

Staffing Impact and Revenue Source:

Staffing Impact: These packages propose a strategic restructuring of existing personnel allocations. Specifically, the action abolishes one vacant Strategic Initiatives Manager position to establish two new frontline roles (one Office Specialist 2 and one Administrative Specialist 1). Additionally, two existing positions will be reclassified to reflect their expanded oversight duties (upgrading one Operations and Policy Analyst 2 to a Level 3, and one Compliance and Regulatory Manager 1 to a Level 2).

Revenue Source: Both packages are strictly cost-neutral. They will be funded entirely through existing resources, salary savings, and vacancy savings, requiring no additional fee increases or legislative revenue allocations.

Quantifying Results:

With the approval of these policy option packages, the agency will be equipped to directly address current operational bottlenecks and maintain critical institutional expertise. The reallocation of frontline staff will reduce the current backlog in processing licensing applications and significantly improve the agency's responsiveness to public records requests, directly elevating overall customer service and operational efficiency.

Concurrently, the reclassification of specialized roles ensures that agency leadership and analysts are compensated appropriately for the increased complexity of their compliance and legislative oversight duties. Together, these strategic adjustments support long-term staff retention, maintain organizational stability, and allow the agency to successfully execute the directives outlined in the Strategic Plan, the DEIB Action Plan, the Affirmative Action Plan, and the Workforce and Succession Plan.

Revenue Source:

The revenue source is Other Funds, Agency 85500 State Board of Pharmacy.

Total Other Funds Request is \$150,578

BUDGET NARRATIVE — 2027–29

ESSENTIAL AND POLICY PACKAGE FISCAL IMPACT SUMMARY

Pharmacy, Board of
Pkg: 010 - Vacancy Factor and Non-ORPICS Personal Services

Cross Reference Name: Board of Pharmacy
Cross Reference Number: 85500-001-00-00-00000

Description	General Fund	Lottery Funds	Other Funds	Federal Funds	Nonlimited Other Funds	Nonlimited Federal Funds	All Funds
Personal Services							
Temporary Appointments	-	-	1,453	-	-	-	1,453
All Other Differential	-	-	10,567	-	-	-	10,567
Public Employees' Retire Cont	-	-	2,612	-	-	-	2,612
Social Security Taxes	-	-	920	-	-	-	920
Paid Family Medical Leave Insurance	-	-	42	-	-	-	42
Mass Transit Tax	-	-	2,766	-	-	-	2,766
Total Personal Services	-	-	\$18,360	-	-	-	\$18,360
Total Expenditures							
Total Expenditures	-	-	18,360	-	-	-	18,360
Total Expenditures	-	-	\$18,360	-	-	-	\$18,360
Ending Balance							
Ending Balance	-	-	(18,360)	-	-	-	(18,360)
Total Ending Balance	-	-	(\$18,360)	-	-	-	(\$18,360)

____ Agency Request
2027-29 Biennium

____ Governor's Budget
Page _____

____ Legislatively Adopted
Essential and Policy Package Fiscal Impact Summary - BPR013

BUDGET NARRATIVE — 2027–29

ESSENTIAL AND POLICY PACKAGE FISCAL IMPACT SUMMARY

Pharmacy, Board of
Pkg: 022 - Phase-out Pgm & One-time Costs

Cross Reference Name: Board of Pharmacy
Cross Reference Number: 85500-001-00-00-00000

<i>Description</i>	General Fund	Lottery Funds	Other Funds	Federal Funds	Nonlimited Other Funds	Nonlimited Federal Funds	All Funds
Services & Supplies							
IT Professional Services	-	-	(1,500,000)	-	-	-	(1,500,000)
Total Services & Supplies	-	-	(\$1,500,000)	-	-	-	(\$1,500,000)
Total Expenditures							
Total Expenditures	-	-	(1,500,000)	-	-	-	(1,500,000)
Total Expenditures	-	-	(\$1,500,000)	-	-	-	(\$1,500,000)
Ending Balance							
Ending Balance	-	-	1,500,000	-	-	-	1,500,000
Total Ending Balance	-	-	\$1,500,000	-	-	-	\$1,500,000

____ Agency Request
2027-29 Biennium

____ Governor's Budget
Page _____

____ Legislatively Adopted
Essential and Policy Package Fiscal Impact Summary - BPR013

BUDGET NARRATIVE — 2027–29

ESSENTIAL AND POLICY PACKAGE FISCAL IMPACT SUMMARY

Pharmacy, Board of
Pkg: 031 - Standard Inflation

Cross Reference Name: Board of Pharmacy
Cross Reference Number: 85500-001-00-00-00000

Description	General Fund	Lottery Funds	Other Funds	Federal Funds	Nonlimited Other Funds	Nonlimited Federal Funds	All Funds
Services & Supplies							
Instate Travel	-	-	6,109	-	-	-	6,109
Out of State Travel	-	-	906	-	-	-	906
Employee Training	-	-	1,517	-	-	-	1,517
Office Expenses	-	-	6,545	-	-	-	6,545
Telecommunications	-	-	3,484	-	-	-	3,484
State Gov. Service Charges	-	-	56,079	-	-	-	56,079
Data Processing	-	-	15,582	-	-	-	15,582
Publicity and Publications	-	-	1,619	-	-	-	1,619
Professional Services	-	-	48,470	-	-	-	48,470
IT Professional Services	-	-	16,804	-	-	-	16,804
Attorney General	-	-	86,599	-	-	-	86,599
Employee Recruitment and Develop	-	-	85	-	-	-	85
Dues and Subscriptions	-	-	337	-	-	-	337
Facilities Rental and Taxes	-	-	16,777	-	-	-	16,777
Facilities Maintenance	-	-	3	-	-	-	3
Medical Services and Supplies	-	-	64	-	-	-	64
Agency Program Related S and S	-	-	13,326	-	-	-	13,326
Other Services and Supplies	-	-	29,266	-	-	-	29,266
Expendable Prop 250 - 5000	-	-	431	-	-	-	431
IT Expendable Property	-	-	1,671	-	-	-	1,671
Total Services & Supplies	-	-	\$305,674	-	-	-	\$305,674

____ Agency Request
2027-29 Biennium

____ Governor's Budget
Page _____

____ Legislatively Adopted
Essential and Policy Package Fiscal Impact Summary - BPR013

BUDGET NARRATIVE — 2027–29

ESSENTIAL AND POLICY PACKAGE FISCAL IMPACT SUMMARY

Pharmacy, Board of
Pkg: 031 - Standard Inflation

Cross Reference Name: Board of Pharmacy
Cross Reference Number: 85500-001-00-00-00000

<i>Description</i>	General Fund	Lottery Funds	Other Funds	Federal Funds	Nonlimited Other Funds	Nonlimited Federal Funds	All Funds
Total Expenditures							
Total Expenditures	-	-	305,674	-	-	-	305,674
Total Expenditures	-	-	\$305,674	-	-	-	\$305,674
Ending Balance							
Ending Balance	-	-	(305,674)	-	-	-	(305,674)
Total Ending Balance	-	-	(\$305,674)	-	-	-	(\$305,674)

____ Agency Request
2027-29 Biennium

____ Governor's Budget
Page _____

____ Legislatively Adopted
Essential and Policy Package Fiscal Impact Summary - BPR013

BUDGET NARRATIVE — 2027–29

ESSENTIAL AND POLICY PACKAGE FISCAL IMPACT SUMMARY

Pharmacy, Board of
Pkg: 060 - Technical Adjustments

Cross Reference Name: Board of Pharmacy
Cross Reference Number: 85500-001-00-00-00000

<i>Description</i>	General Fund	Lottery Funds	Other Funds	Federal Funds	Nonlimited Other Funds	Nonlimited Federal Funds	All Funds
Services & Supplies							
Professional Services	-	-	(36,000)	-	-	-	(36,000)
Facilities Rental and Taxes	-	-	36,000	-	-	-	36,000
Total Services & Supplies	-	-	-	-	-	-	-
Total Expenditures							
Total Expenditures	-	-	-	-	-	-	-
Total Expenditures	-	-	-	-	-	-	-
Ending Balance							
Ending Balance	-	-	-	-	-	-	-
Total Ending Balance	-	-	-	-	-	-	-

____ Agency Request
2027-29 Biennium

____ Governor's Budget
Page _____

____ Legislatively Adopted
Essential and Policy Package Fiscal Impact Summary - BPR013

BUDGET NARRATIVE — 2027–29

ESSENTIAL AND POLICY PACKAGE FISCAL IMPACT SUMMARY

Pharmacy, Board of
Pkg: 101 - New Positions

Cross Reference Name: Board of Pharmacy
Cross Reference Number: 85500-001-00-00-00000

Description	General Fund	Lottery Funds	Other Funds	Federal Funds	Nonlimited Other Funds	Nonlimited Federal Funds	All Funds
Personal Services							
Class/Unclass Sal. and Per Diem	-	-	52,824	-	-	-	52,824
Empl. Rel. Bd. Assessments	-	-	79	-	-	-	79
Public Employees' Retire Cont	-	-	13,058	-	-	-	13,058
Social Security Taxes	-	-	4,041	-	-	-	4,041
Paid Family Medical Leave Insurance	-	-	212	-	-	-	212
Worker's Comp. Assess. (WCD)	-	-	38	-	-	-	38
Flexible Benefits	-	-	44,160	-	-	-	44,160
Total Personal Services	-	-	\$114,412	-	-	-	\$114,412
Services & Supplies							
IT Professional Services	-	-	(114,412)	-	-	-	(114,412)
Total Services & Supplies	-	-	(\$114,412)	-	-	-	(\$114,412)
Total Expenditures							
Total Expenditures	-	-	-	-	-	-	-
Total Expenditures	-	-	-	-	-	-	-
Ending Balance							
Ending Balance	-	-	-	-	-	-	-
Total Ending Balance	-	-	-	-	-	-	-

____ Agency Request
2027-29 Biennium

____ Governor's Budget
Page _____

____ Legislatively Adopted
Essential and Policy Package Fiscal Impact Summary - BPR013

BUDGET NARRATIVE — 2027–29

ESSENTIAL AND POLICY PACKAGE FISCAL IMPACT SUMMARY

Pharmacy, Board of
Pkg: 101 - New Positions

Cross Reference Name: Board of Pharmacy
Cross Reference Number: 85500-001-00-00-00000

<i>Description</i>	General Fund	Lottery Funds	Other Funds	Federal Funds	Nonlimited Other Funds	Nonlimited Federal Funds	All Funds
Total Positions							
Total Positions							1
Total Positions	-	-	-	-	-	-	1
Total FTE							
Total FTE							1.00
Total FTE	-	-	-	-	-	-	1.00

____ Agency Request
2027-29 Biennium

____ Governor's Budget
Page _____

____ Legislatively Adopted
Essential and Policy Package Fiscal Impact Summary - BPR013

BUDGET NARRATIVE — 2027–29

ESSENTIAL AND POLICY PACKAGE FISCAL IMPACT SUMMARY

Pharmacy, Board of
Pkg: 102 - Staffing Reclass

Cross Reference Name: Board of Pharmacy
Cross Reference Number: 85500-001-00-00-00000

Description	General Fund	Lottery Funds	Other Funds	Federal Funds	Nonlimited Other Funds	Nonlimited Federal Funds	All Funds
Personal Services							
Class/Unclass Sal. and Per Diem	-	-	27,240	-	-	-	27,240
Public Employees' Retire Cont	-	-	6,734	-	-	-	6,734
Social Security Taxes	-	-	2,083	-	-	-	2,083
Paid Family Medical Leave Insurance	-	-	109	-	-	-	109
Total Personal Services	-	-	\$36,166	-	-	-	\$36,166
Services & Supplies							
IT Professional Services	-	-	(36,166)	-	-	-	(36,166)
Total Services & Supplies	-	-	(\$36,166)	-	-	-	(\$36,166)
Total Expenditures							
Total Expenditures	-	-	-	-	-	-	-
Total Expenditures	-	-	-	-	-	-	-
Ending Balance							
Ending Balance	-	-	-	-	-	-	-
Total Ending Balance	-	-	-	-	-	-	-

____ Agency Request
2027-29 Biennium

____ Governor's Budget
Page _____

____ Legislatively Adopted
Essential and Policy Package Fiscal Impact Summary - BPR013

BUDGET NARRATIVE — 2027–29

Detail of Lottery Funds, Other Funds, and Federal Funds Revenue

Source	Fund	ORBITS Revenue Acct	2023-25 Actual	2025–27 Leg Adopted	2025–27 Estimates	2027–29		
						Agency Requested	Governor's Budget	Legislatively Adopted
Animal Euthanasia	4360	205	\$3,225	\$4,830	\$4,410	\$4,830		
Certified Pharmacy Technician	4360	205	\$621,666	\$955,500	\$880,600	\$893,900		
Charitable Pharmacy	4360	205	\$900	\$1,260	\$630	\$840		
Community Health Clinic	4360	205	\$23,200	\$33,600	\$32,200	\$33,040		
Controlled Substance	4360	205	\$445,400	\$663,040	\$631,400	\$679,140		
Correctional Facility / Hospital Drug Room	4360	205	\$14,700	\$19,600	\$20,720	\$20,720		
Criminal Conviction Predetermination	4360	205	-	-	\$1,000	\$1,000		
Dispensing Practitioner Drug Outlet	4360	205	\$25,000	\$29,400	\$37,800	\$39,200		
Drug Distribution Agents	4360	205	\$432,150	\$ 594,720	\$577,920	\$637,258		
Interns	4360	205	\$69,350	\$100,800	\$72,800	\$77,000		
Manufacturers	4360	205	\$1,785,125	\$2,462,250	\$2,648,646	\$2,674,114		
Med Device/Equip/Gases-Class C	4360	205	\$83,450	\$121,380	\$116,424	\$118,850		
Mobile Pharmacy	4360	205	-	-	\$1,260	\$10,080		
Non-Prescript – Drug Outlet – Class A	4360	205	\$508,805	\$763,980	\$776,160	\$788,288		
Non-Prescript – Drug Outlet – Class D	4360	205	\$700	\$560	\$560	\$840		
Pharmacist	4360	205	\$2,487,752	\$3,426,500	\$3436,125	\$3,608,115		
Pharmacy Kiosk	4360	205	-	-\$840	\$672	-		
Pharmacy Locker	4360	205	-	-\$1,680	-	-		
Pharmacy Technician	4360	205	\$395,662	\$423,500	\$518,000	\$528,500		
Schedule 2 Precursor	4360	205	\$1,275	\$2,100	\$2,100	\$2,100		
Prophylactic/Contraceptive	4360	205	\$4,100	\$4,200	\$5,600	\$5,600		

BUDGET NARRATIVE — 2027–29

Remote Dispensing /Distribution/Pharmacy Kiosk	4360	205	\$1,210	\$1,344	\$2,352	\$2,352		
Remote Dispensing Site Pharmacy	4360	205	\$550	\$3,150	\$630	\$630		
Retail/Institutional Drug Outlet	4360	205	\$821,624	\$1,172,010	\$1,174,950	\$1,190,936		
Wholesalers	4360	505	\$1,088,250	\$1,528,800	\$1,666,061	\$1,600,316		
Delinquent Fees	4360	205	\$32,670	\$32,000	\$32,000	\$32,000		
Reciprocity	4360	205	\$71,950	\$85,000	\$75,000	\$85,000		
Score Transfer/NAPLEX	4360	505	\$16,700	\$32,500	\$17,500	\$18,000		
Civil Penalty	4360	605	\$232,473	\$182,000	\$182,000	\$182,000		
Interest Income	4360	975	\$452,817	\$504,000	\$504,000	\$508,500		
NSF	4360	975	\$1,890	\$1,750	\$1,750	\$1,750		
Misc Fees	4360	975	\$61,232	\$59,600	\$60,850	\$60,600		
Laws & Rules	4360	205	\$3,100	\$2,500	\$2,500	\$2,250		
Prescription Drug Monitoring Fee – transfer to OHA	4360	210	\$635,368	\$609,000	\$632,247	\$685,542		
Workforce Data Collection – Transfer to OHA	4360	210	\$64,793	\$78,560	\$103, 835	\$140,176		
Fingerprinting Fees – Transfer to OSP	4360	210	\$217,669	\$249,750	\$243,000	\$255,150		

2027–29

107BF07

BUDGET NARRATIVE — 2027–29

POS116 - Net Package Fiscal Impact Report

2027-29 Biennium
Current Service Level

Position Number	Auth No	Workday Id	Classification	Classification Name	Sal Rng	Pos Type	Mos	Step	Rate	Salary	OPE	Total	Pos Cnt	FTE
No records for the phase: CSL														
General Funds										0	0	0		
Lottery Funds										0	0	0		
Other Funds										0	0	0		
Federal Funds										0	0	0		
Total Funds										0	0	0	0	0.00

BUDGET NARRATIVE — 2027–29

POS116 - Net Package Fiscal Impact Report

Board of Pharmacy

2027-29 Biennium

Cross Reference Number: 85500-001-00-00-00000

Agency Request Budget

Package Number: 101

Position Number	Auth No	Workday Id	Classification	Classification Name	Sal Rng	Pos Type	Mos	Step	Rate	Salary	OPE	Total	Pos Cnt	FTE
576	1001760	24514	MESN Z0119 A P	EXECUTIVE SUPPORT SPECIALIST 1	20	PF	0	7	6,275	-150,600	-93,628	-244,228	-1	-1.00
660	1450451		OAS C0103 A P	OFFICE SPECIALIST 1	13	PF	24	5	3,892	93,408	74,887	168,295	1	1.00
661	1450452		OAS C0107 A P	ADMINISTRATIVE SPECIALIST 1	17	PF	24	5	4,584	110,016	80,329	190,345	1	1.00
										0	0	0		
										0	0	0		
										52,824	61,588	114,412		
										0	0	0		
										52,824	61,588	114,412	1	1.00

07/09/26
8:43 AM

Page 1 of 2

POS116 - Net Package Fiscal Impact Report
POS116

BUDGET NARRATIVE — 2027–29

POS116 - Net Package Fiscal Impact Report

Board of Pharmacy

2027-29 Biennium

Cross Reference Number: 85500-001-00-00-00000

Agency Request Budget

Package Number: 102

Position Number	Auth No	Workday Id	Classification	Classification Name	Sal Rng	Pos Type	Mos	Step	Rate	Salary	OPE	Total	Pos Cnt	FTE
574	1001740	35409	MMS X7145 A P	COMPLIANCE AND REGULATORY M	31X	PF		10	11,756	0	0	0	0	0.00
574	1001740	35409	MMS X7144 A P	COMPLIANCE AND REGULATORY M	33X	PF		10	12,968	15,264	5,002	20,266	0	0.00
592	1001830	29466	MMN X0872 A P	OPERATIONS & POLICY ANALYST	30	PF		8	10,683	11,976	3,924	15,900	0	0.00
										0	0	0		
										0	0	0		
										27,240	8,926	36,166		
										0	0	0		
										27,240	8,926	36,166	0	0.00

07/09/26
8:43 AM

Page 2 of 2

POS116 - Net Package Fiscal Impact Report
POS116

BUDGET NARRATIVE — 2027–29

DETAIL OF LOTTERY FUNDS, OTHER FUNDS, AND FEDERAL FUNDS REVENUE

Pharmacy, Board of
2027-29 Biennium

Agency Number: 85500

Cross Reference Number: 85500-000-00-00-00000

Source	2023-25 Actuals	2025-27 Leg Adopted Budget	2025-27 Leg Approved Budget	2027-29 Agency Request Budget	2027-29 Governor's Budget	2027-29 Leg. Adopted Budget
Other Funds						
Business Lic and Fees	9,538,386	13,124,581	13,124,581	13,698,001	-	-
Non-business Lic. and Fees	282,461	330,930	330,930	402,526	-	-
Fines and Forfeitures	265,143	182,000	182,000	214,000	-	-
Interest Income	452,817	504,000	504,000	508,500	-	-
Other Revenues	66,222	63,850	63,850	64,600	-	-
Tsfr To Oregon Health Authority	(635,152)	(629,280)	(629,280)	(764,364)	-	-
Total Other Funds	\$9,969,877	\$13,576,081	\$13,576,081	\$14,123,263	-	-

____ Agency Request
2027-29 Biennium

____ Governor's Budget
Page _____

____ Legislatively Adopted
Detail of LF, OF, and FF Revenues - BPR012

BUDGET NARRATIVE — 2027–29

DETAIL OF LOTTERY FUNDS, OTHER FUNDS, AND FEDERAL FUNDS REVENUE

Pharmacy, Board of
2027-29 Biennium

Agency Number: 85500

Cross Reference Number: 85500-001-00-00-00000

Source	2023-25 Actuals	2025-27 Leg Adopted Budget	2025-27 Leg Approved Budget	2027-29 Agency Request Budget	2027-29 Governor's Budget	2027-29 Leg. Adopted Budget
Other Funds						
Business Lic and Fees	9,538,386	13,124,581	13,124,581	13,698,001	-	-
Non-business Lic. and Fees	282,461	330,930	330,930	402,526	-	-
Fines and Forfeitures	265,143	182,000	182,000	214,000	-	-
Interest Income	452,817	504,000	504,000	508,500	-	-
Other Revenues	66,222	63,850	63,850	64,600	-	-
Tsfr To Oregon Health Authority	(635,152)	(629,280)	(629,280)	(764,364)	-	-
Total Other Funds	\$9,969,877	\$13,576,081	\$13,576,081	\$14,123,263	-	-

____ Agency Request
2027-29 Biennium

____ Governor's Budget
Page _____

____ Legislatively Adopted
Detail of LF, OF, and FF Revenues - BPR012

PAGE LEFT INTENTIONALLY BLANK



SPECIAL REPORTS

BUDGET NARRATIVE — 2027–29

Annual Performance Progress Report (APPR)

The board has the following legislatively approved Key Performance Measures:

- Percent of inspected pharmacies that are in compliance annually
- Percent of individual and facility licensees that are issued within 30 days
- Percent of pharmacies inspected every two years
- Average number of days required to complete an investigation from complaint to board presentation
- Customer Service - Percent of customers rating their satisfaction with the agency's customer services as "good" or "excellent : Overall Customer Service, Timeliness, Accuracy, Helpfulness, Expertise, and Availability of Information."
- Board Best Practices – Percent of total best practices met by the board

The [2025 Annual Performance Progress Report](#) (APPR) which reflects data from reporting year 2025 is available on the board's website.

The [2024 APPR](#) and the [2023 APPR](#) are available on the board's website.

Oregon Board of Pharmacy

2027–2029 Affirmative Action Plan



BUDGET NARRATIVE — 2027–29



Oregon

Tina Kotek, Governor

Oregon Board of Pharmacy

800 NE Oregon St., Suite 150

Portland, OR, 97232

Phone: 971-673-0001

Fax: 971-673-0002

pharmacy.licensing@bop.oregon.gov

www.oregon.gov/pharmacy

The Oregon Board of Pharmacy (Board) prioritizes building a more inclusive and diverse workforce to better serve Oregonians, by recruiting, developing, and retaining high-performing staff. The Board is also committed to and aligned with Governor Kotek's priorities on enhanced education, responsible governance, elevated customer service, and advanced public safety.

The Board's Affirmative Action Plan represents both an unwavering commitment to diversity, equity, inclusion, and belonging (DEIB) initiatives, and dedication to serving Oregonians through equal opportunity and Affirmative Action in employment and public service in compliance with all applicable federal and state laws, including, but not limited to: Executive Order 11246; Title VII of the Civil Rights Act of 1964; Sections 503 and 504 of the Rehabilitation Act of 1974; the Vietnam Era Veterans Readjustment Assistance Act; and the Americans with Disabilities Act. This Affirmative Action Plan has my complete support and commitment.

Gary Runyon, Pharm.D., R.Ph.

Executive Director

Oregon Board of Pharmacy

(971) 673-0001

The Oregon Board of Pharmacy serves to promote and protect public health, safety, and welfare by ensuring high standards in the practice of pharmacy and through effective regulation of the manufacture and distribution of drugs.

BUDGET NARRATIVE — 2027–29

[Table of Contents](#)

Introduction	2
Agency Overview	
Agency Mission, Vision, Values, and Equity Statement	
Key Employees	
Organizational Chart	
Agency Affirmative Action Policy	
Roles for Implementation of the Affirmative Action Plan	8
2025–2027 Affirmative Action Plan Progress Report	10
Progress in Recruitment	
Progress in Retention	
Alignment of the Affirmative Action Plan with the Strategic Plan	
Staff Promotions	
Other Accomplishments	
2027–2029 Affirmative Action Plan Goals	12
Progress in Recruitment	
Recruitment	
Employee Engagement	
Employee Surveys	
Complaint Avenues	13
Succession Plan	13
Contracting and Appendix	14
State Policy Documents	
Federal Employment Law Documents	



Introduction

Agency Overview

The Oregon Board of Pharmacy (Board) was created by the Oregon State Legislature in 1891. Today, the Board consists of nine members: five licensed pharmacists, two licensed pharmacy technicians, and two representatives of the public. The governor appoints each Board member for a four-year term, subject to approval by the State Senate, and they may be reappointed.

The Board is headquartered in Portland, Oregon, and currently consists of 24 dedicated staff members. In addition to supporting the Board, staff provide services across the following departments:

- **The Licensing Department**—manages more than 31,000 active licenses and registrations across 33 different categories for individuals and drug outlets. This team processes all applications for initial licensure and renewals. Their comprehensive workflow also includes providing technical assistance, conducting continuing education audits, performing primary source verification, and processing criminal background checks.
- **The Compliance Department**—conducts pharmacy inspections and investigates alleged violations of laws and rules. This team drafts disciplinary actions, monitors licensees and registrants on probation, responds to public inquiries, and provides educational outreach. Furthermore, they collaborate closely with federal agencies, the Department of Justice, and the Office of Administrative Hearings to ensure patient safety.
- **The Executive Department**—guides day-to-day operations, legislation, and communications, and is responsible for drafting, implementing, and tracking key plans (e.g., Strategic, Affirmative Action, DEIB, and Succession Plans). Additionally, this team ensures agency compliance with state standards for financial management, procurement, and contracts, while managing public record requests, records retention, and overall office operations.

Agency Mission, Vision, Values, and Equity Statement

Mission: The Oregon Board of Pharmacy serves to promote and protect public health, safety, and welfare by ensuring high standards in the practice of pharmacy and through effective regulation of the manufacture and distribution of drugs.

BUDGET NARRATIVE — 2027–29



Vision: All Oregonians have equitable access to medication and pharmacy services, provided safely and conveniently, through a network of highly skilled and dedicated Pharmacists, Interns, and Pharmacy Technicians along with a well-regulated manufacturing and distribution network.

Values: These values direct how Board members and staff strive to conduct ourselves and reflect what we seek to instill across pharmacy practice in Oregon:

- **Equity**—Each individual and group are valued, respected, and treated fairly, ensuring equal access to medications and support for their unique and diverse requirements.
- **Service**—We deliver a consistent standard of excellence in all work and respond promptly to the needs of patients, licensees, registrants, providers, and partners.
- **Safety**—We are committed to protecting the health, safety, and welfare of the public. Safety is the foundation of the Board's mission.
- **Adaptability**—We are open to new ideas and to responding to the changing needs and challenges in the field of healthcare and pharmacy.
- **Integrity and Accountability**—Transparency and honesty govern the Board's work. We accept responsibility for our actions, products, decisions, and policies.
- **Professionalism**—We are committed to promoting excellence in pharmacy practice through expertise, commitment, and competence.

Equity Statement: The Oregon Board of Pharmacy is committed to diversity, equity, inclusion, and belonging (DEIB) within its organization and for the public it serves. This commitment is reflected in board membership, agency staffing, the services provided, and its efforts to promote patient safety and ensure access to quality pharmacy care. Our actions, outlined in our DEIB and Affirmative Action Plans, demonstrate this commitment. The following principles guide our approach:

- Promote a welcoming, safe, and inclusive culture for people of all backgrounds.
- Foster an inclusive environment where all current and prospective licensees and registrants receive fair and unbiased service from the agency staff and Board.
- Advance diversity and equity in access through culturally responsive service that addresses the changing climate within the pharmacy profession.
- Ensure all patients needing pharmacy services can receive safe and timely access to medications, regardless of place of residence, socioeconomic status, physical ability, ethnicity, or gender identity.

BUDGET NARRATIVE — 2027–29

Key Employees

Executive Director

Gary Runyon, Pharm.D., R.Ph.
OBOP Executive Director
Pharmacy.board@bop.oregon.gov
(971) 673-0001

Governor's Policy Advisor

Kristina Narayan
Senior Health Advisor
Kristina.narayan@oregon.gov

Equity Leader

Laura Sonoiki
Strategic Initiatives Manager
Laura.sonoiki@bop.oregon.gov
(971) 673-0001

Lead for Certification Office for Business Inclusion and Diversity Contracting and Procurement

Naomi Graham
Office Manager
Naomi.graham@bop.oregon.gov
(971) 673-0001

Affirmative Action Representatives


Naomi Graham
Office Manager
Naomi.graham@bop.oregon.gov
(971) 673-0001

Laura Sonoiki
Strategic Initiatives Manager
Laura.sonoiki@bop.oregon.gov
(971) 673-0001

Rebecca Avila
DAS Client Agency Human Resources Manager
Rebecca.avila@das.oregon.gov
(971) 301-0110

BUDGET NARRATIVE — 2027–29


Organizational Chart (July 2026)



BUDGET NARRATIVE — 2027–29

PUBLIC HEALTH AND PHARMACY FORMULARY ADVISORY COMMITTEE Established January 1, 2018

Members are appointed by the Governor to make recommendations to the Oregon Board of Pharmacy regarding pharmacist prescriptive authority



BUDGET NARRATIVE — 2027–29

Agency Affirmative Action Policy

Policy Statement: All Board members and staff must adhere to the Affirmative Action Plan and Policy. In accordance with Oregon Revised Statutes (ORS) 659A.012–659A.015, the Board actively enforces policies against discrimination in employment. As an equal-opportunity employer, we are committed to proactive recruitment and selection practices that eliminate barriers, allowing all individuals to attain employment and advancement regardless of an individual's race, religion, color, gender, sexual orientation, marital status, national origin, age, or disability.

Workplace Environment: Our goal is to cultivate a professional workplace that is diverse, and free of discrimination and harassment for employees.

Training and Development: We are committed to providing broad and culturally enriched training and developmental opportunities to all employees on an equal basis. These initiatives enable Board members and staff to further advance their knowledge, skills, and abilities while deepening their appreciation for diversity.

Roles, Responsibilities, and Reporting: The roles and responsibilities related to Affirmative Action are outlined for all staff in this plan, guided by the principles in the Board's equity statement (see page 5).

- **Accessibility:** This plan is posted on the Board's website and in the Executive Director's office. All newly appointed Board and committee members, employees, and contracted vendors are provided with a link to the plan.

Reporting: Board staff are provided with contact information and available resources, and are encouraged to bring all complaints to the attention of the Executive Director or alternate designee, in accordance with ORS Chapter 659A. The current agency designated individuals are:

- Rebecca Avila, DAS Client Agency Human Resources Manager
- Gary Runyon, Pharm.D., R.Ph., OBOP Executive Director



Roles for Implementation of the Affirmative Action Plan

Executive Director:

- **DEIB Communication:** Regularly communicate the importance of a discrimination-free, diverse, and harassment-free workplace. Lead by example by participating in cultural diversity training sessions and orientations.
- **Human Resources Partnership:** Schedule and conduct frequent meetings with the Human Resources Manager to review equal employment opportunities, evaluate affirmative action and diversity progress, and identify issues.

Accountability: In compliance with ORS 659A.012, the Executive Director's biannual evaluation incorporates a comprehensive review of their effectiveness in achieving the affirmative action objectives outlined in this plan.

Manager Accountability: Hold managers accountable for participating in and promoting affirmative action activities. Ensure they communicate this responsibility to their staff.

Managers and Supervisors:

- **DEIB Communication:** Encourage and promote a discrimination-free, diverse, and harassment-free workplace. Support affirmative action goals and objectives. Ensure staff are knowledgeable about the Board's inclusive work environment policies and procedures.
- **Filling Vacancies:** Train managers to have diverse interview panels, including, when possible, at least one member who works outside the hiring department and at least one member from a protected class.
- **Skill-building:** Enhance the skills of Board staff through mentorship, job rotations, and training to prepare them for higher-level positions internally and externally with the State.
- **Internal Harassment:** Act promptly to address and/or report any harassment incidents within the Board.
- **Accountability:** Evaluate managers and supervisors on their effectiveness in implementing DEIB principles during quarterly Performance Accountability and Feedback (PAF) check-ins. Consistent with the statewide PAF model, demonstrating a commitment to equity and inclusive organizational change is a mandatory performance expectation.

BUDGET NARRATIVE — 2027–29



Affirmative Action Representatives:

- **DEIB Engagement:** Collaborate with the Executive Director, managers and supervisors, and committees to promote a diverse workforce and an inclusive work environment. Display the Board's Affirmative Action Policy Statement in the office.
- **Plan Updates:** Amend the Affirmative Action Plan on a biennial basis.
- **Policy and Plan:** Disseminate the Board's Affirmative Action Policy Plan to staff and provide a link to job applicants before each in-person interview.
- **Report Progress:** Report on the Affirmative Action Plan activity progress to the Executive Director and to staff at meetings.

Board Staff:

- **Orientation:** During orientation, all new staff receive information about their rights and responsibilities under the Board's Affirmative Action Plan.
- **DEIB Resources:** Staff are encouraged to read resources about DEIB sent by the Executive Director and the Affirmative Action Representatives.
- **Accountability:** Staff will be evaluated on their ability to apply equity practices in their day-to-day duties during their quarterly check-ins.

Board Members:

- **Onboarding:** While onboarding, all new Board members receive information outlining their rights and responsibilities under the Board's Affirmative Action Plan.
- **Plan Review:** Support the Affirmative Action Plan development by reviewing amended versions every biennium.
- **Meeting Agendas:** Include the mission, vision, values, and equity statement on all Board meeting agendas.

2025–2027 Affirmative Action Plan Progress Report

Progress in Recruitment: The Board underwent an extensive overhaul of hiring practices in partnership with the Executive Director, the Office of Cultural Change, Human Resources, and hiring managers. During this process, the Board developed a robust recruitment toolkit to create process consistency and incorporate DEIB principles, enhancing accessibility and increasing fairness throughout the interview process. Key changes to recruitment include:

- Development of a comprehensive recruitment plan that clearly identifies each step and action items to be used by all staff.
- Inclusion of DEIB language in job listings.
- Identification of additional sources (e.g., the Urban League of Portland and the Coalition of Communities of Color) for posting job listings to reach out to historically excluded groups.
- Continuation of using VidCruiter for first-round structured interviews to promote both accessibility and equity in the interview process.

Utilization of the new recruitment toolkit to fill four vacant positions, resulting in the expansion of staff skill sets and the advancement of workplace diversity through the hiring of individuals from protected classes.

Progress in Retention: The Board has engaged in a multi-step process to understand its current workforce culture. Understanding that employee morale and retention are indicators of culture, the Board created the Employee Engagement Committee, DEIB Champions Committee, and the Leadership Development Committee.

- **DEIB Champions Committee:** Identified key DEIB actions for staff, licensees, and other interested parties to create an actionable DEIB Plan.
- **Employee Engagement Committee:** Presented team-building exercise ideas to the managers and supervisors for quarterly all-staff meetings, including utilizing Canopy to present personal well-being and employee resources.
- **Leadership Development Committee:** Enrolled all staff in a high-performance leadership training program containing four courses regarding effective change, communication, and top-performing teams.

BUDGET NARRATIVE — 2027–29

Alignment of the Affirmative Action Plan with the Strategic Plan: The Board’s Strategic Plan integrates ongoing DEIB and Affirmative Action work with future goals, while addressing internal needs. Key actions included:

- Analyzing staff capacity, budget, and organizational culture to ensure they align with the Board’s workload and core values.
- Executing a succession and development plan to promote personal and professional growth among staff, thereby preventing operational gaps caused by unnecessary turnover.
- Realigning staff roles and responsibilities as needed to meet key performance measures, advance staff diversity, foster morale, and achieve core goals.

Staff Promotions: No promotions to either supervisory or non-supervisory roles by racial category or gender were made as of June 30, 2026.

Other Accomplishments:

- Hired the Strategic Initiatives Manager to lead the planning, execution, and tracking of the Strategic, DEIB, and Affirmative Action Plans, ensuring the agency meets its goals and deadlines. This position developed the Affirmative Action Plan, managed its subsequent updates, and implemented strategic initiatives informed by both internal and external perspectives. Additionally, the manager created and delivered key components of both the Affirmative Action and DEIB Plans.
- Implemented quarterly all-staff meetings to cultivate belonging, deliver high-level updates, and foster continuous learning. These sessions feature subject matter experts from key state partners—including the Governor’s Office, DAS, and Human Resources—while providing a dedicated forum for the Executive Director to answer staff questions directly and ensure ongoing transparency.
- Provided outreach and education to schools and colleges of pharmacy four to six times each year.
- The Board President included the equity statement at all public meetings, following adoption of the 2024–2029 Strategic Plan.
- Enhanced quarterly staff check-ins to discuss DEIB practices and operationalizing equity in day-to-day duties
- Managers and supervisors attended trauma-informed care trainings.



2027–2029 Affirmative Action Plan Goals

Recruitment:

- **Goal:** Increase diversity in recruitment.
- **Action:** Require all hiring managers to utilize the standardized recruitment toolkit and bias-interrupter frameworks during the screening process.
- **Measures:**
 - Drive a year-over-year increase in partnerships with community organizations that serve underrepresented groups (e.g., the Urban League of Portland and the Asian Pacific American Network of Oregon) to diversify agency recruitment by the end of the biennium.
 - Include cross-departmental representation in all interview panels and external representation from other state agencies where appropriate.
- **Implementation:** Managers and supervisors will incorporate this affirmative action principle into the hiring process, in partnership with Human Resources and the Affirmative Action Representatives.

Employee Engagement:

- **Goal:** Deepen staff engagement by offering biannual training sessions and educational materials (such as books, worksheets, and online exercises) that incorporate affirmative action and DEIB principles, deliberately looking outside the agency and standard DAS enterprise for novel, emerging, and impactful resources.

Actions: Actively identify, procure, and facilitate these externally-sourced trainings and educational materials while encouraging staff participation.

Measures: Achieve at least an 80% staff engagement rate with these biannual trainings and educational materials.

Implementation: Affirmative Action Representatives will evaluate and procure these external resources, coordinate the biannual engagements, and track staff participation metrics.

BUDGET NARRATIVE — 2027–29



Employee Surveys:

Goal: Utilize qualitative employee feedback to continuously improve culture, belonging, and retention.

Actions: Offer a standardized exit survey for departing employees, and implement annual stay interviews to assess workplace inclusion and belonging, psychological safety, and equitable opportunities.

Measures: Achieve a 100% offering rate for staff exit surveys and annual stay interviews.

Implementation: Human Resources will administer the exit surveys. The Executive Director will conduct annual stay interviews, compile anonymized themes, and present an annual briefing to guide future DEIB initiatives.

Complaint Avenues

The Board has several options for filing complaints regarding discrimination, harassment, and/or retaliation, including:

- Utilizing collective bargaining grievance procedures.
- Registering a complaint with BOLI's Civil Rights Division.
- Submitting a complaint with the Federal Equal Employment Opportunity Commission.
- Filing a civil suit in State Circuit Court or Federal District Court.

Succession Plan

The Board's Succession Plan proactively forecasts workforce needs by identifying critical roles and building essential competencies before vacancies occur. Integrated directly into the agency's strategic and budget planning, the plan drives targeted recruitment, continuous staff development, and organizational realignment to advance Board goals.

BUDGET NARRATIVE — 2027–29

Contracting

While the Board maintains a streamlined procurement footprint, it strictly adheres to the Oregon Procurement Manual and prioritizes inclusive purchasing. Staff actively leverage OregonBuys and the Certification Office for Business Inclusion and Diversity (COBID) database to source certified businesses. Consequently, during the 2024–2026 biennium, the Board successfully advanced its diversity goals by contracting with Oregon Forward vendors and certified firms, including TVW Inc., the Western Idaho Training Company Inc., and Barbier Inc.

Appendix

State Policy Documents:


- [Statewide Diversity, Equity, and Inclusion Action Plan](#)
- [Executive Order 22-11](#)
- [ADA and Reasonable Accommodation Policy \(Statewide Policy 50.020.10\)](#)
- [Discrimination and Harassment Free Workplace \(Statewide Policy No. 50.010.01\)](#)
- [Equal Opportunity and Affirmative Action Rule \(OAR 105-040-0001\)](#)
- [Affirmative Action Plan Guide](#)

Federal Employment Law Documents:

- [Age Discrimination in Employment Act of 1967 \(ADEA\)](#)
- [Disability Discrimination Title I of the Americans with Disability Act of 1990](#)
- [Title VII of the Civil Rights Act of 1964](#)


BUDGET NARRATIVE — 2027–29

Oregon Board of Pharmacy – 2026 Active Licensees Demographics - Ethnicity & Race



BUDGET NARRATIVE — 2027–29

Oregon Board of Pharmacy – 2026 Bi-Lingual Information – Active Licensees



BUDGET NARRATIVE — 2027–29

Pharmacy, Board of

Summary Cross Reference Listing and Packages
2027-29 Biennium

Agency Number: 85500
BAM Analyst: Patton, Jealinda
Budget Coordinator: Moreland, Katy

Cross Reference Number	Cross Reference Description	Package Number	Priority	Package Description	Package Group
001-00-00-00000	Board of Pharmacy	010	0	Vacancy Factor and Non-ORPICS Personal Services	Essential Packages
001-00-00-00000	Board of Pharmacy	021	0	Phase-in	Essential Packages
001-00-00-00000	Board of Pharmacy	022	0	Phase-out Pgm & One-time Costs	Essential Packages
001-00-00-00000	Board of Pharmacy	031	0	Standard Inflation	Essential Packages
001-00-00-00000	Board of Pharmacy	032	0	Above Standard Inflation	Essential Packages
001-00-00-00000	Board of Pharmacy	033	0	Exceptional Inflation	Essential Packages
001-00-00-00000	Board of Pharmacy	040	0	Mandated Caseload	Essential Packages
001-00-00-00000	Board of Pharmacy	050	0	Fundshifts	Essential Packages
001-00-00-00000	Board of Pharmacy	060	0	Technical Adjustments	Essential Packages
001-00-00-00000	Board of Pharmacy	070	0	Revenue Shortfalls	Policy Packages
001-00-00-00000	Board of Pharmacy	081	0	June 2026 Emergency Board	Policy Packages
001-00-00-00000	Board of Pharmacy	101	0	New Positions	Policy Packages
001-00-00-00000	Board of Pharmacy	102	0	Staffing Reclass	Policy Packages
999-00-00-00000	Suspense	010	0	Vacancy Factor and Non-ORPICS Personal Services	Essential Packages
999-00-00-00000	Suspense	021	0	Phase-in	Essential Packages
999-00-00-00000	Suspense	022	0	Phase-out Pgm & One-time Costs	Essential Packages
999-00-00-00000	Suspense	031	0	Standard Inflation	Essential Packages
999-00-00-00000	Suspense	032	0	Above Standard Inflation	Essential Packages
999-00-00-00000	Suspense	033	0	Exceptional Inflation	Essential Packages
999-00-00-00000	Suspense	040	0	Mandated Caseload	Essential Packages
999-00-00-00000	Suspense	050	0	Fundshifts	Essential Packages
999-00-00-00000	Suspense	060	0	Technical Adjustments	Essential Packages

07/08/26
9:44 PM

Page 1 of 2

Summary Cross Reference Listing and Packages
BSU-003A

BUDGET NARRATIVE — 2027–29

Pharmacy, Board of

Summary Cross Reference Listing and Packages

2027-29 Biennium

Agency Number: 85500

BAM Analyst: Patton, Jealinda

Budget Coordinator: Moreland, Katy

<i>Cross Reference Number</i>	<i>Cross Reference Description</i>	<i>Package Number</i>	<i>Priority</i>	<i>Package Description</i>	<i>Package Group</i>
999-00-00-00000	Suspense	070	0	Revenue Shortfalls	Policy Packages
999-00-00-00000	Suspense	081	0	June 2026 Emergency Board	Policy Packages

07/08/26
9:44 PM

Page 2 of 2

Summary Cross Reference Listing and Packages
BSU-003A

BUDGET NARRATIVE — 2027–29

Pharmacy, Board of

Policy Package List by Priority
2027-29 Biennium

Agency Number: 85500

BAM Analyst: Patton, Jealinda

Budget Coordinator: Moreland, Katy

<i>Priority</i>	<i>Policy Pkg Number</i>	<i>Policy Pkg Description</i>	<i>Summary Cross Reference Number</i>	<i>Cross Reference Description</i>
0	070	Revenue Shortfalls	001-00-00-00000	Board of Pharmacy
			999-00-00-00000	Suspense
	081	June 2026 Emergency Board	001-00-00-00000	Board of Pharmacy
			999-00-00-00000	Suspense
	101	New Positions	001-00-00-00000	Board of Pharmacy
	102	Staffing Reclass	001-00-00-00000	Board of Pharmacy

07/08/26
9:45 PM

Page 1 of 1

Policy Package List by Priority
BSU-004A

BUDGET NARRATIVE — 2027–29

Pharmacy, Board of

Agency Number: 85500

Agency Worksheet - Revenues & Expenditures
2027-29 Biennium
Pharmacy, Board Of

Version: V - 01 - Agency Request Budget
Cross Reference Number: 85500-000-00-00-00000

DESCRIPTION	2023-25 Actuals	2025-27 Leg Adopted Budget	2025-27 Emergency Boards	2025-27 Leg Approved Budget	2027-29 Base Budget	2027-29 Current Service Level
BEGINNING BALANCE						
0025 Beginning Balance						
3400 Other Funds Ltd	4,819,712	2,848,229	-	2,848,229	4,675,273	4,675,273
0030 Beginning Balance Adjustment						
3400 Other Funds Ltd	-	976,052	-	976,052	-	-
TOTAL BEGINNING BALANCE						
3400 Other Funds Ltd	4,819,712	3,824,281	-	3,824,281	4,675,273	4,675,273
TOTAL BEGINNING BALANCE	\$4,819,712	\$3,824,281	-	\$3,824,281	\$4,675,273	\$4,675,273
REVENUE CATEGORIES						
LICENSES AND FEES						
0205 Business Lic and Fees						
3400 Other Funds Ltd	9,538,386	13,124,581	-	13,124,581	13,698,001	13,698,001
0210 Non-business Lic. and Fees						
3400 Other Funds Ltd	282,461	330,930	-	330,930	402,526	402,526
TOTAL LICENSES AND FEES						
3400 Other Funds Ltd	9,820,847	13,455,511	-	13,455,511	14,100,527	14,100,527
TOTAL LICENSES AND FEES	\$9,820,847	\$13,455,511	-	\$13,455,511	\$14,100,527	\$14,100,527
FINES, RENTS AND ROYALTIES						
0505 Fines and Forfeitures						
3400 Other Funds Ltd	265,143	182,000	-	182,000	214,000	214,000
07/08/26 9:45 PM	Page 1 of 14			BDV001A - Agency Worksheet - Revenues & Expenditures BDV001A		

BUDGET NARRATIVE — 2027–29

Pharmacy, Board of

Agency Number: 85500

**Agency Worksheet - Revenues & Expenditures
2027-29 Biennium
Pharmacy, Board Of**

**Version: V - 01 - Agency Request Budget
Cross Reference Number: 85500-000-00-00-00000**

<i>DESCRIPTION</i>	<i>2023-25 Actuals</i>	<i>2025-27 Leg Adopted Budget</i>	<i>2025-27 Emergency Boards</i>	<i>2025-27 Leg Approved Budget</i>	<i>2027-29 Base Budget</i>	<i>2027-29 Current Service Level</i>
INTEREST EARNINGS						
0605 Interest Income						
3400 Other Funds Ltd	452,817	504,000	-	504,000	508,500	508,500
OTHER						
0975 Other Revenues						
3400 Other Funds Ltd	66,222	63,850	-	63,850	64,600	64,600
REVENUES						
3400 Other Funds Ltd	10,605,029	14,205,361	-	14,205,361	14,887,627	14,887,627
TRANSFERS OUT						
2443 Tsfr To Oregon Health Authority						
3400 Other Funds Ltd	(635,152)	(629,280)	-	(629,280)	(764,364)	(764,364)
AVAILABLE REVENUES						
3400 Other Funds Ltd	14,789,589	17,400,362	-	17,400,362	18,798,536	18,798,536
EXPENDITURES						
PERSONAL SERVICES						
SALARIES & WAGES						
3110 Class/Unclass Sal. and Per Diem						
3400 Other Funds Ltd	4,668,758	5,603,420	308,094	5,911,514	6,022,796	6,022,796
3115 Board Member Stipend						
3400 Other Funds Ltd	63,267	90,426	-	90,426	90,426	90,426
3160 Temporary Appointments						

07/08/26
9:45 PM

Page 2 of 14

BDV001A - Agency Worksheet - Revenues & Expenditures
BDV001A

BUDGET NARRATIVE — 2027–29

Pharmacy, Board of

Agency Number: 85500

Agency Worksheet - Revenues & Expenditures
2027-29 Biennium
Pharmacy, Board Of

Version: V - 01 - Agency Request Budget
Cross Reference Number: 85500-000-00-00-00000

DESCRIPTION	2023-25 Actuals	2025-27 Leg Adopted Budget	2025-27 Emergency Boards	2025-27 Leg Approved Budget	2027-29 Base Budget	2027-29 Current Service Level
3400 Other Funds Ltd	1,748	29,648	-	29,648	29,648	31,101
3170 Overtime Payments						
3400 Other Funds Ltd	4,892	-	-	-	-	-
3190 All Other Differential						
3400 Other Funds Ltd	208,535	215,650	-	215,650	215,650	226,217
TOTAL SALARIES & WAGES						
3400 Other Funds Ltd	4,947,200	5,939,144	308,094	6,247,238	6,358,520	6,370,540
TOTAL SALARIES & WAGES	\$4,947,200	\$5,939,144	\$308,094	\$6,247,238	\$6,358,520	\$6,370,540
OTHER PAYROLL EXPENSES						
3210 Empl. Rel. Bd. Assessments						
3400 Other Funds Ltd	1,172	1,728	-	1,728	1,896	1,896
3220 Public Employees' Retire Cont						
3400 Other Funds Ltd	863,311	1,216,147	-	1,216,147	1,532,530	1,535,142
3221 Pension Obligation Bond						
3400 Other Funds Ltd	223,206	226,695	(11,680)	215,015	-	-
3230 Social Security Taxes						
3400 Other Funds Ltd	362,933	429,512	-	429,512	457,175	458,095
3241 Paid Family Medical Leave Insurance						
3400 Other Funds Ltd	18,269	21,969	-	21,969	23,355	23,397
3250 Worker's Comp. Assess. (WCD)						

07/08/26
9:45 PM

Page 3 of 14

BDV001A - Agency Worksheet - Revenues & Expenditures
BDV001A

BUDGET NARRATIVE — 2027–29

Pharmacy, Board of

Agency Number: 85500

Agency Worksheet - Revenues & Expenditures

Version: V - 01 - Agency Request Budget

2027-29 Biennium

Cross Reference Number: 85500-000-00-00-00000

Pharmacy, Board Of

DESCRIPTION	2023-25 Actuals	2025-27 Leg Adopted Budget	2025-27 Emergency Boards	2025-27 Leg Approved Budget	2027-29 Base Budget	2027-29 Current Service Level
3400 Other Funds Ltd	776	1,008	-	1,008	912	912
3260 Mass Transit Tax						
3400 Other Funds Ltd	29,387	35,457	-	35,457	35,457	38,223
3270 Flexible Benefits						
3400 Other Funds Ltd	805,546	1,017,792	37,776	1,055,568	1,059,840	1,059,840
TOTAL OTHER PAYROLL EXPENSES						
3400 Other Funds Ltd	2,304,600	2,950,308	26,096	2,976,404	3,111,165	3,117,505
TOTAL OTHER PAYROLL EXPENSES	\$2,304,600	\$2,950,308	\$26,096	\$2,976,404	\$3,111,165	\$3,117,505
TOTAL PERSONAL SERVICES						
3400 Other Funds Ltd	7,251,800	8,889,452	334,190	9,223,642	9,469,685	9,488,045
TOTAL PERSONAL SERVICES	\$7,251,800	\$8,889,452	\$334,190	\$9,223,642	\$9,469,685	\$9,488,045
SERVICES & SUPPLIES						
4100 Instate Travel						
3400 Other Funds Ltd	105,088	127,176	-	127,176	124,676	130,785
4125 Out of State Travel						
3400 Other Funds Ltd	2,979	18,484	-	18,484	18,484	19,390
4150 Employee Training						
3400 Other Funds Ltd	55,674	30,961	-	30,961	30,961	32,478
4175 Office Expenses						
3400 Other Funds Ltd	89,553	154,577	-	154,577	133,577	140,122

07/08/26

Page 4 of 14

BDV001A - Agency Worksheet - Revenues & Expenditures

9:45 PM

BDV001A

BUDGET NARRATIVE — 2027–29

Pharmacy, Board of

Agency Number: 85500

Agency Worksheet - Revenues & Expenditures

Version: V - 01 - Agency Request Budget

2027-29 Biennium

Cross Reference Number: 85500-000-00-00-00000

Pharmacy, Board Of

<i>DESCRIPTION</i>	<i>2023-25 Actuals</i>	<i>2025-27 Leg Adopted Budget</i>	<i>2025-27 Emergency Boards</i>	<i>2025-27 Leg Approved Budget</i>	<i>2027-29 Base Budget</i>	<i>2027-29 Current Service Level</i>
4200 Telecommunications						
3400 Other Funds Ltd	56,688	71,108	-	71,108	71,108	74,592
4225 State Gov. Service Charges						
3400 Other Funds Ltd	277,711	368,778	-	368,778	368,778	424,857
4250 Data Processing						
3400 Other Funds Ltd	387,224	348,001	-	348,001	318,001	333,583
4275 Publicity and Publications						
3400 Other Funds Ltd	24,418	48,041	-	48,041	33,041	34,660
4300 Professional Services						
3400 Other Funds Ltd	244,164	521,182	-	521,182	521,182	533,652
4315 IT Professional Services						
3400 Other Funds Ltd	5,100	1,680,690	-	1,680,690	1,680,690	197,494
4325 Attorney General						
3400 Other Funds Ltd	599,594	931,176	-	931,176	931,176	1,017,775
4375 Employee Recruitment and Develop						
3400 Other Funds Ltd	-	1,736	-	1,736	1,736	1,821
4400 Dues and Subscriptions						
3400 Other Funds Ltd	4,547	6,879	-	6,879	6,879	7,216
4425 Facilities Rental and Taxes						
3400 Other Funds Ltd	326,532	342,386	-	342,386	342,386	395,163
4475 Facilities Maintenance						

07/08/26

Page 5 of 14

BDV001A - Agency Worksheet - Revenues & Expenditures

9:45 PM

BDV001A

BUDGET NARRATIVE — 2027–29

Pharmacy, Board of

Agency Number: 85500

Agency Worksheet - Revenues & Expenditures

Version: V - 01 - Agency Request Budget

2027-29 Biennium

Cross Reference Number: 85500-000-00-00-00000

Pharmacy, Board Of

DESCRIPTION	2023-25 Actuals	2025-27 Leg Adopted Budget	2025-27 Emergency Boards	2025-27 Leg Approved Budget	2027-29 Base Budget	2027-29 Current Service Level
3400 Other Funds Ltd	13	59	-	59	59	62
4525 Medical Services and Supplies						
3400 Other Funds Ltd	-	1,305	-	1,305	1,305	1,369
4575 Agency Program Related S and S						
3400 Other Funds Ltd	221,237	271,961	-	271,961	271,961	285,287
4650 Other Services and Supplies						
3400 Other Funds Ltd	529,755	503,115	(1,853)	501,262	597,262	626,528
4700 Expendable Prop 250 - 5000						
3400 Other Funds Ltd	-	21,300	-	21,300	8,800	9,231
4715 IT Expendable Property						
3400 Other Funds Ltd	11,926	49,107	-	49,107	34,107	35,778
TOTAL SERVICES & SUPPLIES						
3400 Other Funds Ltd	2,942,203	5,498,022	(1,853)	5,496,169	5,496,169	4,301,843
TOTAL SERVICES & SUPPLIES	\$2,942,203	\$5,498,022	(\$1,853)	\$5,496,169	\$5,496,169	\$4,301,843
EXPENDITURES						
3400 Other Funds Ltd	10,194,003	14,387,474	332,337	14,719,811	14,965,854	13,789,888
ENDING BALANCE						
3400 Other Funds Ltd	4,595,586	3,012,888	(332,337)	2,680,551	3,832,682	5,008,648
TOTAL ENDING BALANCE	\$4,595,586	\$3,012,888	(\$332,337)	\$2,680,551	\$3,832,682	\$5,008,648
AUTHORIZED POSITIONS						

07/08/26

9:45 PM

Page 6 of 14

BDV001A - Agency Worksheet - Revenues & Expenditures

BDV001A

BUDGET NARRATIVE — 2027–29

Pharmacy, Board of

Agency Number: 85500

Agency Worksheet - Revenues & Expenditures

Version: V - 01 - Agency Request Budget

2027-29 Biennium

Cross Reference Number: 85500-000-00-00-00000

Pharmacy, Board Of

<i>DESCRIPTION</i>	<i>2023-25 Actuals</i>	<i>2025-27 Leg Adopted Budget</i>	<i>2025-27 Emergency Boards</i>	<i>2025-27 Leg Approved Budget</i>	<i>2027-29 Base Budget</i>	<i>2027-29 Current Service Level</i>
8150 Class/Unclass Positions	24	24	-	24	24	24
AUTHORIZED FTE POSITIONS						
8250 Class/Unclass FTE Positions	23.63	24.00	-	24.00	24.00	24.00

07/08/26

9:45 PM

Page 7 of 14

BDV001A - Agency Worksheet - Revenues & Expenditures

BDV001A

BUDGET NARRATIVE — 2027–29

Pharmacy, Board of

Agency Number: 85500

Agency Worksheet - Revenues & Expenditures

Version: V - 01 - Agency Request Budget

2027-29 Biennium

Cross Reference Number: 85500-001-00-00-00000

Board of Pharmacy

<i>DESCRIPTION</i>	<i>2023-25 Actuals</i>	<i>2025-27 Leg Adopted Budget</i>	<i>2025-27 Emergency Boards</i>	<i>2025-27 Leg Approved Budget</i>	<i>2027-29 Base Budget</i>	<i>2027-29 Current Service Level</i>
--------------------	------------------------	---------------------------------------	---	--	--------------------------------	--

BEGINNING BALANCE

0025 Beginning Balance

3400 Other Funds Ltd	4,819,712	2,848,229	-	2,848,229	4,675,273	4,675,273
----------------------	-----------	-----------	---	-----------	-----------	-----------

0030 Beginning Balance Adjustment

3400 Other Funds Ltd	-	976,052	-	976,052	-	-
----------------------	---	---------	---	---------	---	---

TOTAL BEGINNING BALANCE

3400 Other Funds Ltd	4,819,712	3,824,281	-	3,824,281	4,675,273	4,675,273
----------------------	-----------	-----------	---	-----------	-----------	-----------

TOTAL BEGINNING BALANCE	\$4,819,712	\$3,824,281	-	\$3,824,281	\$4,675,273	\$4,675,273
--------------------------------	--------------------	--------------------	----------	--------------------	--------------------	--------------------

REVENUE CATEGORIES

LICENSES AND FEES

0205 Business Lic and Fees

3400 Other Funds Ltd	9,538,386	13,124,581	-	13,124,581	13,698,001	13,698,001
----------------------	-----------	------------	---	------------	------------	------------

0210 Non-business Lic. and Fees

3400 Other Funds Ltd	282,461	330,930	-	330,930	402,526	402,526
----------------------	---------	---------	---	---------	---------	---------

TOTAL LICENSES AND FEES

3400 Other Funds Ltd	9,820,847	13,455,511	-	13,455,511	14,100,527	14,100,527
----------------------	-----------	------------	---	------------	------------	------------

TOTAL LICENSES AND FEES	\$9,820,847	\$13,455,511	-	\$13,455,511	\$14,100,527	\$14,100,527
--------------------------------	--------------------	---------------------	----------	---------------------	---------------------	---------------------

FINES, RENTS AND ROYALTIES

0505 Fines and Forfeitures

3400 Other Funds Ltd	265,143	182,000	-	182,000	214,000	214,000
----------------------	---------	---------	---	---------	---------	---------

07/08/26

Page 8 of 14

BDV001A - Agency Worksheet - Revenues & Expenditures

9:45 PM

BDV001A

BUDGET NARRATIVE — 2027–29

Pharmacy, Board of

Agency Number: 85500

Agency Worksheet - Revenues & Expenditures

Version: V - 01 - Agency Request Budget

2027-29 Biennium

Cross Reference Number: 85500-001-00-00-00000

Board of Pharmacy

<i>DESCRIPTION</i>	<i>2023-25 Actuals</i>	<i>2025-27 Leg Adopted Budget</i>	<i>2025-27 Emergency Boards</i>	<i>2025-27 Leg Approved Budget</i>	<i>2027-29 Base Budget</i>	<i>2027-29 Current Service Level</i>
INTEREST EARNINGS						
0605 Interest Income						
3400 Other Funds Ltd	452,817	504,000	-	504,000	508,500	508,500
OTHER						
0975 Other Revenues						
3400 Other Funds Ltd	66,222	63,850	-	63,850	64,600	64,600
REVENUES						
3400 Other Funds Ltd	10,605,029	14,205,361	-	14,205,361	14,887,627	14,887,627
TRANSFERS OUT						
2443 Tsfr To Oregon Health Authority						
3400 Other Funds Ltd	(635,152)	(629,280)	-	(629,280)	(764,364)	(764,364)
AVAILABLE REVENUES						
3400 Other Funds Ltd	14,789,589	17,400,362	-	17,400,362	18,798,536	18,798,536
EXPENDITURES						
PERSONAL SERVICES						
SALARIES & WAGES						
3110 Class/Unclass Sal. and Per Diem						
3400 Other Funds Ltd	4,668,758	5,603,420	308,094	5,911,514	6,022,796	6,022,796
3115 Board Member Stipend						
3400 Other Funds Ltd	63,267	90,426	-	90,426	90,426	90,426
3160 Temporary Appointments						

07/08/26

Page 9 of 14

BDV001A - Agency Worksheet - Revenues & Expenditures

9:45 PM

BDV001A

BUDGET NARRATIVE — 2027–29

Pharmacy, Board of

Agency Number: 85500

Agency Worksheet - Revenues & Expenditures
2027-29 Biennium
Board of Pharmacy

Version: V - 01 - Agency Request Budget
Cross Reference Number: 85500-001-00-00-00000

DESCRIPTION	2023-25 Actuals	2025-27 Leg Adopted Budget	2025-27 Emergency Boards	2025-27 Leg Approved Budget	2027-29 Base Budget	2027-29 Current Service Level
3400 Other Funds Ltd	1,748	29,648	-	29,648	29,648	31,101
3170 Overtime Payments						
3400 Other Funds Ltd	4,892	-	-	-	-	-
3190 All Other Differential						
3400 Other Funds Ltd	208,535	215,650	-	215,650	215,650	226,217
TOTAL SALARIES & WAGES						
3400 Other Funds Ltd	4,947,200	5,939,144	308,094	6,247,238	6,358,520	6,370,540
TOTAL SALARIES & WAGES	\$4,947,200	\$5,939,144	\$308,094	\$6,247,238	\$6,358,520	\$6,370,540
OTHER PAYROLL EXPENSES						
3210 Empl. Rel. Bd. Assessments						
3400 Other Funds Ltd	1,172	1,728	-	1,728	1,896	1,896
3220 Public Employees' Retire Cont						
3400 Other Funds Ltd	863,311	1,216,147	-	1,216,147	1,532,530	1,535,142
3221 Pension Obligation Bond						
3400 Other Funds Ltd	223,206	226,695	(11,680)	215,015	-	-
3230 Social Security Taxes						
3400 Other Funds Ltd	362,933	429,512	-	429,512	457,175	458,095
3241 Paid Family Medical Leave Insurance						
3400 Other Funds Ltd	18,269	21,969	-	21,969	23,355	23,397
3250 Worker's Comp. Assess. (WCD)						

07/08/26
9:45 PM

Page 10 of 14

BDV001A - Agency Worksheet - Revenues & Expenditures
BDV001A

BUDGET NARRATIVE — 2027–29

Pharmacy, Board of

Agency Number: 85500

Agency Worksheet - Revenues & Expenditures

Version: V - 01 - Agency Request Budget

2027-29 Biennium

Cross Reference Number: 85500-001-00-00-00000

Board of Pharmacy

<i>DESCRIPTION</i>	<i>2023-25 Actuals</i>	<i>2025-27 Leg Adopted Budget</i>	<i>2025-27 Emergency Boards</i>	<i>2025-27 Leg Approved Budget</i>	<i>2027-29 Base Budget</i>	<i>2027-29 Current Service Level</i>
3400 Other Funds Ltd	776	1,008	-	1,008	912	912
3260 Mass Transit Tax						
3400 Other Funds Ltd	29,387	35,457	-	35,457	35,457	38,223
3270 Flexible Benefits						
3400 Other Funds Ltd	805,546	1,017,792	37,776	1,055,568	1,059,840	1,059,840
TOTAL OTHER PAYROLL EXPENSES						
3400 Other Funds Ltd	2,304,600	2,950,308	26,096	2,976,404	3,111,165	3,117,505
TOTAL OTHER PAYROLL EXPENSES	\$2,304,600	\$2,950,308	\$26,096	\$2,976,404	\$3,111,165	\$3,117,505
TOTAL PERSONAL SERVICES						
3400 Other Funds Ltd	7,251,800	8,889,452	334,190	9,223,642	9,469,685	9,488,045
TOTAL PERSONAL SERVICES	\$7,251,800	\$8,889,452	\$334,190	\$9,223,642	\$9,469,685	\$9,488,045
SERVICES & SUPPLIES						
4100 Instate Travel						
3400 Other Funds Ltd	105,088	127,176	-	127,176	124,676	130,785
4125 Out of State Travel						
3400 Other Funds Ltd	2,979	18,484	-	18,484	18,484	19,390
4150 Employee Training						
3400 Other Funds Ltd	55,674	30,961	-	30,961	30,961	32,478
4175 Office Expenses						
3400 Other Funds Ltd	89,553	154,577	-	154,577	133,577	140,122

07/08/26
9:45 PM

Page 11 of 14

BDV001A - Agency Worksheet - Revenues & Expenditures
BDV001A

BUDGET NARRATIVE — 2027–29

Pharmacy, Board of

Agency Number: 85500

Agency Worksheet - Revenues & Expenditures
2027-29 Biennium
Board of Pharmacy

Version: V - 01 - Agency Request Budget
Cross Reference Number: 85500-001-00-00-00000

DESCRIPTION	2023-25 Actuals	2025-27 Leg Adopted Budget	2025-27 Emergency Boards	2025-27 Leg Approved Budget	2027-29 Base Budget	2027-29 Current Service Level
4200 Telecommunications						
3400 Other Funds Ltd	56,688	71,108	-	71,108	71,108	74,592
4225 State Gov. Service Charges						
3400 Other Funds Ltd	277,711	368,778	-	368,778	368,778	424,857
4250 Data Processing						
3400 Other Funds Ltd	387,224	348,001	-	348,001	318,001	333,583
4275 Publicity and Publications						
3400 Other Funds Ltd	24,418	48,041	-	48,041	33,041	34,660
4300 Professional Services						
3400 Other Funds Ltd	244,164	521,182	-	521,182	521,182	533,652
4315 IT Professional Services						
3400 Other Funds Ltd	5,100	1,680,690	-	1,680,690	1,680,690	197,494
4325 Attorney General						
3400 Other Funds Ltd	599,594	931,176	-	931,176	931,176	1,017,775
4375 Employee Recruitment and Develop						
3400 Other Funds Ltd	-	1,736	-	1,736	1,736	1,821
4400 Dues and Subscriptions						
3400 Other Funds Ltd	4,547	6,879	-	6,879	6,879	7,216
4425 Facilities Rental and Taxes						
3400 Other Funds Ltd	326,532	342,386	-	342,386	342,386	395,163
4475 Facilities Maintenance						

07/08/26
9:45 PM

Page 12 of 14

BDV001A - Agency Worksheet - Revenues & Expenditures
BDV001A

BUDGET NARRATIVE — 2027–29

Pharmacy, Board of

Agency Number: 85500

Agency Worksheet - Revenues & Expenditures
2027-29 Biennium
Board of Pharmacy

Version: V - 01 - Agency Request Budget
Cross Reference Number: 85500-001-00-00-00000

DESCRIPTION	2023-25 Actuals	2025-27 Leg Adopted Budget	2025-27 Emergency Boards	2025-27 Leg Approved Budget	2027-29 Base Budget	2027-29 Current Service Level
3400 Other Funds Ltd	13	59	-	59	59	62
4525 Medical Services and Supplies						
3400 Other Funds Ltd	-	1,305	-	1,305	1,305	1,369
4575 Agency Program Related S and S						
3400 Other Funds Ltd	221,237	271,961	-	271,961	271,961	285,287
4650 Other Services and Supplies						
3400 Other Funds Ltd	529,755	503,115	(1,853)	501,262	597,262	626,528
4700 Expendable Prop 250 - 5000						
3400 Other Funds Ltd	-	21,300	-	21,300	8,800	9,231
4715 IT Expendable Property						
3400 Other Funds Ltd	11,926	49,107	-	49,107	34,107	35,778
TOTAL SERVICES & SUPPLIES						
3400 Other Funds Ltd	2,942,203	5,498,022	(1,853)	5,496,169	5,496,169	4,301,843
TOTAL SERVICES & SUPPLIES	\$2,942,203	\$5,498,022	(\$1,853)	\$5,496,169	\$5,496,169	\$4,301,843
EXPENDITURES						
3400 Other Funds Ltd	10,194,003	14,387,474	332,337	14,719,811	14,965,854	13,789,888
ENDING BALANCE						
3400 Other Funds Ltd	4,595,586	3,012,888	(332,337)	2,680,551	3,832,682	5,008,648
TOTAL ENDING BALANCE	\$4,595,586	\$3,012,888	(\$332,337)	\$2,680,551	\$3,832,682	\$5,008,648
AUTHORIZED POSITIONS						

07/08/26
9:45 PM

Page 13 of 14

BDV001A - Agency Worksheet - Revenues & Expenditures
BDV001A

BUDGET NARRATIVE — 2027–29

Pharmacy, Board of

Agency Number: 85500

Agency Worksheet - Revenues & Expenditures
2027-29 Biennium
Board of Pharmacy

Version: V - 01 - Agency Request Budget
Cross Reference Number: 85500-001-00-00-00000

<i>DESCRIPTION</i>	<i>2023-25 Actuals</i>	<i>2025-27 Leg Adopted Budget</i>	<i>2025-27 Emergency Boards</i>	<i>2025-27 Leg Approved Budget</i>	<i>2027-29 Base Budget</i>	<i>2027-29 Current Service Level</i>
8150 Class/Unclass Positions	24	24	-	24	24	24
AUTHORIZED FTE POSITIONS						
8250 Class/Unclass FTE Positions	23.63	24.00	-	24.00	24.00	24.00

BUDGET NARRATIVE — 2027–29

Pharmacy, Board of

Agency Number: 85500

Detail Revenues & Expenditures - Requested Budget

Version: V - 01 - Agency Request Budget

2027-29 Biennium

Cross Reference Number: 85500-000-00-00-00000

Pharmacy, Board Of

Description	2027-29 Base Budget	Essential Packages	2027-29 Current Service Level	Policy Packages	2027-29 Agency Request Budget
BEGINNING BALANCE					
0025 Beginning Balance					
3400 Other Funds Ltd	4,675,273	-	4,675,273	-	4,675,273
REVENUE CATEGORIES					
LICENSES AND FEES					
0205 Business Lic and Fees					
3400 Other Funds Ltd	13,698,001	-	13,698,001	-	13,698,001
0210 Non-business Lic. and Fees					
3400 Other Funds Ltd	402,526	-	402,526	-	402,526
TOTAL LICENSES AND FEES					
3400 Other Funds Ltd	14,100,527	-	14,100,527	-	14,100,527
FINES, RENTS AND ROYALTIES					
0505 Fines and Forfeitures					
3400 Other Funds Ltd	214,000	-	214,000	-	214,000
INTEREST EARNINGS					
0605 Interest Income					
3400 Other Funds Ltd	508,500	-	508,500	-	508,500
OTHER					
0975 Other Revenues					
3400 Other Funds Ltd	64,600	-	64,600	-	64,600
TOTAL REVENUES					
3400 Other Funds Ltd	14,887,627	-	14,887,627	-	14,887,627

TRANSFERS OUT

07/08/26

Page 1 of 10

BDV002A - Detail Revenues & Expenditures - Requested Budget

9:46 PM

BDV002A

BUDGET NARRATIVE — 2027–29

Pharmacy, Board of

Agency Number: 85500

Detail Revenues & Expenditures - Requested Budget

Version: V - 01 - Agency Request Budget

2027-29 Biennium

Cross Reference Number: 85500-000-00-00-00000

Pharmacy, Board Of

Description	2027-29 Base Budget	Essential Packages	2027-29 Current Service Level	Policy Packages	2027-29 Agency Request Budget
2443 Tsfr To Oregon Health Authority					
3400 Other Funds Ltd	(764,364)	-	(764,364)	-	(764,364)
AVAILABLE REVENUES					
3400 Other Funds Ltd	18,798,536	-	18,798,536	-	18,798,536
EXPENDITURES					
PERSONAL SERVICES					
SALARIES & WAGES					
3110 Class/Unclass Sal. and Per Diem					
3400 Other Funds Ltd	6,022,796	-	6,022,796	80,064	6,102,860
3115 Board Member Stipend					
3400 Other Funds Ltd	90,426	-	90,426	-	90,426
3160 Temporary Appointments					
3400 Other Funds Ltd	29,648	1,453	31,101	-	31,101
3190 All Other Differential					
3400 Other Funds Ltd	215,650	10,567	226,217	-	226,217
TOTAL SALARIES & WAGES					
3400 Other Funds Ltd	6,358,520	12,020	6,370,540	80,064	6,450,604
OTHER PAYROLL EXPENSES					
3210 Empl. Rel. Bd. Assessments					
3400 Other Funds Ltd	1,896	-	1,896	79	1,975
3220 Public Employees' Retire Cont					
3400 Other Funds Ltd	1,532,530	2,612	1,535,142	19,792	1,554,934
3230 Social Security Taxes					

07/08/26

Page 2 of 10

BDV002A - Detail Revenues & Expenditures - Requested Budget

9:46 PM

BDV002A

BUDGET NARRATIVE — 2027–29

Pharmacy, Board of

Agency Number: 85500

Detail Revenues & Expenditures - Requested Budget

Version: V - 01 - Agency Request Budget

2027-29 Biennium

Cross Reference Number: 85500-000-00-00-00000

Pharmacy, Board Of

Description	2027-29 Base Budget	Essential Packages	2027-29 Current Service Level	Policy Packages	2027-29 Agency Request Budget
3400 Other Funds Ltd	457,175	920	458,095	6,124	464,219
3241 Paid Family Medical Leave Insurance					
3400 Other Funds Ltd	23,355	42	23,397	321	23,718
3250 Worker's Comp. Assess. (WCD)					
3400 Other Funds Ltd	912	-	912	38	950
3260 Mass Transit Tax					
3400 Other Funds Ltd	35,457	2,766	38,223	-	38,223
3270 Flexible Benefits					
3400 Other Funds Ltd	1,059,840	-	1,059,840	44,160	1,104,000
TOTAL OTHER PAYROLL EXPENSES					
3400 Other Funds Ltd	3,111,165	6,340	3,117,505	70,514	3,188,019
TOTAL PERSONAL SERVICES					
3400 Other Funds Ltd	9,469,685	18,360	9,488,045	150,578	9,638,623
SERVICES & SUPPLIES					
4100 Instate Travel					
3400 Other Funds Ltd	124,676	6,109	130,785	-	130,785
4125 Out of State Travel					
3400 Other Funds Ltd	18,484	906	19,390	-	19,390
4150 Employee Training					
3400 Other Funds Ltd	30,961	1,517	32,478	-	32,478
4175 Office Expenses					
3400 Other Funds Ltd	133,577	6,545	140,122	-	140,122
4200 Telecommunications					

07/08/26

Page 3 of 10

BDV002A - Detail Revenues & Expenditures - Requested Budget

9:46 PM

BDV002A

BUDGET NARRATIVE — 2027–29

Pharmacy, Board of

Agency Number: 85500

Detail Revenues & Expenditures - Requested Budget

Version: V - 01 - Agency Request Budget

2027-29 Biennium

Cross Reference Number: 85500-000-00-00-00000

Pharmacy, Board Of

Description	2027-29 Base Budget	Essential Packages	2027-29 Current Service Level	Policy Packages	2027-29 Agency Request Budget
3400 Other Funds Ltd	71,108	3,484	74,592	-	74,592
4225 State Gov. Service Charges					
3400 Other Funds Ltd	368,778	56,079	424,857	-	424,857
4250 Data Processing					
3400 Other Funds Ltd	318,001	15,582	333,583	-	333,583
4275 Publicity and Publications					
3400 Other Funds Ltd	33,041	1,619	34,660	-	34,660
4300 Professional Services					
3400 Other Funds Ltd	521,182	12,470	533,652	-	533,652
4315 IT Professional Services					
3400 Other Funds Ltd	1,680,690	(1,483,196)	197,494	(150,578)	46,916
4325 Attorney General					
3400 Other Funds Ltd	931,176	86,599	1,017,775	-	1,017,775
4375 Employee Recruitment and Develop					
3400 Other Funds Ltd	1,736	85	1,821	-	1,821
4400 Dues and Subscriptions					
3400 Other Funds Ltd	6,879	337	7,216	-	7,216
4425 Facilities Rental and Taxes					
3400 Other Funds Ltd	342,386	52,777	395,163	-	395,163
4475 Facilities Maintenance					
3400 Other Funds Ltd	59	3	62	-	62
4525 Medical Services and Supplies					
3400 Other Funds Ltd	1,305	64	1,369	-	1,369

07/08/26

Page 4 of 10

BDV002A - Detail Revenues & Expenditures - Requested Budget

9:46 PM

BDV002A

BUDGET NARRATIVE — 2027–29

Pharmacy, Board of

Agency Number: 85500

Detail Revenues & Expenditures - Requested Budget

Version: V - 01 - Agency Request Budget

2027-29 Biennium

Cross Reference Number: 85500-000-00-00-00000

Pharmacy, Board Of

Description	2027-29 Base Budget	Essential Packages	2027-29 Current Service Level	Policy Packages	2027-29 Agency Request Budget
4575 Agency Program Related S and S					
3400 Other Funds Ltd	271,961	13,326	285,287	-	285,287
4650 Other Services and Supplies					
3400 Other Funds Ltd	597,262	29,266	626,528	-	626,528
4700 Expendable Prop 250 - 5000					
3400 Other Funds Ltd	8,800	431	9,231	-	9,231
4715 IT Expendable Property					
3400 Other Funds Ltd	34,107	1,671	35,778	-	35,778
TOTAL SERVICES & SUPPLIES					
3400 Other Funds Ltd	5,496,169	(1,194,326)	4,301,843	(150,578)	4,151,265
TOTAL EXPENDITURES					
3400 Other Funds Ltd	14,965,854	(1,175,966)	13,789,888	-	13,789,888
ENDING BALANCE					
3400 Other Funds Ltd	3,832,682	1,175,966	5,008,648	-	5,008,648
AUTHORIZED POSITIONS					
8150 Class/Unclass Positions	24	-	24	1	25
AUTHORIZED FTE					
8250 Class/Unclass FTE Positions	24.00	-	24.00	1.00	25.00

07/08/26

Page 5 of 10

BDV002A - Detail Revenues & Expenditures - Requested Budget

9:46 PM

BDV002A

BUDGET NARRATIVE — 2027–29

Pharmacy, Board of

Agency Number: 85500

Detail Revenues & Expenditures - Requested Budget

Version: V - 01 - Agency Request Budget

2027-29 Biennium

Cross Reference Number: 85500-001-00-00-00000

Board of Pharmacy

Description	2027-29 Base Budget	Essential Packages	2027-29 Current Service Level	Policy Packages	2027-29 Agency Request Budget
BEGINNING BALANCE					
0025 Beginning Balance					
3400 Other Funds Ltd	4,675,273	-	4,675,273	-	4,675,273
REVENUE CATEGORIES					
LICENSES AND FEES					
0205 Business Lic and Fees					
3400 Other Funds Ltd	13,698,001	-	13,698,001	-	13,698,001
0210 Non-business Lic. and Fees					
3400 Other Funds Ltd	402,526	-	402,526	-	402,526
TOTAL LICENSES AND FEES					
3400 Other Funds Ltd	14,100,527	-	14,100,527	-	14,100,527
FINES, RENTS AND ROYALTIES					
0505 Fines and Forfeitures					
3400 Other Funds Ltd	214,000	-	214,000	-	214,000
INTEREST EARNINGS					
0605 Interest Income					
3400 Other Funds Ltd	508,500	-	508,500	-	508,500
OTHER					
0975 Other Revenues					
3400 Other Funds Ltd	64,600	-	64,600	-	64,600
TOTAL REVENUES					
3400 Other Funds Ltd	14,887,627	-	14,887,627	-	14,887,627
TRANSFERS OUT					

07/08/26

Page 6 of 10

BDV002A - Detail Revenues & Expenditures - Requested Budget

9:46 PM

BDV002A

BUDGET NARRATIVE — 2027–29

Pharmacy, Board of

Agency Number: 85500

Detail Revenues & Expenditures - Requested Budget

Version: V - 01 - Agency Request Budget

2027-29 Biennium

Cross Reference Number: 85500-001-00-00-00000

Board of Pharmacy

Description	2027-29 Base Budget	Essential Packages	2027-29 Current Service Level	Policy Packages	2027-29 Agency Request Budget
2443 Tsfr To Oregon Health Authority					
3400 Other Funds Ltd	(764,364)	-	(764,364)	-	(764,364)
AVAILABLE REVENUES					
3400 Other Funds Ltd	18,798,536	-	18,798,536	-	18,798,536
EXPENDITURES					
PERSONAL SERVICES					
SALARIES & WAGES					
3110 Class/Unclass Sal. and Per Diem					
3400 Other Funds Ltd	6,022,796	-	6,022,796	80,064	6,102,860
3115 Board Member Stipend					
3400 Other Funds Ltd	90,426	-	90,426	-	90,426
3160 Temporary Appointments					
3400 Other Funds Ltd	29,648	1,453	31,101	-	31,101
3190 All Other Differential					
3400 Other Funds Ltd	215,650	10,567	226,217	-	226,217
TOTAL SALARIES & WAGES					
3400 Other Funds Ltd	6,358,520	12,020	6,370,540	80,064	6,450,604
OTHER PAYROLL EXPENSES					
3210 Empl. Rel. Bd. Assessments					
3400 Other Funds Ltd	1,896	-	1,896	79	1,975
3220 Public Employees' Retire Cont					
3400 Other Funds Ltd	1,532,530	2,612	1,535,142	19,792	1,554,934
3230 Social Security Taxes					

07/08/26

Page 7 of 10

BDV002A - Detail Revenues & Expenditures - Requested Budget

9:46 PM

BDV002A

BUDGET NARRATIVE — 2027–29

Pharmacy, Board of

Agency Number: 85500

Detail Revenues & Expenditures - Requested Budget

Version: V - 01 - Agency Request Budget

2027-29 Biennium

Cross Reference Number: 85500-001-00-00-00000

Board of Pharmacy

Description	2027-29 Base Budget	Essential Packages	2027-29 Current Service Level	Policy Packages	2027-29 Agency Request Budget
3400 Other Funds Ltd	457,175	920	458,095	6,124	464,219
3241 Paid Family Medical Leave Insurance					
3400 Other Funds Ltd	23,355	42	23,397	321	23,718
3250 Worker's Comp. Assess. (WCD)					
3400 Other Funds Ltd	912	-	912	38	950
3260 Mass Transit Tax					
3400 Other Funds Ltd	35,457	2,766	38,223	-	38,223
3270 Flexible Benefits					
3400 Other Funds Ltd	1,059,840	-	1,059,840	44,160	1,104,000
TOTAL OTHER PAYROLL EXPENSES					
3400 Other Funds Ltd	3,111,165	6,340	3,117,505	70,514	3,188,019
TOTAL PERSONAL SERVICES					
3400 Other Funds Ltd	9,469,685	18,360	9,488,045	150,578	9,638,623
SERVICES & SUPPLIES					
4100 Instate Travel					
3400 Other Funds Ltd	124,676	6,109	130,785	-	130,785
4125 Out of State Travel					
3400 Other Funds Ltd	18,484	906	19,390	-	19,390
4150 Employee Training					
3400 Other Funds Ltd	30,961	1,517	32,478	-	32,478
4175 Office Expenses					
3400 Other Funds Ltd	133,577	6,545	140,122	-	140,122
4200 Telecommunications					

07/08/26

Page 8 of 10

BDV002A - Detail Revenues & Expenditures - Requested Budget

9:46 PM

BDV002A

BUDGET NARRATIVE — 2027–29

Pharmacy, Board of

Agency Number: 85500

Detail Revenues & Expenditures - Requested Budget

Version: V - 01 - Agency Request Budget

2027-29 Biennium

Cross Reference Number: 85500-001-00-00-00000

Board of Pharmacy

Description	2027-29 Base Budget	Essential Packages	2027-29 Current Service Level	Policy Packages	2027-29 Agency Request Budget
3400 Other Funds Ltd	71,108	3,484	74,592	-	74,592
4225 State Gov. Service Charges					
3400 Other Funds Ltd	368,778	56,079	424,857	-	424,857
4250 Data Processing					
3400 Other Funds Ltd	318,001	15,582	333,583	-	333,583
4275 Publicity and Publications					
3400 Other Funds Ltd	33,041	1,619	34,660	-	34,660
4300 Professional Services					
3400 Other Funds Ltd	521,182	12,470	533,652	-	533,652
4315 IT Professional Services					
3400 Other Funds Ltd	1,680,690	(1,483,196)	197,494	(150,578)	46,916
4325 Attorney General					
3400 Other Funds Ltd	931,176	86,599	1,017,775	-	1,017,775
4375 Employee Recruitment and Develop					
3400 Other Funds Ltd	1,736	85	1,821	-	1,821
4400 Dues and Subscriptions					
3400 Other Funds Ltd	6,879	337	7,216	-	7,216
4425 Facilities Rental and Taxes					
3400 Other Funds Ltd	342,386	52,777	395,163	-	395,163
4475 Facilities Maintenance					
3400 Other Funds Ltd	59	3	62	-	62
4525 Medical Services and Supplies					
3400 Other Funds Ltd	1,305	64	1,369	-	1,369

07/08/26

Page 9 of 10

BDV002A - Detail Revenues & Expenditures - Requested Budget

9:46 PM

BDV002A

BUDGET NARRATIVE — 2027–29

Pharmacy, Board of

Agency Number: 85500

Detail Revenues & Expenditures - Requested Budget

Version: V - 01 - Agency Request Budget

2027-29 Biennium

Cross Reference Number: 85500-001-00-00-00000

Board of Pharmacy

Description	2027-29 Base Budget	Essential Packages	2027-29 Current Service Level	Policy Packages	2027-29 Agency Request Budget
4575 Agency Program Related S and S					
3400 Other Funds Ltd	271,961	13,326	285,287	-	285,287
4650 Other Services and Supplies					
3400 Other Funds Ltd	597,262	29,266	626,528	-	626,528
4700 Expendable Prop 250 - 5000					
3400 Other Funds Ltd	8,800	431	9,231	-	9,231
4715 IT Expendable Property					
3400 Other Funds Ltd	34,107	1,671	35,778	-	35,778
TOTAL SERVICES & SUPPLIES					
3400 Other Funds Ltd	5,496,169	(1,194,326)	4,301,843	(150,578)	4,151,265
TOTAL EXPENDITURES					
3400 Other Funds Ltd	14,965,854	(1,175,966)	13,789,888	-	13,789,888
ENDING BALANCE					
3400 Other Funds Ltd	3,832,682	1,175,966	5,008,648	-	5,008,648
AUTHORIZED POSITIONS					
8150 Class/Unclass Positions	24	-	24	1	25
AUTHORIZED FTE					
8250 Class/Unclass FTE Positions	24.00	-	24.00	1.00	25.00

07/08/26

Page 10 of 10

BDV002A - Detail Revenues & Expenditures - Requested Budget

9:46 PM

BDV002A

BUDGET NARRATIVE — 2027–29

Pharmacy, Board of

Agency Number 85500

BDV004B

Version: V - 01 - Agency Request Budget

2027-29 Biennium

Cross Reference Number: 85500-000-00-00-00000

Pharmacy, Board Of

Description	Total Essential Packages	Pkg: 010 Vacancy Factor and Non-ORPICS Personal Services Priority: 00	Pkg: 022 Phase-out Pgm & One-time Costs Priority: 00	Pkg: 031 Standard Inflation Priority: 00	Pkg: 060 Technical Adjustments Priority: 00	
-------------	--------------------------	---	---	--	--	--

EXPENDITURES

PERSONAL SERVICES

SALARIES & WAGES

3160 Temporary Appointments

3400 Other Funds Ltd	1,453	1,453	-	-	-
----------------------	-------	-------	---	---	---

3190 All Other Differential

3400 Other Funds Ltd	10,567	10,567	-	-	-
----------------------	--------	--------	---	---	---

SALARIES & WAGES

3400 Other Funds Ltd	12,020	12,020	-	-	-
----------------------	--------	--------	---	---	---

TOTAL SALARIES & WAGES	\$12,020	\$12,020	-	-	-
-----------------------------------	-----------------	-----------------	---	---	---

OTHER PAYROLL EXPENSES

3220 Public Employees Retire Cont

3400 Other Funds Ltd	2,612	2,612	-	-	-
----------------------	-------	-------	---	---	---

3230 Social Security Taxes

3400 Other Funds Ltd	920	920	-	-	-
----------------------	-----	-----	---	---	---

3241 Paid Family Medical Leave Insurance

3400 Other Funds Ltd	42	42	-	-	-
----------------------	----	----	---	---	---

3260 Mass Transit Tax

3400 Other Funds Ltd	2,766	2,766	-	-	-
----------------------	-------	-------	---	---	---

OTHER PAYROLL EXPENSES

3400 Other Funds Ltd	6,340	6,340	-	-	-
----------------------	-------	-------	---	---	---

TOTAL OTHER PAYROLL EXPENSES	\$6,340	\$6,340	-	-	-
-------------------------------------	----------------	----------------	---	---	---

07/08/26

Page 1 of 8

Detail Revenues & Expenditures - Essential Packages

9:46 PM

BDV004B

BUDGET NARRATIVE — 2027–29

Pharmacy, Board of

Agency Number 85500

BDV004B

Version: V - 01 - Agency Request Budget

2027-29 Biennium

Cross Reference Number: 85500-000-00-00-00000

Pharmacy, Board Of

Description	Total Essential Packages	Pkg: 010 Vacancy Factor and Non-ORPICS Personal Services Priority: 00	Pkg: 022 Phase-out Pgm & One-time Costs Priority: 00	Pkg: 031 Standard Inflation Priority: 00	Pkg: 060 Technical Adjustments Priority: 00	
PERSONAL SERVICES						
3400 Other Funds Ltd	18,360	18,360	-	-	-	
TOTAL PERSONAL SERVICES	\$18,360	\$18,360	-	-	-	
SERVICES & SUPPLIES						
4100 Instate Travel						
3400 Other Funds Ltd	6,109	-	-	6,109	-	
4125 Out of State Travel						
3400 Other Funds Ltd	906	-	-	906	-	
4150 Employee Training						
3400 Other Funds Ltd	1,517	-	-	1,517	-	
4175 Office Expenses						
3400 Other Funds Ltd	6,545	-	-	6,545	-	
4200 Telecommunications						
3400 Other Funds Ltd	3,484	-	-	3,484	-	
4225 State Gov. Service Charges						
3400 Other Funds Ltd	56,079	-	-	56,079	-	
4250 Data Processing						
3400 Other Funds Ltd	15,582	-	-	15,582	-	
4275 Publicity and Publications						
3400 Other Funds Ltd	1,619	-	-	1,619	-	
4300 Professional Services						
3400 Other Funds Ltd	12,470	-	-	48,470	(36,000)	
4315 IT Professional Services						

07/08/26

Page 2 of 8

Detail Revenues & Expenditures - Essential Packages

9:46 PM

BDV004B

BUDGET NARRATIVE — 2027–29

Pharmacy, Board of

Agency Number 85500

BDV004B

Version: V - 01 - Agency Request Budget

2027-29 Biennium

Cross Reference Number: 85500-000-00-00-00000

Pharmacy, Board Of

Description	Total Essential Packages	Pkg: 010 Vacancy Factor and Non-ORPICS Personal Services Priority: 00	Pkg: 022 Phase-out Pgm & One-time Costs Priority: 00	Pkg: 031 Standard Inflation Priority: 00	Pkg: 060 Technical Adjustments Priority: 00	
3400 Other Funds Ltd	(1,483,196)	-	(1,500,000)	16,804	-	
4325 Attorney General						
3400 Other Funds Ltd	86,599	-	-	86,599	-	
4375 Employee Recruitment and Develop						
3400 Other Funds Ltd	85	-	-	85	-	
4400 Dues and Subscriptions						
3400 Other Funds Ltd	337	-	-	337	-	
4425 Facilities Rental and Taxes						
3400 Other Funds Ltd	52,777	-	-	16,777	36,000	
4475 Facilities Maintenance						
3400 Other Funds Ltd	3	-	-	3	-	
4525 Medical Services and Supplies						
3400 Other Funds Ltd	64	-	-	64	-	
4575 Agency Program Related S and S						
3400 Other Funds Ltd	13,326	-	-	13,326	-	
4650 Other Services and Supplies						
3400 Other Funds Ltd	29,266	-	-	29,266	-	
4700 Expendable Prop 250 - 5000						
3400 Other Funds Ltd	431	-	-	431	-	
4715 IT Expendable Property						
3400 Other Funds Ltd	1,671	-	-	1,671	-	
SERVICES & SUPPLIES						
3400 Other Funds Ltd	(1,194,326)	-	(1,500,000)	305,674	-	

07/08/26

Page 3 of 8

Detail Revenues & Expenditures - Essential Packages

9:46 PM

BDV004B

BUDGET NARRATIVE — 2027–29

Pharmacy, Board of

Agency Number 85500

BDV004B

Version: V - 01 - Agency Request Budget

2027-29 Biennium

Cross Reference Number: 85500-000-00-00-00000

Pharmacy, Board Of

Description	Total Essential Packages	Pkg: 010 Vacancy Factor and Non-ORPICS Personal Services Priority: 00	Pkg: 022 Phase-out Pgm & One-time Costs Priority: 00	Pkg: 031 Standard Inflation Priority: 00	Pkg: 060 Technical Adjustments Priority: 00	
TOTAL SERVICES & SUPPLIES	(\$1,194,326)	-	(\$1,500,000)	\$305,674	-	
EXPENDITURES						
3400 Other Funds Ltd	(1,175,966)	18,360	(1,500,000)	305,674	-	
TOTAL EXPENDITURES	(\$1,175,966)	\$18,360	(\$1,500,000)	\$305,674	-	
ENDING BALANCE						
3400 Other Funds Ltd	1,175,966	(18,360)	1,500,000	(305,674)	-	
TOTAL ENDING BALANCE	\$1,175,966	(\$18,360)	\$1,500,000	(\$305,674)	-	

07/08/26

Page 4 of 8

Detail Revenues & Expenditures - Essential Packages

9:46 PM

BDV004B

BUDGET NARRATIVE — 2027–29

Pharmacy, Board of

Agency Number 85500

BDV004B

Version: V - 01 - Agency Request Budget

2027-29 Biennium

Cross Reference Number: 85500-001-00-00-00000

Board of Pharmacy

Description	Total Essential Packages	Pkg: 010 Vacancy Factor and Non-ORPICS Personal Services Priority: 00	Pkg: 022 Phase-out Pgm & One-time Costs Priority: 00	Pkg: 031 Standard Inflation Priority: 00	Pkg: 060 Technical Adjustments Priority: 00	
-------------	--------------------------	---	---	--	--	--

EXPENDITURES

PERSONAL SERVICES

SALARIES & WAGES

3160 Temporary Appointments

3400 Other Funds Ltd	1,453	1,453	-	-	-
----------------------	-------	-------	---	---	---

3190 All Other Differential

3400 Other Funds Ltd	10,567	10,567	-	-	-
----------------------	--------	--------	---	---	---

SALARIES & WAGES

3400 Other Funds Ltd	12,020	12,020	-	-	-
----------------------	--------	--------	---	---	---

TOTAL SALARIES & WAGES	\$12,020	\$12,020	-	-	-
-----------------------------------	-----------------	-----------------	---	---	---

OTHER PAYROLL EXPENSES

3220 Public Employees Retire Cont

3400 Other Funds Ltd	2,612	2,612	-	-	-
----------------------	-------	-------	---	---	---

3230 Social Security Taxes

3400 Other Funds Ltd	920	920	-	-	-
----------------------	-----	-----	---	---	---

3241 Paid Family Medical Leave Insurance

3400 Other Funds Ltd	42	42	-	-	-
----------------------	----	----	---	---	---

3260 Mass Transit Tax

3400 Other Funds Ltd	2,766	2,766	-	-	-
----------------------	-------	-------	---	---	---

OTHER PAYROLL EXPENSES

3400 Other Funds Ltd	6,340	6,340	-	-	-
----------------------	-------	-------	---	---	---

TOTAL OTHER PAYROLL EXPENSES	\$6,340	\$6,340	-	-	-
-------------------------------------	----------------	----------------	---	---	---

07/08/26

Page 5 of 8

Detail Revenues & Expenditures - Essential Packages

9:46 PM

BDV004B

BUDGET NARRATIVE — 2027–29

Pharmacy, Board of

Agency Number 85500

BDV004B

Version: V - 01 - Agency Request Budget

2027-29 Biennium

Cross Reference Number: 85500-001-00-00-00000

Board of Pharmacy

Description	Total Essential Packages	Pkg: 010 Vacancy Factor and Non-ORPICS Personal Services Priority: 00	Pkg: 022 Phase-out Pgm & One-time Costs Priority: 00	Pkg: 031 Standard Inflation Priority: 00	Pkg: 060 Technical Adjustments Priority: 00	
PERSONAL SERVICES						
3400 Other Funds Ltd	18,360	18,360	-	-	-	
TOTAL PERSONAL SERVICES	\$18,360	\$18,360	-	-	-	
SERVICES & SUPPLIES						
4100 Instate Travel						
3400 Other Funds Ltd	6,109	-	-	6,109	-	
4125 Out of State Travel						
3400 Other Funds Ltd	906	-	-	906	-	
4150 Employee Training						
3400 Other Funds Ltd	1,517	-	-	1,517	-	
4175 Office Expenses						
3400 Other Funds Ltd	6,545	-	-	6,545	-	
4200 Telecommunications						
3400 Other Funds Ltd	3,484	-	-	3,484	-	
4225 State Gov. Service Charges						
3400 Other Funds Ltd	56,079	-	-	56,079	-	
4250 Data Processing						
3400 Other Funds Ltd	15,582	-	-	15,582	-	
4275 Publicity and Publications						
3400 Other Funds Ltd	1,619	-	-	1,619	-	
4300 Professional Services						
3400 Other Funds Ltd	12,470	-	-	48,470	(36,000)	
4315 IT Professional Services						

07/08/26

Page 6 of 8

Detail Revenues & Expenditures - Essential Packages

9:46 PM

BDV004B

BUDGET NARRATIVE — 2027–29

Pharmacy, Board of

Agency Number 85500

BDV004B

Version: V - 01 - Agency Request Budget

2027-29 Biennium

Cross Reference Number: 85500-001-00-00-00000

Board of Pharmacy

Description	Total Essential Packages	Pkg: 010 Vacancy Factor and Non-ORPICS Personal Services Priority: 00	Pkg: 022 Phase-out Pgm & One-time Costs Priority: 00	Pkg: 031 Standard Inflation Priority: 00	Pkg: 060 Technical Adjustments Priority: 00	
3400 Other Funds Ltd	(1,483,196)	-	(1,500,000)	16,804	-	
4325 Attorney General						
3400 Other Funds Ltd	86,599	-	-	86,599	-	
4375 Employee Recruitment and Develop						
3400 Other Funds Ltd	85	-	-	85	-	
4400 Dues and Subscriptions						
3400 Other Funds Ltd	337	-	-	337	-	
4425 Facilities Rental and Taxes						
3400 Other Funds Ltd	52,777	-	-	16,777	36,000	
4475 Facilities Maintenance						
3400 Other Funds Ltd	3	-	-	3	-	
4525 Medical Services and Supplies						
3400 Other Funds Ltd	64	-	-	64	-	
4575 Agency Program Related S and S						
3400 Other Funds Ltd	13,326	-	-	13,326	-	
4650 Other Services and Supplies						
3400 Other Funds Ltd	29,266	-	-	29,266	-	
4700 Expendable Prop 250 - 5000						
3400 Other Funds Ltd	431	-	-	431	-	
4715 IT Expendable Property						
3400 Other Funds Ltd	1,671	-	-	1,671	-	
SERVICES & SUPPLIES						
3400 Other Funds Ltd	(1,194,326)	-	(1,500,000)	305,674	-	

07/08/26

Page 7 of 8

Detail Revenues & Expenditures - Essential Packages

9:46 PM

BDV004B

BUDGET NARRATIVE — 2027–29

Pharmacy, Board of

Agency Number 85500

BDV004B

Version: V - 01 - Agency Request Budget

2027-29 Biennium

Cross Reference Number: 85500-001-00-00-00000

Board of Pharmacy

Description	Total Essential Packages	Pkg: 010 Vacancy Factor and Non-ORPICS Personal Services Priority: 00	Pkg: 022 Phase-out Pgm & One-time Costs Priority: 00	Pkg: 031 Standard Inflation Priority: 00	Pkg: 060 Technical Adjustments Priority: 00	
TOTAL SERVICES & SUPPLIES	(\$1,194,326)	-	(\$1,500,000)	\$305,674	-	
EXPENDITURES						
3400 Other Funds Ltd	(1,175,966)	18,360	(1,500,000)	305,674	-	
TOTAL EXPENDITURES	(\$1,175,966)	\$18,360	(\$1,500,000)	\$305,674	-	
ENDING BALANCE						
3400 Other Funds Ltd	1,175,966	(18,360)	1,500,000	(305,674)	-	
TOTAL ENDING BALANCE	\$1,175,966	(\$18,360)	\$1,500,000	(\$305,674)	-	

07/08/26

Page 8 of 8

Detail Revenues & Expenditures - Essential Packages

9:46 PM

BDV004B

BUDGET NARRATIVE — 2027–29

Pharmacy, Board of

Agency Number 85500

BDV004B

Version: V - 01 - Agency Request Budget

2027-29 Biennium

Cross Reference Number: 85500-000-00-00-00000

Pharmacy, Board Of

Description	Total Policy Packages	Pkg: 101 New Positions Priority: 00	Pkg: 102 Staffing Reclass Priority: 00			
-------------	-----------------------	---	--	--	--	--

EXPENDITURES

PERSONAL SERVICES

SALARIES & WAGES

3110 Class/Unclass Sal. and Per Diem

3400 Other Funds Ltd	80,064	52,824	27,240
----------------------	--------	--------	--------

OTHER PAYROLL EXPENSES

3210 Empl. Rel. Bd. Assessments

3400 Other Funds Ltd	79	79	-
----------------------	----	----	---

3220 Public Employees Retire Cont

3400 Other Funds Ltd	19,792	13,058	6,734
----------------------	--------	--------	-------

3230 Social Security Taxes

3400 Other Funds Ltd	6,124	4,041	2,083
----------------------	-------	-------	-------

3241 Paid Family Medical Leave Insurance

3400 Other Funds Ltd	321	212	109
----------------------	-----	-----	-----

3250 Workers Comp. Assess. (WCD)

3400 Other Funds Ltd	38	38	-
----------------------	----	----	---

3270 Flexible Benefits

3400 Other Funds Ltd	44,160	44,160	-
----------------------	--------	--------	---

OTHER PAYROLL EXPENSES

3400 Other Funds Ltd	70,514	61,588	8,926
----------------------	--------	--------	-------

TOTAL OTHER PAYROLL EXPENSES	\$70,514	\$61,588	\$8,926
-------------------------------------	-----------------	-----------------	----------------

PERSONAL SERVICES

3400 Other Funds Ltd	150,578	114,412	36,166
----------------------	---------	---------	--------

07/08/26

Page 1 of 4

Detail Revenues & Expenditures - Policy Packages

9:46 PM

BDV004B

BUDGET NARRATIVE — 2027–29

Pharmacy, Board of

Agency Number 85500

BDV004B

Version: V - 01 - Agency Request Budget

2027-29 Biennium

Cross Reference Number: 85500-000-00-00-00000

Pharmacy, Board Of

Description	Total Policy Packages	Pkg: 101 New Positions Priority: 00	Pkg: 102 Staffing Reclass Priority: 00			
TOTAL PERSONAL SERVICES	\$150,578	\$114,412	\$36,166			
SERVICES & SUPPLIES						
4315 IT Professional Services						
3400 Other Funds Ltd	(150,578)	(114,412)	(36,166)			
EXPENDITURES						
3400 Other Funds Ltd	-	-	-			
TOTAL EXPENDITURES	-	-	-			
ENDING BALANCE						
3400 Other Funds Ltd	-	-	-			
TOTAL ENDING BALANCE	-	-	-			
AUTHORIZED POSITIONS						
8150 Class/Unclass Positions	1	1	-			
AUTHORIZED FTE						
8250 Class/Unclass FTE Positions	1.00	1.00	-			

07/08/26

9:46 PM

Page 2 of 4

Detail Revenues & Expenditures - Policy Packages

BDV004B

BUDGET NARRATIVE — 2027–29

Pharmacy, Board of

Agency Number 85500

BDV004B

Version: V - 01 - Agency Request Budget

2027-29 Biennium

Cross Reference Number: 85500-001-00-00-00000

Board of Pharmacy

Description	Total Policy Packages	Pkg: 101 New Positions Priority: 00	Pkg: 102 Staffing Reclass Priority: 00			
-------------	-----------------------	---	--	--	--	--

EXPENDITURES

PERSONAL SERVICES

SALARIES & WAGES

3110 Class/Unclass Sal. and Per Diem

3400 Other Funds Ltd	80,064	52,824	27,240
----------------------	--------	--------	--------

OTHER PAYROLL EXPENSES

3210 Empl. Rel. Bd. Assessments

3400 Other Funds Ltd	79	79	-
----------------------	----	----	---

3220 Public Employees Retire Cont

3400 Other Funds Ltd	19,792	13,058	6,734
----------------------	--------	--------	-------

3230 Social Security Taxes

3400 Other Funds Ltd	6,124	4,041	2,083
----------------------	-------	-------	-------

3241 Paid Family Medical Leave Insurance

3400 Other Funds Ltd	321	212	109
----------------------	-----	-----	-----

3250 Workers Comp. Assess. (WCD)

3400 Other Funds Ltd	38	38	-
----------------------	----	----	---

3270 Flexible Benefits

3400 Other Funds Ltd	44,160	44,160	-
----------------------	--------	--------	---

OTHER PAYROLL EXPENSES

3400 Other Funds Ltd	70,514	61,588	8,926
----------------------	--------	--------	-------

TOTAL OTHER PAYROLL EXPENSES

\$70,514	\$61,588	\$8,926
-----------------	-----------------	----------------

PERSONAL SERVICES

3400 Other Funds Ltd	150,578	114,412	36,166
----------------------	---------	---------	--------

07/08/26

Page 3 of 4

Detail Revenues & Expenditures - Policy Packages

9:46 PM

BDV004B

BUDGET NARRATIVE — 2027–29

Pharmacy, Board of

Agency Number 85500

BDV004B

Version: V - 01 - Agency Request Budget

2027-29 Biennium

Cross Reference Number: 85500-001-00-00-00000

Board of Pharmacy

Description	Total Policy Packages	Pkg: 101 New Positions Priority: 00	Pkg: 102 Staffing Reclass Priority: 00			
TOTAL PERSONAL SERVICES	\$150,578	\$114,412	\$36,166			
SERVICES & SUPPLIES						
4315 IT Professional Services						
3400 Other Funds Ltd	(150,578)	(114,412)	(36,166)			
EXPENDITURES						
3400 Other Funds Ltd	-	-	-			
TOTAL EXPENDITURES	-	-	-			
ENDING BALANCE						
3400 Other Funds Ltd	-	-	-			
TOTAL ENDING BALANCE	-	-	-			
AUTHORIZED POSITIONS						
8150 Class/Unclass Positions	1	1	-			
AUTHORIZED FTE						
8250 Class/Unclass FTE Positions	1.00	1.00	-			

07/08/26

Page 4 of 4

Detail Revenues & Expenditures - Policy Packages

9:46 PM

BDV004B

BUDGET NARRATIVE — 2027–29

PIC100 - Position Budget Report

Pharmacy, Board Of

2027-29 Biennium

Cross Reference Number: 85500-000-00-00-00000

Budget Preparation

Agency Request Budget

Position Number	Classification	Classification Name	Sal Rng	Pos Type	Pos Cnt	FTE	Mos	Step	Rate	SAL/ OPE	Salary/OPE					
											GF	LF	OF	FF	AF	
Total Salary												-	-	6,102,860	-	6,102,860
Total OPE												-	-	3,073,285	-	3,073,285
Total Personal Services						25	25.00	-	-	9,176,145	-	9,176,145				

07/09/26
8:42 AM

Page 1 of 4

PIC100 - Position Budget Report
PIC100

BUDGET NARRATIVE — 2027–29

PIC100 - Position Budget Report

Board of Pharmacy

2027-29 Biennium

Cross Reference Number: 85500-001-01-00-00000

Budget Preparation

Agency Request Budget

Position Number	Classification	Classification Name	Sal Rng	Pos Type	Pos Cnt	FTE	Mos	Step	Rate	SAL/ OPE	Salary/OPE				
											GF	LF	OF	FF	AF
0000570	MEAH Z7586 HF	AGENCY HEAD 6	39X	PF	1	1.00	24	11	19390	SAL	-	-	465,360	-	465,360
										OPE	-	-	190,416	-	190,416
0000571	MMS X0806 AP	OFFICE MANAGER 2	22	PF	1	1.00	24	10	7974	SAL	-	-	191,376	-	191,376
										OPE	-	-	106,991	-	106,991
0000572	OAS C0323 AP	PUBLIC SERVICE REPRESENTATIVE 3	15	PF	1	1.00	24	11	5525	SAL	-	-	132,600	-	132,600
										OPE	-	-	87,730	-	87,730
0000573	OAS C5911 EP	HEALTH CARE INVESTIGATOR/ADVISOR	26	PF	1	1.00	24	11	17343	SAL	-	-	416,232	-	416,232
										OPE	-	-	177,559	-	177,559
0000574	MMS X7144 AP	COMPLIANCE AND REGULATORY MANA	33X	PF	1	1.00	24	10	12968	SAL	-	-	311,232	-	311,232
										OPE	-	-	146,268	-	146,268
0000575	OAS C5911 EP	HEALTH CARE INVESTIGATOR/ADVISOR	26	PF	1	1.00	24	11	17343	SAL	-	-	416,232	-	416,232
										OPE	-	-	177,559	-	177,559
0000577	OAS C5911 EP	HEALTH CARE INVESTIGATOR/ADVISOR	26	PF	1	1.00	24	11	17343	SAL	-	-	416,232	-	416,232
										OPE	-	-	177,559	-	177,559
0000578	OAS C0107 AP	ADMINISTRATIVE SPECIALIST 1	17	PF	1	1.00	24	7	5026	SAL	-	-	120,624	-	120,624
										OPE	-	-	83,805	-	83,805
0000582	OAS C5911 EP	HEALTH CARE INVESTIGATOR/ADVISOR	26	PF	1	1.00	24	11	17343	SAL	-	-	416,232	-	416,232
										OPE	-	-	177,559	-	177,559
0000584	OAS C0323 AP	PUBLIC SERVICE REPRESENTATIVE 3	15	PF	1	1.00	24	11	5525	SAL	-	-	132,600	-	132,600
										OPE	-	-	87,730	-	87,730
0000585	OAS C0323 AP	PUBLIC SERVICE REPRESENTATIVE 3	15	PF	1	1.00	24	7	4584	SAL	-	-	110,016	-	110,016
										OPE	-	-	80,329	-	80,329
0000586	OAS C5911 EP	HEALTH CARE INVESTIGATOR/ADVISOR	26	PF	1	1.00	24	11	17343	SAL	-	-	416,232	-	416,232
										OPE	-	-	177,559	-	177,559
0000590	OAS C0323 AP	PUBLIC SERVICE REPRESENTATIVE 3	15	PF	1	1.00	24	6	4390	SAL	-	-	105,360	-	105,360
										OPE	-	-	78,803	-	78,803
0000591	MMS X7086 AP	BUSINESS OPERATIONS SUPERVISOR : 28X		PF	1	1.00	24	5	7984	SAL	-	-	191,616	-	191,616
										OPE	-	-	107,069	-	107,069
0000592	MMN X0872 AP	OPERATIONS & POLICY ANALYST 3	30	PF	1	1.00	24	8	10683	SAL	-	-	256,392	-	256,392
										OPE	-	-	128,297	-	128,297
0000650	OAS C0323 AP	PUBLIC SERVICE REPRESENTATIVE 3	15	PF	1	1.00	24	11	5525	SAL	-	-	132,600	-	132,600

07/09/26

Page 2 of 4

PIC100 - Position Budget Report

8:42 AM

PIC100

BUDGET NARRATIVE — 2027–29

PIC100 - Position Budget Report

Board of Pharmacy

2027-29 Biennium

Cross Reference Number: 85500-001-01-00-00000

Budget Preparation

Agency Request Budget

Position Number	Classification	Classification Name	Sal Rng	Pos Type	Pos Cnt	FTE	Mos	Step	Rate	SAL/OPE	Salary/OPE				
											GF	LF	OF	FF	AF
0000651	OAS C0107 AP	ADMINISTRATIVE SPECIALIST 1	17	PF	1	1.00	24	9	5510	OPE	-	-	87,730	-	87,730
										SAL	-	-	132,240	-	132,240
										OPE	-	-	87,612	-	87,612
0000652	OAS C5911 EP	HEALTH CARE INVESTIGATOR/ADVISOR	26	PF	1	1.00	24	5	12992	SAL	-	-	311,808	-	311,808
										OPE	-	-	146,456	-	146,456
0000654	MMS X7435 AP	LICENSING AND PERMITTING MANAGER	31X	PF	1	1.00	24	4	8798	SAL	-	-	211,152	-	211,152
										OPE	-	-	113,472	-	113,472
0000655	OAS C5911 EP	HEALTH CARE INVESTIGATOR/ADVISOR	26	PF	1	1.00	24	10	16527	SAL	-	-	396,648	-	396,648
										OPE	-	-	172,433	-	172,433
0000656	OAS C0323 AP	PUBLIC SERVICE REPRESENTATIVE 3	15	PF	1	1.00	24	6	4390	SAL	-	-	105,360	-	105,360
										OPE	-	-	78,803	-	78,803
0000657	OAS C5911 EP	HEALTH CARE INVESTIGATOR/ADVISOR	26	PF	1	1.00	24	6	13629	SAL	-	-	327,096	-	327,096
										OPE	-	-	151,466	-	151,466
0000659	OAS C0107 AP	ADMINISTRATIVE SPECIALIST 1	17	PF	1	1.00	24	11	6054	SAL	-	-	145,296	-	145,296
										OPE	-	-	91,890	-	91,890
0000660	OAS C0103 AP	OFFICE SPECIALIST 1	13	PF	1	1.00	24	5	3892	SAL	-	-	93,408	-	93,408
										OPE	-	-	74,887	-	74,887
0000661	OAS C0107 AP	ADMINISTRATIVE SPECIALIST 1	17	PF	1	1.00	24	5	4584	SAL	-	-	110,016	-	110,016
										OPE	-	-	80,329	-	80,329
0004401	B Y7500 AE	BOARD AND COMMISSION MEMBER	0	PP	0	0.00	0	0	0	SAL	-	-	3,700	-	3,700
										OPE	-	-	283	-	283
0004402	B Y7500 AE	BOARD AND COMMISSION MEMBER	0	PP	0	0.00	0	0	0	SAL	-	-	3,700	-	3,700
										OPE	-	-	283	-	283
0004403	B Y7500 AE	BOARD AND COMMISSION MEMBER	0	PP	0	0.00	0	0	0	SAL	-	-	3,700	-	3,700
										OPE	-	-	283	-	283
0004404	B Y7500 AE	BOARD AND COMMISSION MEMBER	0	PP	0	0.00	0	0	0	SAL	-	-	3,700	-	3,700
										OPE	-	-	283	-	283
0004405	B Y7500 AE	BOARD AND COMMISSION MEMBER	0	PP	0	0.00	0	0	0	SAL	-	-	3,700	-	3,700
										OPE	-	-	283	-	283
0004406	B Y7500 AE	BOARD AND COMMISSION MEMBER	0	PP	0	0.00	0	0	0	SAL	-	-	3,700	-	3,700
										OPE	-	-	283	-	283

07/09/26

Page 3 of 4

PIC100 - Position Budget Report

8:42 AM

PIC100

BUDGET NARRATIVE — 2027–29

PIC100 - Position Budget Report

Board of Pharmacy

2027-29 Biennium

Cross Reference Number: 85500-001-01-00-00000

Budget Preparation

Agency Request Budget

Position Number	Classification	Classification Name	Sal Rng	Pos Type	Pos Cnt	FTE	Mos	Step	Rate	SAL/ OPE	Salary/OPE				
											GF	LF	OF	FF	AF
0004407	B Y7500 AE	BOARD AND COMMISSION MEMBER	0	PP	0	0.00	0	0	0	SAL	-	-	3,700	-	3,700
										OPE	-	-	283	-	283
0004408	B Y7500 AE	BOARD AND COMMISSION MEMBER	0	PP	0	0.00	0	0	0	SAL	-	-	3,700	-	3,700
										OPE	-	-	283	-	283
0004413	B Y7500 AE	BOARD AND COMMISSION MEMBER	0	PP	0	0.00	0	0	0	SAL	-	-	3,700	-	3,700
										OPE	-	-	283	-	283
0004421	B Y7500 AE	BOARD AND COMMISSION MEMBER	0	PP	0	0.00	0	0	0	SAL	-	-	800	-	800
										OPE	-	-	61	-	61
0004422	B Y7500 AE	BOARD AND COMMISSION MEMBER	0	PP	0	0.00	0	0	0	SAL	-	-	800	-	800
										OPE	-	-	61	-	61
0004423	B Y7500 AE	BOARD AND COMMISSION MEMBER	0	PP	0	0.00	0	0	0	SAL	-	-	800	-	800
										OPE	-	-	61	-	61
0004424	B Y7500 AE	BOARD AND COMMISSION MEMBER	0	PP	0	0.00	0	0	0	SAL	-	-	800	-	800
										OPE	-	-	61	-	61
0004425	B Y7500 AE	BOARD AND COMMISSION MEMBER	0	PP	0	0.00	0	0	0	SAL	-	-	800	-	800
										OPE	-	-	61	-	61
0004426	B Y7500 AE	BOARD AND COMMISSION MEMBER	0	PP	0	0.00	0	0	0	SAL	-	-	800	-	800
										OPE	-	-	61	-	61
0004427	B Y7500 AE	BOARD AND COMMISSION MEMBER	0	PP	0	0.00	0	0	0	SAL	-	-	800	-	800
										OPE	-	-	61	-	61
Total Salary											-	-	6,102,860	-	6,102,860
Total OPE											-	-	3,073,285	-	3,073,285
Total Personal Services					25	25.00					-	-	9,176,145	-	9,176,145

07/09/26

Page 4 of 4

PIC100 - Position Budget Report

8:42 AM

PIC100